CA2140772C - Needleless hypodermic injection methods and device - Google Patents
Needleless hypodermic injection methods and device Download PDFInfo
- Publication number
- CA2140772C CA2140772C CA002140772A CA2140772A CA2140772C CA 2140772 C CA2140772 C CA 2140772C CA 002140772 A CA002140772 A CA 002140772A CA 2140772 A CA2140772 A CA 2140772A CA 2140772 C CA2140772 C CA 2140772C
- Authority
- CA
- Canada
- Prior art keywords
- ampule
- valve
- pressure
- poppet
- plunger
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
- A61M2005/31516—Piston or piston-rod constructions, e.g. connection of piston with piston-rod reducing dead-space in the syringe barrel after delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum
Abstract
A needleless injection device (20) includes an initiator valve (144) controlling flow of compressed gas into a reservoir (168).
A poppet valve (170) connecting to the reservoir has a gas pressure regulation end to regulate flow from the initiator valve into the reservoir. A clamp piston (210) is driven forward by gas pressure from the reservoir and causes jaws (236) to clamp onto a plunger (362) extending into an ampule (360). The poppet valve opens when reservoir pressure reaches the cracking pressure of the poppet valve. Gas from the reservoir rushes through the poppet valve into a drive chamber and forces a drive piston (212), containing the clamp piston and jaws, forward causing the plunger to slide into the ampule. A jet of injectant is ejected out of the nozzle of the ampule and penetrates through the patient's skin. An improved method of needleless injection uses a specific pressure profile, ampule nozzle diameter, patient, injection site, and injectant parameters.
A poppet valve (170) connecting to the reservoir has a gas pressure regulation end to regulate flow from the initiator valve into the reservoir. A clamp piston (210) is driven forward by gas pressure from the reservoir and causes jaws (236) to clamp onto a plunger (362) extending into an ampule (360). The poppet valve opens when reservoir pressure reaches the cracking pressure of the poppet valve. Gas from the reservoir rushes through the poppet valve into a drive chamber and forces a drive piston (212), containing the clamp piston and jaws, forward causing the plunger to slide into the ampule. A jet of injectant is ejected out of the nozzle of the ampule and penetrates through the patient's skin. An improved method of needleless injection uses a specific pressure profile, ampule nozzle diameter, patient, injection site, and injectant parameters.
Description
"' WO 94/02188 ~ ~ PCT/US93/06940 DESCRIPTION
NEEDLELEBB HYPODERMIC INJECTION METHODB l~TD DEVICE
FIELD OF THE INVENTION
The field of the present invention is needleless hypodenaic injection methods and devices.
Various needleless hypodermic injection devices have been known and used in the past. These devices, also known as jet injectors, typically use spring or compressed gas driven plungers to accelerate an injectant to a velocity sufficient to pierce through the skin and enter the underlying tissues.
While large j et inj ection apparatus have been success-fully used for mass inoculations, e.g. in the military services, these apparatus are relatively complex, costly, limited in performance and are not portable. Thus, injections using needles remain as the standard despite their disadvantages (for example, accidental needle sticks and risk of spreading infection to both the patient and medical professional; safe disposal of the used needle, patient's fear of needles: and pain caused by needle . injections). Jet injection avoids or diminishes these disadvantages.
Although many portable needleless injectors have been proposed, these known devices have not achieved widespread acceptance in the medical field, due to a variety of f actors .
WO 94/02188 PCT/US93/0694cr Significantly, the characteristics of needleless or jet injections typically vary'with the pressures exerted by the injection device, the nozzle diameter of the ampule, the patient's size, age and weight, the nature of the injection site, and the viscosity of the injectant.
A long standing basic difficulty with jet injection has been the complex problem of deter'~ining which are the preferred injection variables. These variables include:
1) pressure profile, 2) nozzle size, 3) patient factors, i.e., age, sex and size, 4) injection site, and 5) medica-tion viscosity. The repeated failures of the prior art to adequately solve these complex variables problems has contributed to the lack of acceptance of a handheld and portable jet injector in the medical community.
The pressure profile is the pressure exerted on the liquid injectant, typically measured over time, from the beginning to the end of the injection. The pressure profile must be selected, in combination with the nozzle size and other factors, to deliver the injectant through the skin to the desired depth, preferably with minimum pain.
The patient factors are also important. Gender is significant as women typically have a different adipose distribution than men. Men also typically have tougher tissue that women. The patient's age is important because infants are born with very little muscle, thick layers of adipose, and very easily penetrated skin. As infants age and become mobile the adipose is gradually replaced by 2 ~ 4 ~ 7 7 ~ PCT/US93/06940 muscle. At adolescence the introduction of hormones - changes tissue composition. Aging through mid-life is usually associated with gradual weight gain and decrease in tissue strength.
Injection sites are very significant because in all patients the thickness of the skin and adipose tissue varies at different regions of the body. The medical profession has established generally accepted injection sites for conventional needle syringes that are best suited for specific types of injection. The subcutaneous sites typically have a thick adipose layer and are free of major nerves and vasculature. Intramuscular sites typi-cally have a thin adipose layer, a thick muscle layer, and are free of major nerves and vasculature.
Finally, the viscosity of the injectant must be considered as it effects characteristics of the jet injection. In addition, it has been discovered that viscosity effects have been widely misunderstood in the prior art.
The prior art has generally not been able to overcome the complexities and difficulties of simultaneously accounting for all of the foregoing variables. Thus, jet injection, despite its great potential advantages, remains virtually unused. Accordingly, it is an object of the '25 invention to provide improved methods and devices for needleless injection, so that the advantages of jet injection may be brought into use.
6379E~-494 DISCLOSURE OF THE INVENTION
To these ends, in a needleless injection device, actuation of the device initially causes a valve to open.
The device engages a plunger extending from an ampule. The plunder is then driven into the ampule generating a high velocity jet of injectant from the nozzle of the ampule.
variable doses of injectant can be provided as the device can engage any position of the plunger regardless of the plunger position.
l0 An interlock system is advantageously provided to prevent the trigger from actuating the initiator valve unle:~s~an ampule is properly installed in the device.
Preferably, filters prevent stray liquefied compressed gas from entering into internal chambers of the device.
In novel methods of needleless injection, the pres;~ure profiles of the injectant, nozzle diameter, patient and injection site parameters, as well as injectant viscosity, are selected to achieve desired injection characteristics.
According to one aspect of the present invention, there. is provided a method of providing a jet injection by pressurizing a fluid injectant within an ampule, comprising the steps of: driving a plunger into the ampule with sufficient force to generate a pressure of from 26000-30000 kPa within 6 milliseconds; reducing the pressure generally linearly until 0.5 ml is expelled and the pressure 4a is 8000-14000 kPa; maintaining the pressure at 8000-14000 kPa until a desired volume injectant is expelled from the ampule; and reducing the pressure to about 0.0 kPa within 5.0 milliseconds.
According to another aspect of the present invention, there is provided a method as aforesaid wherein a subcutaneous injection is performed at a standard subcutaneous injection site using a nozzle diameter of from 0.07 to 0.13 mm.
WO 94/OZ188 2 O ~ ~ PCT/US93/06940 BRIEF DEBCRIPTION OF THE DRAWIN~iB
In the drawings, wherein similar reference characters denote similar elements throughout the several views:
Fig. 1 is a perspective view of the present needleless 5 injection device;
Fig. 2 is a section view of the present needleless injection device taken along line 2-2 of Fig. 8:
Fig. 2a is a section view thereof further illustrating an ampule and plunger installed in the device with the device in a ready to inject position, except for the piercing mechanism, Which is not shown having pierced the cartridge:
Fig. 2b is a section view thereof illustrating a clamping mechanism of the device in a pre-injection position:
Fig. 2c is a section view thereof illustrating a drive piston, clamping mechanism and plunger in a post-injection position;
Fig. 3 is an enlarged view fragment of the section view of Fig. 2, generally showing the back half of the device:
Fig. 4 is an enlarged view fragment of the section . view of Fig. 2, generally showing the front half of the device;
'25 Figs. 4a and 4b are section view fragments thereof showing an alternate embodiment;
Fig. 5 is a further enlarged section view fragment of a valve shown in Fig. 3;
NEEDLELEBB HYPODERMIC INJECTION METHODB l~TD DEVICE
FIELD OF THE INVENTION
The field of the present invention is needleless hypodenaic injection methods and devices.
Various needleless hypodermic injection devices have been known and used in the past. These devices, also known as jet injectors, typically use spring or compressed gas driven plungers to accelerate an injectant to a velocity sufficient to pierce through the skin and enter the underlying tissues.
While large j et inj ection apparatus have been success-fully used for mass inoculations, e.g. in the military services, these apparatus are relatively complex, costly, limited in performance and are not portable. Thus, injections using needles remain as the standard despite their disadvantages (for example, accidental needle sticks and risk of spreading infection to both the patient and medical professional; safe disposal of the used needle, patient's fear of needles: and pain caused by needle . injections). Jet injection avoids or diminishes these disadvantages.
Although many portable needleless injectors have been proposed, these known devices have not achieved widespread acceptance in the medical field, due to a variety of f actors .
WO 94/02188 PCT/US93/0694cr Significantly, the characteristics of needleless or jet injections typically vary'with the pressures exerted by the injection device, the nozzle diameter of the ampule, the patient's size, age and weight, the nature of the injection site, and the viscosity of the injectant.
A long standing basic difficulty with jet injection has been the complex problem of deter'~ining which are the preferred injection variables. These variables include:
1) pressure profile, 2) nozzle size, 3) patient factors, i.e., age, sex and size, 4) injection site, and 5) medica-tion viscosity. The repeated failures of the prior art to adequately solve these complex variables problems has contributed to the lack of acceptance of a handheld and portable jet injector in the medical community.
The pressure profile is the pressure exerted on the liquid injectant, typically measured over time, from the beginning to the end of the injection. The pressure profile must be selected, in combination with the nozzle size and other factors, to deliver the injectant through the skin to the desired depth, preferably with minimum pain.
The patient factors are also important. Gender is significant as women typically have a different adipose distribution than men. Men also typically have tougher tissue that women. The patient's age is important because infants are born with very little muscle, thick layers of adipose, and very easily penetrated skin. As infants age and become mobile the adipose is gradually replaced by 2 ~ 4 ~ 7 7 ~ PCT/US93/06940 muscle. At adolescence the introduction of hormones - changes tissue composition. Aging through mid-life is usually associated with gradual weight gain and decrease in tissue strength.
Injection sites are very significant because in all patients the thickness of the skin and adipose tissue varies at different regions of the body. The medical profession has established generally accepted injection sites for conventional needle syringes that are best suited for specific types of injection. The subcutaneous sites typically have a thick adipose layer and are free of major nerves and vasculature. Intramuscular sites typi-cally have a thin adipose layer, a thick muscle layer, and are free of major nerves and vasculature.
Finally, the viscosity of the injectant must be considered as it effects characteristics of the jet injection. In addition, it has been discovered that viscosity effects have been widely misunderstood in the prior art.
The prior art has generally not been able to overcome the complexities and difficulties of simultaneously accounting for all of the foregoing variables. Thus, jet injection, despite its great potential advantages, remains virtually unused. Accordingly, it is an object of the '25 invention to provide improved methods and devices for needleless injection, so that the advantages of jet injection may be brought into use.
6379E~-494 DISCLOSURE OF THE INVENTION
To these ends, in a needleless injection device, actuation of the device initially causes a valve to open.
The device engages a plunger extending from an ampule. The plunder is then driven into the ampule generating a high velocity jet of injectant from the nozzle of the ampule.
variable doses of injectant can be provided as the device can engage any position of the plunger regardless of the plunger position.
l0 An interlock system is advantageously provided to prevent the trigger from actuating the initiator valve unle:~s~an ampule is properly installed in the device.
Preferably, filters prevent stray liquefied compressed gas from entering into internal chambers of the device.
In novel methods of needleless injection, the pres;~ure profiles of the injectant, nozzle diameter, patient and injection site parameters, as well as injectant viscosity, are selected to achieve desired injection characteristics.
According to one aspect of the present invention, there. is provided a method of providing a jet injection by pressurizing a fluid injectant within an ampule, comprising the steps of: driving a plunger into the ampule with sufficient force to generate a pressure of from 26000-30000 kPa within 6 milliseconds; reducing the pressure generally linearly until 0.5 ml is expelled and the pressure 4a is 8000-14000 kPa; maintaining the pressure at 8000-14000 kPa until a desired volume injectant is expelled from the ampule; and reducing the pressure to about 0.0 kPa within 5.0 milliseconds.
According to another aspect of the present invention, there is provided a method as aforesaid wherein a subcutaneous injection is performed at a standard subcutaneous injection site using a nozzle diameter of from 0.07 to 0.13 mm.
WO 94/OZ188 2 O ~ ~ PCT/US93/06940 BRIEF DEBCRIPTION OF THE DRAWIN~iB
In the drawings, wherein similar reference characters denote similar elements throughout the several views:
Fig. 1 is a perspective view of the present needleless 5 injection device;
Fig. 2 is a section view of the present needleless injection device taken along line 2-2 of Fig. 8:
Fig. 2a is a section view thereof further illustrating an ampule and plunger installed in the device with the device in a ready to inject position, except for the piercing mechanism, Which is not shown having pierced the cartridge:
Fig. 2b is a section view thereof illustrating a clamping mechanism of the device in a pre-injection position:
Fig. 2c is a section view thereof illustrating a drive piston, clamping mechanism and plunger in a post-injection position;
Fig. 3 is an enlarged view fragment of the section view of Fig. 2, generally showing the back half of the device:
Fig. 4 is an enlarged view fragment of the section . view of Fig. 2, generally showing the front half of the device;
'25 Figs. 4a and 4b are section view fragments thereof showing an alternate embodiment;
Fig. 5 is a further enlarged section view fragment of a valve shown in Fig. 3;
Fig. 6 is a partial section view fragment taken along line 6-6 of Fig. 8 and showing selected features only;
Fig. 6a is a partial section view of a preferred alternative housing and piston plenum shut-off valve design;
Fig. 6b is a partial section view fragment of an alternative preferred exhaust valve used in the housing shown in Fig. 6a;
Fig. 6c is an enlarged partial section view of a bleed gas valve shown in Fig. 6a;
Fig. 7 is an enlarged section view fragment of the initiator valve:
Fig. 7a is a section view fragment of an alternate preferred initiator valve body;
Fig. 7b is an enlarged section view fragment of an alternative preferred initiator valve:
Fig. 8 is a back end elevation view of the device;
Fig. 9 is a front elevation view thereof;
Fig. 10 is a side elevation view in part section of the present plunger and an ampule;
Fig. 10a, lOb and lOc are section view fragments of alternate plunger and ampule embodiments;
Fig. 11 is a section view taken along line 11-11 of Fig. 10;
Fig. 12 is a graphic illustration of operation of ' certain features of the present device;
Fig. 13 is a front elevation view of the indicator ring shown in Fig. 4;
~t~o772 Fig. 13a is a side elevation view fragment taken along line 13a-13a of Fig. 13;
Fig. 14 is a side elevation view thereof in part section;
Fig. 15 is a graphic illustration of a pressure-volume preferred injectant°pressure profile;
Fig. 16 is a schematic illustration of the present peri-fascial needleless injection:
Fig. 17 is a table showing ampule selection and to parameters; and Figs. 18, 19, and 20 are graphic illustrations of pressure-time preferred injectant pressure profiies for ampules having 0.10, 0.20 and 0.36 mm diameter nozzles, respectively.
MODEB FOR CARRYING OUT THE INVENTION
Turning now in detail to the drawings, as shown in Figs. 1 and 2, an injector or needleless injection device has a front end 22, a back end 24, a top surface 26 and a bottom surface 28. A trigger 30 is slidably mounted on 20 the injector 20 adjacent the bottom surface 28. The injector 20 includes an upper housing ~2 and a shorter lower housing 44 attached to the upper housing 42. The lower housing ~4 has a flat upper surface 82 which lies against a flat lower surface 84 of the upper housing 42.
The upper housing ~2 and lower housing 44 are attached together with four (4) pins 86.
Fig. 6a is a partial section view of a preferred alternative housing and piston plenum shut-off valve design;
Fig. 6b is a partial section view fragment of an alternative preferred exhaust valve used in the housing shown in Fig. 6a;
Fig. 6c is an enlarged partial section view of a bleed gas valve shown in Fig. 6a;
Fig. 7 is an enlarged section view fragment of the initiator valve:
Fig. 7a is a section view fragment of an alternate preferred initiator valve body;
Fig. 7b is an enlarged section view fragment of an alternative preferred initiator valve:
Fig. 8 is a back end elevation view of the device;
Fig. 9 is a front elevation view thereof;
Fig. 10 is a side elevation view in part section of the present plunger and an ampule;
Fig. 10a, lOb and lOc are section view fragments of alternate plunger and ampule embodiments;
Fig. 11 is a section view taken along line 11-11 of Fig. 10;
Fig. 12 is a graphic illustration of operation of ' certain features of the present device;
Fig. 13 is a front elevation view of the indicator ring shown in Fig. 4;
~t~o772 Fig. 13a is a side elevation view fragment taken along line 13a-13a of Fig. 13;
Fig. 14 is a side elevation view thereof in part section;
Fig. 15 is a graphic illustration of a pressure-volume preferred injectant°pressure profile;
Fig. 16 is a schematic illustration of the present peri-fascial needleless injection:
Fig. 17 is a table showing ampule selection and to parameters; and Figs. 18, 19, and 20 are graphic illustrations of pressure-time preferred injectant pressure profiies for ampules having 0.10, 0.20 and 0.36 mm diameter nozzles, respectively.
MODEB FOR CARRYING OUT THE INVENTION
Turning now in detail to the drawings, as shown in Figs. 1 and 2, an injector or needleless injection device has a front end 22, a back end 24, a top surface 26 and a bottom surface 28. A trigger 30 is slidably mounted on 20 the injector 20 adjacent the bottom surface 28. The injector 20 includes an upper housing ~2 and a shorter lower housing 44 attached to the upper housing 42. The lower housing ~4 has a flat upper surface 82 which lies against a flat lower surface 84 of the upper housing 42.
The upper housing ~2 and lower housing 44 are attached together with four (4) pins 86.
8 ~ PCT/US93/0694U
The upper housing 42 and lower housing ~~ together are sized and shaped to readily fit the user's hand, with the user's palm resting over the top surface 26 and side of the injector 20, and with the user's index finger easily positionable over the trigger 30. The top surface 26 has a step or incline 34 at approximately the center of the injector 20. The upper and lower housings may alterna-tively be formed as a single housing.
Turning to Fig. 3, the lower housing 44 is substan tially hollow and defines a lower housing space 48.
Similarly, the upper housing 42 defines an upper housing space ~6 (Fig. 6). Within the lower housing 44 is a cartridge chamber 50 for receiving and holding a com pressed gas cartridge 54, e.g., a C02 cartridge. A
cartridge seat 52 at the forward end of the cartridge chamber 50 supports the back of the cartridge 54. A
generally u-shaped plastic cartridge chamber cover 56 snaps into place on the lower housing 44 over the car-tridge chamber 50.
A generally cylindrical piercing housing 58 is slida-bly positioned behind the cartridge chamber 50 within the lower housing 44. O-rings 60 seal the piercing housing 58 against the lower housing 44 while allowing the piercing housing 58 to slide within the lower housing 44. An annulus 62 extends around the circumference of the pierc-ing housing 58 in between the o-rings 60. A cylindrical piercing body 66 is positioned within the piercing housing 58 and sealed against the piercing housing 58 by o-rings WO 94/02188 ~ ~ ~ ~ 7 ~ PCT/US93/06940 88. A piercing point 68 extends forward from the front surface of the piercing body 66 and is centrally aligned with the neck of the cartridge 51. A seal 64 on the front end of the piercing body 66 surrounds the piercing point 68. The seal 64 extends sufficiently forward to seal against the neck of the--cartridge 54 before the piercing point 68 penetrates into the cartridge 54.
A bore 70 extends through the piercing point 68 and piercing body 66 connecting to the annulus 62. A piercing body nut 74 threads into the back end of the piercing housing 58, to secure the piercing body 66 and seal 64 in position within and against the forward end of the pierc-ing housing 58. A piercing housing nut 76 threads into the back of the lower housing 44. Spanner tool openings are provided in the piercing body nut 74 and the piercing housing nut 76 for assembly purposes.
A threaded shaft 72 extends through and engages threads in the piercing housing nut 76. A knob 78 at-tached to the threaded shaft 72 has a flip handle 80 which can be flipped up perpendicular to the plane of the knob 78 to allow the knob 78 and threaded shaft 72 to be more easily turned by hand. The forward end of the threaded shaft 72 bears against the back surface of the piercing body 66.
A hole 92 extends through the upper surface 82 of the lower housing to connect the annulus 62 to a bore 96 leading into the upper housing space 46. An o-ring 94 seals the connection of the hole 92 and bore 96.
14o~~t~
At the back end of the upper housing 42 is a transpar-ent window lens 98 secured to an end nut 108 by a rubber window retainer i00. A Bourdon tube 116 is soldered into a gauge base 114 and has an open end 124 extending into a gauge chamber 122. The pointer 102,.extends perpendicular-ly from the back end of the Bourdon,tube ii6. As shown in Fig. 8, a gauge label 104 apg~ ied to the back end of a gauge body 106 around the Bourdon tube 116 provides a calibrated pressure scale with the scale and pointer visible through the lens 98. Stop pins extending from the back end of the gauge body 106 provide high and low pressure end point stops for the pointer 102.
The end nut 108 has threads 110 at its forward end which engage the upper housing 42. To calibrate the gauge for a given pressure, the gauge body 106 is rotated relative to the gauge base 114. When the correct index is achieved, the gauge body 106 and gauge base 114 are adhered together. A guiding pin 112 extends from the upper housing 42 into a keyway groove and holds the gauge body 106 in place while the end nut 108 is tightened.
Shims 118 are provided at the front surface at the gauge base 114, as required, for proper stack up and positioning of components in the upper housing 42.
An initiator valve housing 142 is spaced apart from the gauge base 114 by a filter retainer ring 120. A
sandwiched assembly of filter disks 130 and synthetic filters 132 are contained within the back end of the housing 142. O-rings 140 seal the filter disks 130 WO 94/02188 21 ~ ~ ~ ~ PCT/US93/06940 against the retainer i40 and synthetic filter 132. O-ring 126 seals the filter retainer 140 within the upper housing 42. O-ring 126 and o-ring 150 seal the gauge chamber 122 such that compressed gas provided through the bore 96 can flow out of the gauge chamber 122 only through the fil-ters.
A port 148 extends t3irough the back wall of the initiator valve housing 142 into an initiator valve chamber 146 within the housing 142. An initiator valve 144 within the initiator valve chamber 146 controls gas flow from the port 148 through the initiator valve chamber 146 to a reservoir port 154 formed through the forward wall of the initiator valve housing 142.
A regulation valve 156 includes a regulation seat 158 formed around the reservoir port 154. A dart 160 moves into and out of the regulation seat 158. The dart 160 has a threaded dart shaft 162 threaded into the narrower tube section at the back end of a poppet body 172. A dart pin 164 extending through the tube section of the poppet body 172 and the threaded dart shaft 162 secures the adjustment of the longitudinal position of the dart 160 in relation to the regulation seat 158. A reservoir spacer 166 within . the upper housing 42 extends from the forward end of the initiator valve housing 142 to a poppet housing 178, forming a reservoir 168 around the tube section of the poppet body 172. O-rings 126 seal the reservoir spacer 166 against the upper housing 42 and seal the initiator valve housing 142 to the reservoir spacer 166.
A poppet valve 170 within the poppet housing 178 has a conical plastic poppet seat 188 centered within and positioned against a forward wall of the poppet housing 178. Referring to Fig. 5, the poppet body 172 has a sharp sealing edge 200 biased against thew.poppet seat 188 by a compression spring 186 held in position within the poppet housing 178 by a poppet nut 180. Alternatively, the sealing edge 200 and poppet seat 188 may be configured with unlike angles selected so that the inner diameter contacts first, to minimize creep effects. The poppet nut 180 has a threaded forward section 184 engaged to a threaded rear section i82 of the poppet housing 178. The poppet nut 180 is turned to adjust the compression on the spring 186 and correspondingly set the cracking pressure of the poppet valve 170.
The diameter of the poppet seat 188 exposed to reser-voir pressure prior to crack (thus that which governs cracking pressure) remains constant although the conical seat may creep, as the sealing surface, facing reservoir pressure, is parallel to the axis of poppet movement.
The conical seat is attached to the poppet housing 178 rather than the poppet body 172 while all hard (poppet) parts are made concentric and perpendicular. Thus, irregularities in the seat 188 or soft part will creep to conform to hard parts. The hard parts are free to rotate but will still conform to the existing soft part deforma-tion.
,...
WO 94/02188 - ~ ~ ~ ~ PCT/US93/06940 Sliding friction of the poppet body 172 is advanta-geously minimized and consistent. Hence, the seal 206 used with the back up ring 204 may be a low friction seal.
In addition, since this seal is pressurized only after cracking due to the poppet body being pressurized inter-nally before cracking, seal friction is greatly minimized.
The poppet body begins to move during opening before this seal is pressurized. Thus, breakway friction is not increased by gas pressure.
By appropriate selection of the poppet sealing diame-ters (i.e., the tube section o.d., poppet housing i.d. and conical seal contact diameter) and spring force, the poppet and regulation valves together can act as a low pressure regulator.
A cannula 176 is attached to and extends back from a drive piston 212 in front of the poppet valve 170 through the poppet housing 178 and poppet seat i88 and into the back section of the poppet body 172. Poppet body supply holes 174 extend through the poppet body 172 (Fig. 3). A
cannula exhaust hole is provided through the cannula 176 at a position just slightly behind the o-ring 207 which slidably seals the cannula 176.
Referring still to Fig. 5, radially spaced apart drive bores 194 extend through the poppet housing 178 and connect a poppet annulus 198 to the front surface of the poppet housing 178. The poppet annulus 198, a ring-shaped space, is formed by the inside walls of the poppet housing 178, the front surface of the poppet 172 and the conical surface of the poppet seat 188. The front ends of the drive bores 194 are sealed by a preferably rubber disk drive bore seal 196 adhered to. the back surface of the drive piston 212.
A joggle 192 in the poppet housing 178, which engages a corresponding lip within the upper housing 42, acts as a stop for the poppet housing 178. The reservoir spacer 166, initiator valve housing 142, filter ring, shims and the gauge body 106 are then subsequently installed within the upper housing 42 and stack up against the poppet housing 178, with the end nut 108 clamping these compo-nents in place.
Still referring to Fig. 5, o-rings 206 slidably seal the poppet body 172 against the poppet housing 178 and poppet nut 180. The o-rings 206 and back up rings 204 prevent metal to metal contact during movement of the poppet body 172 and also act as pivots and guides to allow slight eccentricity between the poppet body 172 and poppet nut 180.
With the drive piston 212 at its rear most position (i.e., with the injector 20 in the "ready" condition), a ring-shaped plenum 202 is formed between the poppet housing 178 and the drive piston 212 , or the o-ring 21~
which slidably seals the drive piston 212 within the upper housing 42. The plenum 202 is just wide enough to insure compression on the face seal 195. During actuation, the entire back surface of the drive piston 212 is acted upon by compressed gas. A backup ring 218 is provided adjacent °
" WO 94/02188 ~ ~ O ~ PCT/US93/06940 to the drive piston seal 214 which is preferably a low friction U-seal.
Turning to Fig. 4, a clamp piston 210 is slidably positioned within the drive piston 212 and slidably seals 5 against the drive piston 212 with a clamp piston o-ring 222. The back surface of the clamp piston 210 and the front vertical wall of the drive piston 212 form a clamp piston plenum 216 (Fig. 3).
An o-ring joggle 220 adjacent the back end of the l0 drive piston 212 acts as a stop for the clamp piston o-ring 222. A clamp piston spring 229 within the clamp piston 210 biases forward a jaw plate 228 butting against two opposing flange walls 229 (shown in phantom in Fig. 4) extending from a jaw retainer nut 242, allowing just 15 enough clearance for the jaws to move freely. The force of the clamp piston spring 224 is accordingly transferred from the plate 228 to the flange walls 229 to the jaw retainer nut 242 and bypasses the clamp jaws 236. The clamp jaws 236 are biased outwardly or apart and away from each other by a pair of spaced apart jaw springs 238. The clamp jaws 236 have fine teeth 240. Each clamp jaw 236 has a planar ramp surface 234 flatly engaged by a corre-sponding planar ramp drive surface 232 on the forward end of the clamp piston 210. The jaw retainer nut 242 is -25 threaded into the front end of the drive piston 212.
A return spring 244 is compressed in between the jaw retainer nut 242 and a pressure plate 248. A forward nut WO 94/0218 ~ ~ PCT/US93/06940 ~1 ~0 246 threaded into the forward end of the upper housing 42 supports the pressure plate 248.
An indicator ring 250, as shown in Figs. 13 and 14, is rotatably positioned in between the front end of the upper housing 42 and a front collar 252 threaded onto the front end of the upper housing 42. The indicator ring 250 has colored sections on its outside edge visible through view ports 256 in the front collar 252, when the indicator ring 25o is turned to a ready to actuate position signifying that the ampule lugs are fully engaged with the injector lugs. A detent pin 288 biased against the back surface of the indicator ring 250 holds the indicator ring in either the ampule loading/unloading position or the ready posi-tion, and provides a positive tactile (and optionally an audible click) indication that the ampule is correctly and fully installed. Referring to Fig. 13a, the detent pin 288 slides in or slides against a track 324 cut into the back of the indicator ring.
The return spring 244 biases the pressure plate 248 forward, to clamp an ampule behind the lugs 254 on the front collar 252, and it also acts to return the drive piston after an injection.
The indicator ring 250 has three equally spaced apart turning lugs 258 extending inwardly, for engaging the lugs 382 at the back of an ampule 360 (Fig. 10). The front collar 252 has three equally spaced apart retaining lugs 254 extending radially inwardly, for engaging the front surfaces of the ampule lugs 382, to hold the ampule into the injector 20.
Referring to Figs. 2 and 4, an actuator link 262 has a forward hook 264 in front of the indicator ring 250. A
rear hook 260 on the actuator link 262 is attached to an actuator slide block 266 slidably mounted in between the upper housing a2 and lower housing 4~. A slide block spring 268 pushing off of the lower housing 44 forwardly biases the actuator slide block 266. The forward surface of the actuator slide block 266 forms the trigger 30.
Referring to Figs. 2 and 6, an exhaust valve fork 270 extends laterally and upwardly from the actuator slide block 266 to engage a collar on a spool valve 286. The slide block 266 has a rounded back end 272 facing an initiator valve cam 274 pivotally attached to a holder with a roll pivot pin 278. Together they are held in a cavity in the upper housing by the upper surface of the lower housing. A gap 280 separates the rounded slide block end 272 and the initiator valve cam 274 (Fig. 3).
A set screw 276 threaded into the initiator valve cam 274 engages an initiator pin in the initiator valve i44.
As shown in Fig. 6, an orifice 282 in the upper housing 42 connects to a drive plenum exhaust bore 284 to continuously vent or bleed the drive plenum 202 to ambient pressure. The orifice has an approximately 0.10 mm diameter opening. The spool valve 286 attached to the exhaust valve fork 27o is slidably positioned within a spool housing 294 secured within an exhaust passage 296 in d the upper housing 42. The spool valve 286 fits within a spool bore 302 in the spool housing 294 with a very close tolerance. While the spool valve 286 does not absolutely seal against the spool bore 302, leakage between them is very low.
A reservoir exhaust bore 290 links the reservoir 168 to a spool valve plenum 300 around the spool valve 286.
A spool valve hole 301 leads from the spool valve plenum 300 to an exhaust duct 309 behind the spool valve 286. O-l0 rings 292 are positioned on either side of the spool valve plenum 300 to seal the stationary spool valve housing 294 around the reservoir exhaust bore 290. Muffler seals 306 seal the forward end of the spool valve housing 296 against a muffler tube 308 filled with fiberglass wool 310 or other acoustic material and leading to an exhaust port 316 open to ambient pressure. A muffler retainer 312 and set screw 314 secure the spool valve housing 296, muffler seals 306 and muffler tube 308 within the exhaust passage 296.
The initiator valve 164, as shown in more detail in Fig. 7, has an initiator valve pin 330 extending from a pin socket 332. A socket spring 334 overlying the pin socket 332 biases the initiator valve pin 330 outwardly or downwardly into engagement with the set screw 276 in the initiator valve cam 274. A valve stem 336 spaced slightly apart from the pin socket 332 has a stem collar 342 with a rubber seat ring 340 sealably engaging a seat neck 350, within an upper chamber 344 of the initiator valve 14 q .
~-- WO 94/02188 - ~ ~ ~ ~ ~ ~ ~ PCT/US93/06940 A stem collar spring 346 positioned in between a valve nut - 348 and the stem collar 342 biases the seat ring 340 into engagement with the seat nut 350 to maintain the valve i44 in a closed position. The seat nut 350 is supported by, or part of a valve seat 352 sealed within the initiator valve chamber i46 by an o-ring 338.
As shown in Fig. 6a, in an alternate preferred design, the housing is a single piece housing 303, rather than the two-piece housing shown in Fig. 2.
An alternative preferred design to the exhaust valve shown in Fig. 6 is illustrated in Fig. 6b wherein a valve stem 29i slides inside of a front seal 293 and a rear seal 295. A seal spacer 297 separates the front seal 293 and the rear seal 295. The rear end of the valve stem 291 has two narrow slots 305 which provide a channel for flow of gas when the valve is opened, while giving support to the pressurized rear seal 295 to prevent it from collapsing inwardly. The slots 305 form a gradual angle with the rear seal 295 to prevent it from catching on an abrupt edge which could damage the seal. When actuated, the valve stem 291 is pushed forward and the front edge of the valve slots 305 moves forward to the forward edge of the rear seal 295. This allows pressurized exhaust gas to flow from an inlet port 307, through the seal spacer 297, out of the valve slots 305, through a muffler 309 and into an outlet port iii. The front and rear seals 293 and 295 are both u-cup type seals to provide for low friction.
The exhaust valve is virtually gas tight and requires very i . v little force for actuation. The only significant force that is translated to the valve stem is after opening, the stem is forced to open further which assists in returning the actuator of the injector.
5 Fig. 6c shows a piston plenum shut-off valve 321 used in the housing 303, as an alternative to the continuously venting orifice 282 and drive plenum exhaust bore 284 shown in Fig. 6. Shut-off valve 321 includes a piston 323 which has a filter 325, an orifice 327 and a seal 329.
The upper housing 42 and lower housing ~~ together are sized and shaped to readily fit the user's hand, with the user's palm resting over the top surface 26 and side of the injector 20, and with the user's index finger easily positionable over the trigger 30. The top surface 26 has a step or incline 34 at approximately the center of the injector 20. The upper and lower housings may alterna-tively be formed as a single housing.
Turning to Fig. 3, the lower housing 44 is substan tially hollow and defines a lower housing space 48.
Similarly, the upper housing 42 defines an upper housing space ~6 (Fig. 6). Within the lower housing 44 is a cartridge chamber 50 for receiving and holding a com pressed gas cartridge 54, e.g., a C02 cartridge. A
cartridge seat 52 at the forward end of the cartridge chamber 50 supports the back of the cartridge 54. A
generally u-shaped plastic cartridge chamber cover 56 snaps into place on the lower housing 44 over the car-tridge chamber 50.
A generally cylindrical piercing housing 58 is slida-bly positioned behind the cartridge chamber 50 within the lower housing 44. O-rings 60 seal the piercing housing 58 against the lower housing 44 while allowing the piercing housing 58 to slide within the lower housing 44. An annulus 62 extends around the circumference of the pierc-ing housing 58 in between the o-rings 60. A cylindrical piercing body 66 is positioned within the piercing housing 58 and sealed against the piercing housing 58 by o-rings WO 94/02188 ~ ~ ~ ~ 7 ~ PCT/US93/06940 88. A piercing point 68 extends forward from the front surface of the piercing body 66 and is centrally aligned with the neck of the cartridge 51. A seal 64 on the front end of the piercing body 66 surrounds the piercing point 68. The seal 64 extends sufficiently forward to seal against the neck of the--cartridge 54 before the piercing point 68 penetrates into the cartridge 54.
A bore 70 extends through the piercing point 68 and piercing body 66 connecting to the annulus 62. A piercing body nut 74 threads into the back end of the piercing housing 58, to secure the piercing body 66 and seal 64 in position within and against the forward end of the pierc-ing housing 58. A piercing housing nut 76 threads into the back of the lower housing 44. Spanner tool openings are provided in the piercing body nut 74 and the piercing housing nut 76 for assembly purposes.
A threaded shaft 72 extends through and engages threads in the piercing housing nut 76. A knob 78 at-tached to the threaded shaft 72 has a flip handle 80 which can be flipped up perpendicular to the plane of the knob 78 to allow the knob 78 and threaded shaft 72 to be more easily turned by hand. The forward end of the threaded shaft 72 bears against the back surface of the piercing body 66.
A hole 92 extends through the upper surface 82 of the lower housing to connect the annulus 62 to a bore 96 leading into the upper housing space 46. An o-ring 94 seals the connection of the hole 92 and bore 96.
14o~~t~
At the back end of the upper housing 42 is a transpar-ent window lens 98 secured to an end nut 108 by a rubber window retainer i00. A Bourdon tube 116 is soldered into a gauge base 114 and has an open end 124 extending into a gauge chamber 122. The pointer 102,.extends perpendicular-ly from the back end of the Bourdon,tube ii6. As shown in Fig. 8, a gauge label 104 apg~ ied to the back end of a gauge body 106 around the Bourdon tube 116 provides a calibrated pressure scale with the scale and pointer visible through the lens 98. Stop pins extending from the back end of the gauge body 106 provide high and low pressure end point stops for the pointer 102.
The end nut 108 has threads 110 at its forward end which engage the upper housing 42. To calibrate the gauge for a given pressure, the gauge body 106 is rotated relative to the gauge base 114. When the correct index is achieved, the gauge body 106 and gauge base 114 are adhered together. A guiding pin 112 extends from the upper housing 42 into a keyway groove and holds the gauge body 106 in place while the end nut 108 is tightened.
Shims 118 are provided at the front surface at the gauge base 114, as required, for proper stack up and positioning of components in the upper housing 42.
An initiator valve housing 142 is spaced apart from the gauge base 114 by a filter retainer ring 120. A
sandwiched assembly of filter disks 130 and synthetic filters 132 are contained within the back end of the housing 142. O-rings 140 seal the filter disks 130 WO 94/02188 21 ~ ~ ~ ~ PCT/US93/06940 against the retainer i40 and synthetic filter 132. O-ring 126 seals the filter retainer 140 within the upper housing 42. O-ring 126 and o-ring 150 seal the gauge chamber 122 such that compressed gas provided through the bore 96 can flow out of the gauge chamber 122 only through the fil-ters.
A port 148 extends t3irough the back wall of the initiator valve housing 142 into an initiator valve chamber 146 within the housing 142. An initiator valve 144 within the initiator valve chamber 146 controls gas flow from the port 148 through the initiator valve chamber 146 to a reservoir port 154 formed through the forward wall of the initiator valve housing 142.
A regulation valve 156 includes a regulation seat 158 formed around the reservoir port 154. A dart 160 moves into and out of the regulation seat 158. The dart 160 has a threaded dart shaft 162 threaded into the narrower tube section at the back end of a poppet body 172. A dart pin 164 extending through the tube section of the poppet body 172 and the threaded dart shaft 162 secures the adjustment of the longitudinal position of the dart 160 in relation to the regulation seat 158. A reservoir spacer 166 within . the upper housing 42 extends from the forward end of the initiator valve housing 142 to a poppet housing 178, forming a reservoir 168 around the tube section of the poppet body 172. O-rings 126 seal the reservoir spacer 166 against the upper housing 42 and seal the initiator valve housing 142 to the reservoir spacer 166.
A poppet valve 170 within the poppet housing 178 has a conical plastic poppet seat 188 centered within and positioned against a forward wall of the poppet housing 178. Referring to Fig. 5, the poppet body 172 has a sharp sealing edge 200 biased against thew.poppet seat 188 by a compression spring 186 held in position within the poppet housing 178 by a poppet nut 180. Alternatively, the sealing edge 200 and poppet seat 188 may be configured with unlike angles selected so that the inner diameter contacts first, to minimize creep effects. The poppet nut 180 has a threaded forward section 184 engaged to a threaded rear section i82 of the poppet housing 178. The poppet nut 180 is turned to adjust the compression on the spring 186 and correspondingly set the cracking pressure of the poppet valve 170.
The diameter of the poppet seat 188 exposed to reser-voir pressure prior to crack (thus that which governs cracking pressure) remains constant although the conical seat may creep, as the sealing surface, facing reservoir pressure, is parallel to the axis of poppet movement.
The conical seat is attached to the poppet housing 178 rather than the poppet body 172 while all hard (poppet) parts are made concentric and perpendicular. Thus, irregularities in the seat 188 or soft part will creep to conform to hard parts. The hard parts are free to rotate but will still conform to the existing soft part deforma-tion.
,...
WO 94/02188 - ~ ~ ~ ~ PCT/US93/06940 Sliding friction of the poppet body 172 is advanta-geously minimized and consistent. Hence, the seal 206 used with the back up ring 204 may be a low friction seal.
In addition, since this seal is pressurized only after cracking due to the poppet body being pressurized inter-nally before cracking, seal friction is greatly minimized.
The poppet body begins to move during opening before this seal is pressurized. Thus, breakway friction is not increased by gas pressure.
By appropriate selection of the poppet sealing diame-ters (i.e., the tube section o.d., poppet housing i.d. and conical seal contact diameter) and spring force, the poppet and regulation valves together can act as a low pressure regulator.
A cannula 176 is attached to and extends back from a drive piston 212 in front of the poppet valve 170 through the poppet housing 178 and poppet seat i88 and into the back section of the poppet body 172. Poppet body supply holes 174 extend through the poppet body 172 (Fig. 3). A
cannula exhaust hole is provided through the cannula 176 at a position just slightly behind the o-ring 207 which slidably seals the cannula 176.
Referring still to Fig. 5, radially spaced apart drive bores 194 extend through the poppet housing 178 and connect a poppet annulus 198 to the front surface of the poppet housing 178. The poppet annulus 198, a ring-shaped space, is formed by the inside walls of the poppet housing 178, the front surface of the poppet 172 and the conical surface of the poppet seat 188. The front ends of the drive bores 194 are sealed by a preferably rubber disk drive bore seal 196 adhered to. the back surface of the drive piston 212.
A joggle 192 in the poppet housing 178, which engages a corresponding lip within the upper housing 42, acts as a stop for the poppet housing 178. The reservoir spacer 166, initiator valve housing 142, filter ring, shims and the gauge body 106 are then subsequently installed within the upper housing 42 and stack up against the poppet housing 178, with the end nut 108 clamping these compo-nents in place.
Still referring to Fig. 5, o-rings 206 slidably seal the poppet body 172 against the poppet housing 178 and poppet nut 180. The o-rings 206 and back up rings 204 prevent metal to metal contact during movement of the poppet body 172 and also act as pivots and guides to allow slight eccentricity between the poppet body 172 and poppet nut 180.
With the drive piston 212 at its rear most position (i.e., with the injector 20 in the "ready" condition), a ring-shaped plenum 202 is formed between the poppet housing 178 and the drive piston 212 , or the o-ring 21~
which slidably seals the drive piston 212 within the upper housing 42. The plenum 202 is just wide enough to insure compression on the face seal 195. During actuation, the entire back surface of the drive piston 212 is acted upon by compressed gas. A backup ring 218 is provided adjacent °
" WO 94/02188 ~ ~ O ~ PCT/US93/06940 to the drive piston seal 214 which is preferably a low friction U-seal.
Turning to Fig. 4, a clamp piston 210 is slidably positioned within the drive piston 212 and slidably seals 5 against the drive piston 212 with a clamp piston o-ring 222. The back surface of the clamp piston 210 and the front vertical wall of the drive piston 212 form a clamp piston plenum 216 (Fig. 3).
An o-ring joggle 220 adjacent the back end of the l0 drive piston 212 acts as a stop for the clamp piston o-ring 222. A clamp piston spring 229 within the clamp piston 210 biases forward a jaw plate 228 butting against two opposing flange walls 229 (shown in phantom in Fig. 4) extending from a jaw retainer nut 242, allowing just 15 enough clearance for the jaws to move freely. The force of the clamp piston spring 224 is accordingly transferred from the plate 228 to the flange walls 229 to the jaw retainer nut 242 and bypasses the clamp jaws 236. The clamp jaws 236 are biased outwardly or apart and away from each other by a pair of spaced apart jaw springs 238. The clamp jaws 236 have fine teeth 240. Each clamp jaw 236 has a planar ramp surface 234 flatly engaged by a corre-sponding planar ramp drive surface 232 on the forward end of the clamp piston 210. The jaw retainer nut 242 is -25 threaded into the front end of the drive piston 212.
A return spring 244 is compressed in between the jaw retainer nut 242 and a pressure plate 248. A forward nut WO 94/0218 ~ ~ PCT/US93/06940 ~1 ~0 246 threaded into the forward end of the upper housing 42 supports the pressure plate 248.
An indicator ring 250, as shown in Figs. 13 and 14, is rotatably positioned in between the front end of the upper housing 42 and a front collar 252 threaded onto the front end of the upper housing 42. The indicator ring 250 has colored sections on its outside edge visible through view ports 256 in the front collar 252, when the indicator ring 25o is turned to a ready to actuate position signifying that the ampule lugs are fully engaged with the injector lugs. A detent pin 288 biased against the back surface of the indicator ring 250 holds the indicator ring in either the ampule loading/unloading position or the ready posi-tion, and provides a positive tactile (and optionally an audible click) indication that the ampule is correctly and fully installed. Referring to Fig. 13a, the detent pin 288 slides in or slides against a track 324 cut into the back of the indicator ring.
The return spring 244 biases the pressure plate 248 forward, to clamp an ampule behind the lugs 254 on the front collar 252, and it also acts to return the drive piston after an injection.
The indicator ring 250 has three equally spaced apart turning lugs 258 extending inwardly, for engaging the lugs 382 at the back of an ampule 360 (Fig. 10). The front collar 252 has three equally spaced apart retaining lugs 254 extending radially inwardly, for engaging the front surfaces of the ampule lugs 382, to hold the ampule into the injector 20.
Referring to Figs. 2 and 4, an actuator link 262 has a forward hook 264 in front of the indicator ring 250. A
rear hook 260 on the actuator link 262 is attached to an actuator slide block 266 slidably mounted in between the upper housing a2 and lower housing 4~. A slide block spring 268 pushing off of the lower housing 44 forwardly biases the actuator slide block 266. The forward surface of the actuator slide block 266 forms the trigger 30.
Referring to Figs. 2 and 6, an exhaust valve fork 270 extends laterally and upwardly from the actuator slide block 266 to engage a collar on a spool valve 286. The slide block 266 has a rounded back end 272 facing an initiator valve cam 274 pivotally attached to a holder with a roll pivot pin 278. Together they are held in a cavity in the upper housing by the upper surface of the lower housing. A gap 280 separates the rounded slide block end 272 and the initiator valve cam 274 (Fig. 3).
A set screw 276 threaded into the initiator valve cam 274 engages an initiator pin in the initiator valve i44.
As shown in Fig. 6, an orifice 282 in the upper housing 42 connects to a drive plenum exhaust bore 284 to continuously vent or bleed the drive plenum 202 to ambient pressure. The orifice has an approximately 0.10 mm diameter opening. The spool valve 286 attached to the exhaust valve fork 27o is slidably positioned within a spool housing 294 secured within an exhaust passage 296 in d the upper housing 42. The spool valve 286 fits within a spool bore 302 in the spool housing 294 with a very close tolerance. While the spool valve 286 does not absolutely seal against the spool bore 302, leakage between them is very low.
A reservoir exhaust bore 290 links the reservoir 168 to a spool valve plenum 300 around the spool valve 286.
A spool valve hole 301 leads from the spool valve plenum 300 to an exhaust duct 309 behind the spool valve 286. O-l0 rings 292 are positioned on either side of the spool valve plenum 300 to seal the stationary spool valve housing 294 around the reservoir exhaust bore 290. Muffler seals 306 seal the forward end of the spool valve housing 296 against a muffler tube 308 filled with fiberglass wool 310 or other acoustic material and leading to an exhaust port 316 open to ambient pressure. A muffler retainer 312 and set screw 314 secure the spool valve housing 296, muffler seals 306 and muffler tube 308 within the exhaust passage 296.
The initiator valve 164, as shown in more detail in Fig. 7, has an initiator valve pin 330 extending from a pin socket 332. A socket spring 334 overlying the pin socket 332 biases the initiator valve pin 330 outwardly or downwardly into engagement with the set screw 276 in the initiator valve cam 274. A valve stem 336 spaced slightly apart from the pin socket 332 has a stem collar 342 with a rubber seat ring 340 sealably engaging a seat neck 350, within an upper chamber 344 of the initiator valve 14 q .
~-- WO 94/02188 - ~ ~ ~ ~ ~ ~ ~ PCT/US93/06940 A stem collar spring 346 positioned in between a valve nut - 348 and the stem collar 342 biases the seat ring 340 into engagement with the seat nut 350 to maintain the valve i44 in a closed position. The seat nut 350 is supported by, or part of a valve seat 352 sealed within the initiator valve chamber i46 by an o-ring 338.
As shown in Fig. 6a, in an alternate preferred design, the housing is a single piece housing 303, rather than the two-piece housing shown in Fig. 2.
An alternative preferred design to the exhaust valve shown in Fig. 6 is illustrated in Fig. 6b wherein a valve stem 29i slides inside of a front seal 293 and a rear seal 295. A seal spacer 297 separates the front seal 293 and the rear seal 295. The rear end of the valve stem 291 has two narrow slots 305 which provide a channel for flow of gas when the valve is opened, while giving support to the pressurized rear seal 295 to prevent it from collapsing inwardly. The slots 305 form a gradual angle with the rear seal 295 to prevent it from catching on an abrupt edge which could damage the seal. When actuated, the valve stem 291 is pushed forward and the front edge of the valve slots 305 moves forward to the forward edge of the rear seal 295. This allows pressurized exhaust gas to flow from an inlet port 307, through the seal spacer 297, out of the valve slots 305, through a muffler 309 and into an outlet port iii. The front and rear seals 293 and 295 are both u-cup type seals to provide for low friction.
The exhaust valve is virtually gas tight and requires very i . v little force for actuation. The only significant force that is translated to the valve stem is after opening, the stem is forced to open further which assists in returning the actuator of the injector.
5 Fig. 6c shows a piston plenum shut-off valve 321 used in the housing 303, as an alternative to the continuously venting orifice 282 and drive plenum exhaust bore 284 shown in Fig. 6. Shut-off valve 321 includes a piston 323 which has a filter 325, an orifice 327 and a seal 329.
10 The piston 323 is biased upwardly and into an open posi-tion via a spring 331. When the main piston space is pressurized during the first millisecond of the injection event, and when the pressure builds sufficiently, the pressure drop across the orifice 327 acts against the 15 piston 323 and drives the piston 323 downwardly against a shut-off seal 333. After the piston 323 seals against the shut-off seal 333, the force keeping the piston 323 down against the seal is provided by the pressure acting on the area of the annulus created by the piston seal 329 and the 20 shut-off seal 333. The shut-off seal 333 is supported by a valve base 335 which has a vent 337 beneath the shut-off seal 333 to prevent seal escape. Passageways 339 are provided for venting gas. When the pressure acting on the valve is reduced, the piston 323 moves away from the shut-off seal 333 due to force provided by a spring 331, and gas flows freely through the filter 325, the orifice 327, and through the passages 339 in the valve base 335.
-- WO 94/02188 ~ ~ ~ ~ ~ ~ PCT/US93/06940 Figs. 7a and 7b show an alternate preferred embodiment initiator valve 145 (illustrated in the closed position).
The initiator valve 145 includes an initiator valve body 147 having an inlet 149 and an outlet 151. A valve poppet 153 is biased against ..a valve seat 155 by a spring 157 .
The valve seat 155 is preferably ethylene-propylene which resists absorption by carbon dioxide. A valve seat retainer 159 supports the valve seat 155. A valve stem 169 passes through a valve stem guide 161 and a valve stem seal 163. A valve stem spring 165 biases the valve stem into a closed position. A valve stem seal 167 slidably seals the valve stem against the valve stem guide 161.
As shown in Fig. 10, an ampule 360 has three spaced apart lugs 382 at its back end. A flare 380 leads into an ampule chamber 384 to guide a contoured end 364 of a plunger 362 to engage the ampule 360. In between the contoured end 364 and a plunger head 370 of the plunger 362 are an o-ring 366 and a split Teflon back up ring 368.
As shown in Fig. 11, the plunger shaft 372 has a cruciform cross section to provide a high moment of inertia using minimum material for the disposable plunger and ampule. A collar 374 on the plunger 362 is spaced apart from the tip of the contoured end 364 so that the collar 374 contacts the back surface 388 of the ampule 360 just before the contoured end 364 of the plunger 362 reaches the front end of the ampule 360. This prevents the contoured end 364 from colliding with the front end of the ampule 360 and overstressing the ampule or buckling i ~~ 4p~ 7 ~
the plunger shaft 372. Webs 376 extending from the plunger shaft 372 support the collar 374. Although the back section 390 of the plunger shaft 372 may have teeth or ridges 378 matching the teeth or ridges 240 on the inside surfaces of the clamp jaws 236, a smooth back section 390 is preferred to avoid variations.
In operation, the cartridge 54 is loaded into the injector 20 by removing or unsnapping the plastic car-tridge chamber cover 56, placing the cartridge 5a into the cartridge chamber 50, with the neck of the cartridge 54 facing the piercing point 68, and then replacing the cartridge chamber cover 56. The cartridge chamber cover 56 snaps into position on the lower housing 44. A wavy brass liner 32 may be provided in the cartridge chamber 50 to increase thermal conductivity between~the cartridge 54 and the injector 20.
Referring to Figs. 2 and 3, the flip handle 80 on the knob 78 is flipped outwardly so that the knob 78 can be more easily turned. The knob 78 is turned by hand causing the threaded shaft 72 to advance forwardly and drive the piercing body 66 and housing 58 towards the cartridge 54.
As the piercing body 66 approaches the neck of the car-tridge 54, the seal 64 engages and seals against a perime-ter on the flat end surface of the cartridge 54. As the user continues to turn the knob 78, the piercing point 68 engages and pierces the cartridge seal. Compressed gas from the cartridge 54 flows through the bore 70, into the annulus 62, through the hole 92 and moves through the bore 2~.~0~72 96 into the gauge chamber 122. The seal 64 prevents leakage of compressed gas into the cartridge chamber 50 which remains at ambient pressure. The cartridge seat 52 supports the cartridge 54 longitudinally against the force exerted by the seal 64 and piercing pin 68. O-rings 60, 88 and 94 prevent leakage from the passageways from the cartridge 54 to the gauge chamber 122.
As the piercing body 66 and housing 58 slide forward within the lower body to pierce the cartridge 54, the knob 78 moves forward towards the piercing housing nut 76.
With the piercing body 66 fully sealed and engaged against the cartridge 54. The piercing body 66 and housing are in a fully forward position and the back surface of the knob 78 is approximately flush with the back surface of the upper housing 42.
Compressed gas fills the gauge chamber 122, passes through the filters 130 and 132, flows through the port 148 (Fig. 3) and into the upper chamber 34,: of the initia-for valve 144 (Fig. 7). Within the initiator valve 144, the stem collar spring 346 biases the seat ring 340 on the stem collar 342 against the seat neck 350, thereby sealing the upper chamber 344 and preventing the compressed gas from moving forward.
The cartridge 54 contains a saturated propellant gas, such as Co2, in both liquid and gas states, at temperatures near room temperature. The filters 130 and 132 substan-tially prevent any liquid from the cartridge 54 from passing. This allows the device to be used in any orien-tation without affecting injection characteristics.
Without the filters, liquid C02 could pass into the initiator valve 144 and reservoir 168 and flash into gas during actuation of the injector-2D, causing unpredictable injection characteristics.
As compressed gas fills the gauge chamber 122, the Bourdon tube 116 which opens into the gauge chamber 122 is also pressurized. The pressure within the Bourdon tube 116 causes it to spiral outwardly resulting in movement of the pointer 102 to indicate the gas pressure on the gauge label 104 (after the gauge body 106 and gauge base 114 have been properly calibrated). The user can then check the available gas pressure within the injector 20 by looking at the pointer 102 through the lens 98, as shown in Fig. 8.
The ampule 360, plunger 362 and a filling needle may be provided in a sterile package. The filling needle has a fitting to engage the Luer fitting 392 on the ampule.
The ampule may be filled in the same way as a conventional needle and syringe. The filling needle is inserted into a vial of injectant and the injectant is drawn up into the ampule by pulling back on the plunger. Dosage is read by the alignment of the red o-ring 364 with volume gradua-tions on the transparent ampule. The filling needle is removed and safely discarded. The ampule is then ready to be placed into the injector. Variable dosage injections are accordingly achieved by loading the ampule in the same manner as for a needle and syringe. In contrast to other _ ~~.~0772 injectors, the present injector 20 can inject various dosages without adjusting the injector. The ampule 360 may be filled to e.g., 1/3, 1/2, 3/4, etc. of its full volume capacity. Referring to Fig. 10, loading the ampule 5 360 with differing volumes of injectant will cause the plunger 362 to extend from the ampule 360 by varying amounts. However, since the injector 20 can successfully drive the plunger 362 from any plunger starting position, a single size ampule 360 can be used for various dosage 10 injections. Ampules of varying volumes are not required.
With the ampule 360 loaded with the desired dosage and the plunger 362 extending from the ampule 360, the plunger and ampule are installed into the injector 20. The lugs 382 on the ampule 360 are aligned to pass through the lugs 15 25t~ on the front collar 252. The back end of the plunger 362 is passed through the front collar 252, through the return spring 44 and through the clamp piston spring 224:.
Since the teeth or ridges 378 on the plunger 362 extend continuously in between the webs 376 and the back end of 20 the plunger, regardless of the dosage carried by the ampule 360, the teeth 240 of the clamp jaws 236 will over lie the plunger 362.
The back surface 388 of the ampule 360 comes to rest against the pressure plate 2,:8. The lugs 382 on the 25 ampule 360 fit in between the lugs 258 on the indicator ring 250. The user then turns the ampule (clockwise as viewed from the front) through an acute angle e.g., approximately 45°, from an ampule loading position to an ~.
ampule ready position. As the ampule turns, it causes the indicator ring 250 to turn with it as the sides of the ampule lugs 382 push against the sides of the indicator ring lugs 258. A step on each ampule lug prevents the indicator ring and ampule from being turned beyond range.
In addition, as shown in Fig. 13a, the track on which the detent pin 288 acts is deep enough that the detent cannot be forced out of the track. The two ends of the track act as detent stops. As the indicator ring 250 turns and locks into an injection ready position (Fig. 2a), the colored or painted sections on the outside perimeter of the indicator ring 250 moves into view through the view ports 256. This indicates to the user that the ampule is properly installed in the injector 20 and ready for injection.
As the indicator ring 250 turns with the ampule 360 from the ampule loading position to the ready position, a cut out 320 in the indicator ring (Fig. 13) moves into alignment with the hook 264 on the actuator link 262. The trigger 30 can then be pulled back to actuate the injector 20 to provide an injection to a patient.
If the cut out 320 in the indicator ring 250 is not aligned with the hook 264, the actuator link 262 prevents the trigger 30 from moving to actuate the device. There-fore, the injector 20 cannot be actuated unless an ampule is properly installed and aligned in the ready position.
With a cartridge 54 and an ampule 36o properly installed within the injector 20, the nozzle 386 of the ampule 360 WO 94/02188 _ ~ ~ ~ ~ 7 PCT/US93/06940 is placed against the patient's skin and the trigger 30 on the actuator slide block 266 is pulled back by the user's index finger. As the slide block end 272 approaches the initiator valve cam 274, the exhaust valve fork 270 slides the spool valve 286 from -an open position (which allows the reservoir 168 to bleed or exhaust through the exhaust bore to ambient) to a closed position wherein the spool valve 286 substantially seals off the reservoir exhaust bore 290. The reservoir 168 is accordingly sealed off before the slide block end 272 engages the initiator valve cam 274. The spool valve serves as an exhaust control valve.
As the actuator slide block 266 continues to move rearwardly, the slide block end 272 pushes against the initiator valve cam 274 levering the set screw 276 against the initiator valve pin 330.
The sliding movement of the trigger performs three functions: It controls the initiator valve, it controls the spool valve, and it provides an interlock when dis-abled by the actuator link 262.
Referring to Figs. 3 and 7, as the actuator slide block 266 moves against the initiator valve cam 274, the set screw 276 pushes up on the initiator valve pin 330.
The pin socket 332 is driven up against the valve stem 336 causing the stem collar to shift upwardly and separate the seat ring 340 from the seat neck 350, thereby opening the initiator valve 144. Similarly, in the embodiment of Figs. 7a and 7b, the valve poppet spring 157 biases the WO 94/0 ~~ ~ ~ PCT/US93/06940 valve poppet 153 toward the valve seat 155. Gas pressure from the gas inlet 149 drives the poppet 153 into the valve seat 155 creating a gas tight seal. The valve seat 155 is vented on the bottom side 171 to prevent the seat from escaping from the groove 173. The valve seat retain-er 159 retains and vents the valve seal 155. The valve stem 169 is mechanically isolated from the poppet 153 to assure that the poppet closes without interference from the stem.
When the initiator valve 147 is actuated, the valve stem 169 slides up and contacts the valve poppet 153, pushing it away from the valve seat 155. Gas flows from the inlet 149 through a gap between the valve poppet and valve seat, through a side hole 175, around an annulus 177, and out through the outlet 151. When the valve stem is released, the valve stem spring 165 returns the valve stem to the neutral position and the valve poppet 153 also returns to the closed position.
Referring once again to Figs. 3 and 7, with the initiator valve 144 opened, compressed gas flows from the cartridge 54 through the filters and initiator valve 144, through the reservoir port 154 past the dart 160 and into the reservoir 168. Referring to Figs. 3 and 5, as the reservoir 168 fills with compressed gas, gas pressure also builds within the poppet chamber 208, as gas flows from the reservoir 168 through the poppet body supply holes 174.
- WO 94/02188 2 ~. 4 0 7 7 2 PCT/US93/06940 Since the cannula 176 is opened to the reservoir 168, compressed gas flows from the reservoir 168 through the cannula 176 into the clamp piston plenum 216.
Referring to Figs. 2b and 4, as pressure builds within the clamp piston plenum 216, the clamp piston 210 is driven forward compressing the clamp piston spring 224 and driving the clamp jaws 236 together, through the interac-tion of the ramp drive 232 on the clamp piston 210 and the clamp piston ramps 234 on the clamp jaws 236. The teeth 240 on the clamp jaws 236 clamp down and around the plunger 362.
The clamp jaws 236 and their driving mechanism perform two functions: They grab onto the plunger at whatever position the plunger is in, and they transfer driving force from the drive piston to the plunger.
If the ampule 360 is loaded with a maximum volume, the plunger 362 will be fully extended to the rear such that the clamp jaws 236 will engage the plunger 362 close behind the webs 376. On the other hand, if the ampule 360 is loaded with a minimal dosage, the plunger 362 will extend a shorter distance behind the ampule 360 and the clamp jaws 236 will engage the plunger 362 towards the back end of the plunger. However, regardless of the volume of the injectant in the ampule, the clamp jaws 236 securely clamp and engage the plunger 362 with the teeth 240 on the clamp jaws 236 locked into the teeth 378 on the plunger 362. The gas pressure in the clamp piston plenum 216 maintains the engagement of the clamp jaws 236 to the plunger 362 during the injection sequence. As represented in Fig. 12, the clamp jaws clamp onto the plunger before the poppet valve opens.
Referring to Figs. 3, 4 and 5, pressure in the poppet 5 chamber 208 continues to build until it is sufficient to crack the poppet valve 170 open. Specifically, the poppet spring chamber 226 is sealed from the reservoir 168 and the poppet chamber 208 and is vented to ambient pressure.
As pressure increases within the poppet chamber 208, the 10 rearward acting force resulting from the gas pressure acting on the incline surfaces 152 of the poppet body 172 will exceed the forward acting force of the poppet spring 186. When this "cracking point" is reached, the poppet valve 170 snaps open. The poppet body 172 shifts or 15 slides rearwardly. The sealing edge surface 200 separates from its sealing engagement against the conical poppet seat 188 allowing gas from the reservoir 168 to flow through the poppet chamber 208 to the drive bores 194. As the poppet valve 170 begins to open and the poppet body 20 172 moves away from the conical poppet seal 188, the annular front surface 230 of the poppet body 172 is acted on by gas pressure now in the poppet annulus 198. Since the surface areas acted on by the compressed gas are vastly increased with the addition of the front surface 25 230 of the poppet body, the force acting on the poppet body 172 rapidly escalates. The poppet valve 170 there-fore opens with an "over-center" or hard-over action.
When the poppet valve 170 opens and the poppet body 172 shifts rearwardly, the regulation valve 156 closes down via the dart 160 engaging and sealing against the regula-tion seat 158. Thus, additional gas supply to the reser-voir 168 is, at least initially, restricted by the regula-tion valve 156, with substantially only the reservoir 168 then acting as a source of compressed gas.
To maintain at least the minimum pressure on the drive piston throughout the injection, pressure regulation of the reservoir is provided through poppet area ratios and spring forces (which may be readily determined for various capacity injectors by those skilled in the art). During injection of larger dosages, the reservoir pressure reaches a desired minimum pressure. Up to this time, the drive piston plenum has been supplied by a fixed supply of gas from the reservoir. At this point, the spring force, acting forwardly on the poppet body, overcomes the net pressure force, acting rearwardly on the poppet body. As the reservoir pressure drops below this value, the poppet body moves forward, lessening the regulation valve re-striction to incoming flow. Specifically, the dart 160 moves with the poppet body away from the seat 158 to allow commencement or increase of gas flow. Thus, the opening of the regulator valve consequently increases gas flow into the reservoir and increases the reservoir pressure.
As gas pressure then increases above the desired minimum value, the poppet body again moves rearwardly to restrict the incoming flow. Thus the poppet valve and regulator valve act together as a reservoir pressure regulator (and y*
consequently drive piston plenum pressure and ampule pressure). Referring to Fig. 12, regulation movement, when present, occurs generally during the last half of the injection.
The C02 cartridge is filled with saturated CO2. Thus the source pressure is highly dependent on temperature.
The peak ampule pressure is determined by the poppet valve cracking pressure which is independent of source pressure.
The minimum delivery pressure, governed by the pressure regulation is also independent of source pressure. Both of these features are controlled by area ratios and spring rates. Thus the injector is substantially temperature independent.
Fig. 12 illustrates the effect of pressure regulation.
With a smaller dosage of e.g., 1/2 ml or~less, generally there is no pressure regulation. With larger dosages of e.g., over 3/4 ml, pressure regulation occurs. With intermediate range dosages of e.g., between 1/2 and 3/4 ml, some pressure regulation may occur.
The rubber or elastomeric face seal 196 adhered to the back of the drive piston 212 assists to rapidly open the poppet valve 170. The face seal 196 encourages the build up of pressure in the drive bores 194 and poppet annulus 198 before pressurizing the drive plenum 202. According-ly, the rapid pressure increase within the drive bores 194 and poppet annulus 198 shorten the time required for opening the poppet valve 170 providing a quick ampule pressure rise time and a more uniform ampule peak pres-sure. The poppet body supply holes i7~ have a large diameter to minimize pressure drop from the reservoir 168 to the poppet chamber 208.
With the poppet valve 170 open, gas flows through the poppet annulus 198 and drive bores i94 into the drive plenum 202. The gas pressure in the drive plenum 202 acting on the relatively large surface area of the entire back surface of the drive piston 212 generates a large force on the drive piston 212 in the forward direction.
The drive piston 212 accelerates forward with the clamp piston 210 driving the plunger 362 into the ampule 360.
The injectant dose within the ampule chamber 38~ is sprayed out of the ampule nozzle 386 in a high velocity jet which penetrates through the patient's skin. Fig. 2c shows the position of the plunger 362 and piston 212 after injection.
If the trigger 30 is held back for longer than neces-sary for the injection, only a small amount of gas is wasted since all spaces within the injector, except the drive plenum, remain virtually sealed while the trigger is held back. The drive plenum is opened to ambient pres-sure, but only through orifice 282 which severely re-stricts flow. The regulation valve i56 restricts flow while the trigger is held back.
After the injection, the trigger is released. The slide block spring 268 assisted by exhaust gas pressure returns the slide block 266 to its forward position. The initiator valve then closes. Then the exhaust valve fork 1 y.
2140'72 270 moving with the slide block 266 pulls the spool valve 286 forward reconnecting the spool valve bore 302 and spool plenum 300 to the reservoir exhaust bore 290. The spool valve and exhaust passage allow the injector to be quickly and quietly reset for another injection. Gas in the reservoir exhausts out through the reservoir exhaust bore 290 and exhaust passage 296. As this occurs, the exhaust gas pressure in the exhaust passage 296 pushes on the back of the spool valve 286 and helps to return the spool valve and slide block forward to their original ready positions. The slide block spring 268 consequently need only exert a slight force, thereby helping to reduce the finger force necessary to pull the trigger 30.
Immediately after the injection, the drive piston 212 is in the forward position (Fig. 2c), with the plunger shoulder in contact with and exerting a large force on the back end 388 of the ampule 360. The drive piston return spring 244, clamp piston spring 224 and jaw springs 238 are compressed. The jaws 236 are engaged with the plunger and the clamp piston 210 is forward. Each part must then return to the ready position.
Upon release of the trigger 30, the reservoir 168 is able to rapidly vent to atmosphere. Drive piston plenum gas vents into the reservoir, in part, through the poppet body, until the poppet valve closes. Gas also vents into the reservoir through the cannula 176, until the holes in the cannula are sealed by the o-ring 190 contained within the poppet seat 188. This remaining gas, which occupies 2.~~07~2 ~- WO 94/02188 PCT/US93/06940 a relatively small volume, and is at a very low pressure, vents through the bleed orifice 282 connecting the drive piston plenum directly to the atmosphere through the drive plenum exhaust bore 284. Since the orifice 282 is always 5 open, even during the injection, some beneficial drive gas is lost, thus it is a very small, restrictive orifice.
Because the orifice 282 is small, if it was the only vent for drive piston plenum gas (i.e., if there were no cannula side holes), venting and reset time would be 10 unacceptably long.
During venting, the following reset sequence occurs and is controlled by component areas and spring forces, which may be readily determined by those skilled in the art. First, the clamp jaws 236 and clamp piston 2i0 15 release. This must occur before the drive piston is released so that the plunger is not pulled back. The clamp piston spring force overcomes the opposing pressure force. This release occurs when the drive piston 212 is close to a force equilibrium condition. The pressure 20 force must be close to the opposing spring force. If not, then the drive piston 212 will rapidly return (if the spring force is larger) or plunge forward (if pressure force is larger) causing noise and possible damage to the injector. Thus a force balance is established at the 25 point of plunger release, regardless of the dosage.
After the plunger release, the drive piston 2i2 returns as the reservoir bleeds. The drive piston 212 is forced rearward by the drive piston return spring against .
01~
_ 36 the opposing pressure force. Gas exhaust and reset occurs quietly and quickly.
O-ring 222 serves as a seal and a bumper to quiet the clamp piston return.
During the injection, the plunger 362 is driven forward until the collar 374 contacts the back surface 388 of the ampule 360. Accordingly, if the trigger 30 is squeezed once and an injection given, released and squeezed again after some delay (i.e., "second fire") without replacing the ampule, the jaws will grab the plunger with the plunger collar in the forward most position, i.e., in contact with the rear ampule face.
Thus no forward movement of the drive piston will occur.
A second fire does not damage the ampule, plunger or injector.
The cannula 176 is attached to and moves with the drive piston 212. The cannula exhaust hole 190 in the cannula 176 speeds the return stroke of the piston 212.
The poppet valve closes before the drive piston begins its return. Thus a bleed hole in the cannula is required for gas to flow from the drive piston plenum to the reservoir.
During the return stroke, up until the time the cannula exhaust hole 190 passes behind the o-ring 206, gas in the drive plenum 202 flows through the cannula exhaust hole 190 through the cannula 176, back into the reservoir 168 and out through the relatively unobstructed exhaust system of the reservoir exhaust bore 290 and the exhaust passage 296. After the cannula exhaust hole 19o passes behind the ~i~o~~~
o-ring 206, the gas remaining in the now very small volume drive plenum 202, which is a very low pressure, is ex-hausted through the orifice 282 and drive plenum exhaust bore 28~ to ambient. Gas in the clamp piston plenum 216 similarly exhausts through the cannula 176 through the reservoir 168 and out through the reservoir exhaust bore 290 and the exhaust passage 296.
The spent ampule and plunger are turned and removed from the injector 20 which is then prepared for the next injection sequence.
The ampule and plunger are preferably a single use dispos-able unit.
As shown in Figs. 10a and 10b, the plunger may have tapered sections at the front or back which engage a generally cpmplimentary tapered section in the ampule.
During an injection, the injector exerts hundreds of pounds of force on the plunger which drives the tapered section of the plunger of Figs. l0a and lOb into an interference fit with the tapered section of the ampule.
The used and non sterile plunger and ampule cannot easily then be re-used. The tapered sections can also act as a plunger stop, in place of the collar on the plunger of Fig. 10. The taper on the plunger and ampule are slightly mismatched and lock together only with high forces (at the end of an injection) and not at low forces (during filling of the ampule). Fig. lOc shows another non-reusable ampule and plunger having a detent. The detent is dimens-Toned so that only a large force will cause engagement.
WO 94/02188 ~ ~ PCT/US93/06940 The injector can be modified to give multiple sequen-tial injections to the same patient. As shown in Figs. 4a and 4b, a drive piston stop 394 is added; and acts to stop the drive piston, as the plunger shoulder does in variable delivery. When the injector actuates, a small dose is delivered. The jaws then disengage and the injector resets. The plunger will automatically be in a "ready"
position for the next shot, and the injector may be fired again to deliver the same small dosage. This sequence may be repeated to deliver several small dosage injections until the plunger shoulder contacts the ampule. Dosage may be adjusted by rotating the outer ring 396 to the desired value, indicated by graduations 398 on the injec tor housing. A longer ampule can be provided to allow for more sequential shots.
The present method of needleless injection uses a system of an injector and compatible ampules. The injec-for is designed to apply a specific force on the plunger of the ampules. The force applied to the plunger by the injector is varied, forming a force - displacement curve.
At the beginning of the injection, the force applied to the plunger is quite high. As the plunger is advanced, the applied force is reduced substantially linearly until the volume injected reaches approximately 0.5 ml, and thereafter the force is held substantially constant. This force displacement curve is independent of the ampule nozzle size. This force - displacement curve translates directly to an ampule pressure - volume injected curve.
WO 94/02188 ~ O ~ ~ PCT/US93/06940 The injection system employs a singular pressure profile and a family of ampules with various orifice sizes to achieve various depths of penetration. Fig. 17 shows preferred uses of various diameter nozzles with the pressure profile described below.
The traditional approach to measuring pressure profile is to use a pressure - time curve. However, a pressure-volume profile is particularly useful because this pres-sure profile is nearly the same for any size nozzle. In the following discussion, both time and volume will be used as a reference.
Referring to Figs. 15 and 18-20, the preferred pres-sure profile has the following properties: First the pressure rapidly increases from 0 to a value of about 26900-29670 kPa, and preferably about 28290 kPa, (4100 psi) in less than 6 milliseconds (and preferably less than 1 ms). This quick pressure rise avoids "splash-back" and loss of injectant. This pressure range is sufficient to pierce the tissues, but not so high as to cause the excessive pain associated with higher pressures. The pressure is gradually reduced to approximately 8280 -13800 kPa, and preferably 12420 kPa, (1800 psi) in a generally linear (pressure - volume) fashion corresponding with volume discharged of 0.5 ml. In a pressure - time 2'5 framework, the curve forms an exponential decay. At this point, the pressure is held constant until the end of the injection, at which time the pressure abruptly goes to 0 (optimally in less than 5 ms.) Final pressures below 14~4'~ ~ ~
about 8280 kPa tend to result in "leak-back" of the injectant after the injection. The pressure profile is defined as the pressure immediately proximal to the nozzle. The above- described pressure profile covers an 5 injection larger than approximately 0.5 ml. If the injection is less than this amount, the pressure - profile curve is simply truncated at the end of the delivered volume.
Medication viscosity affects penetration of intramus 10 cular injections in a direction contrary to prior art.
Experimental data shows that more viscous medications, in the range of from 0.01 to 0.70 poise, have greater fascia penetrating capability, apparently because of reduced turbulence and lower Reynold s number. Thus, the present 15 invention also includes the appropriate guidelines for selection of nozzle size with viscous medications.
Viscous medications preferably use the same size orifice as for water based medications. Nearly all viscous medications are intramuscular injections. Testing shows 2o that viscous medications have more energy to penetrate the deep fascia than water based medications, but do not go substantially deeper into the muscle. Therefore, the deposition into the muscle is comparable independent of medication viscosity.
25 The present peri-fascial injection is provided by using a nozzle diameter which is smaller than that which would ordinarily be used for an intramuscular injection.
The peri-fascial injection is provided by using a SC
WO 94/02188 _ ~ ~ ~ ~ ~ ~ ~ PCT/US93/06940 nozzle (0.10 mm) at an IM injection site preferably with less than 5 mm adipose. This works well because IM sites tend to have very thin layers of adipose tissue. The SC
nozzle has sufficient penetrating energy to deposit the medication on the deep fascia when injected into a thin layer of adipose. A peri-fascial injection can.also be given at an IM injection site having a 10-15 mm adipose layer using a 0.15 mm diameter nozzle and the above-described pressure profile. As shown in Fig. 16, the injectant 800 in a peri-fascial injection bores through the skin 802 and adipose 804, but not the fascia 806.
Rather, the injectant forms a thin layer 808 over the fascia. The thin layer 808 may provide the same pharmaco-logical effect as an IM injection, without penetrating the muscle.
-- WO 94/02188 ~ ~ ~ ~ ~ ~ PCT/US93/06940 Figs. 7a and 7b show an alternate preferred embodiment initiator valve 145 (illustrated in the closed position).
The initiator valve 145 includes an initiator valve body 147 having an inlet 149 and an outlet 151. A valve poppet 153 is biased against ..a valve seat 155 by a spring 157 .
The valve seat 155 is preferably ethylene-propylene which resists absorption by carbon dioxide. A valve seat retainer 159 supports the valve seat 155. A valve stem 169 passes through a valve stem guide 161 and a valve stem seal 163. A valve stem spring 165 biases the valve stem into a closed position. A valve stem seal 167 slidably seals the valve stem against the valve stem guide 161.
As shown in Fig. 10, an ampule 360 has three spaced apart lugs 382 at its back end. A flare 380 leads into an ampule chamber 384 to guide a contoured end 364 of a plunger 362 to engage the ampule 360. In between the contoured end 364 and a plunger head 370 of the plunger 362 are an o-ring 366 and a split Teflon back up ring 368.
As shown in Fig. 11, the plunger shaft 372 has a cruciform cross section to provide a high moment of inertia using minimum material for the disposable plunger and ampule. A collar 374 on the plunger 362 is spaced apart from the tip of the contoured end 364 so that the collar 374 contacts the back surface 388 of the ampule 360 just before the contoured end 364 of the plunger 362 reaches the front end of the ampule 360. This prevents the contoured end 364 from colliding with the front end of the ampule 360 and overstressing the ampule or buckling i ~~ 4p~ 7 ~
the plunger shaft 372. Webs 376 extending from the plunger shaft 372 support the collar 374. Although the back section 390 of the plunger shaft 372 may have teeth or ridges 378 matching the teeth or ridges 240 on the inside surfaces of the clamp jaws 236, a smooth back section 390 is preferred to avoid variations.
In operation, the cartridge 54 is loaded into the injector 20 by removing or unsnapping the plastic car-tridge chamber cover 56, placing the cartridge 5a into the cartridge chamber 50, with the neck of the cartridge 54 facing the piercing point 68, and then replacing the cartridge chamber cover 56. The cartridge chamber cover 56 snaps into position on the lower housing 44. A wavy brass liner 32 may be provided in the cartridge chamber 50 to increase thermal conductivity between~the cartridge 54 and the injector 20.
Referring to Figs. 2 and 3, the flip handle 80 on the knob 78 is flipped outwardly so that the knob 78 can be more easily turned. The knob 78 is turned by hand causing the threaded shaft 72 to advance forwardly and drive the piercing body 66 and housing 58 towards the cartridge 54.
As the piercing body 66 approaches the neck of the car-tridge 54, the seal 64 engages and seals against a perime-ter on the flat end surface of the cartridge 54. As the user continues to turn the knob 78, the piercing point 68 engages and pierces the cartridge seal. Compressed gas from the cartridge 54 flows through the bore 70, into the annulus 62, through the hole 92 and moves through the bore 2~.~0~72 96 into the gauge chamber 122. The seal 64 prevents leakage of compressed gas into the cartridge chamber 50 which remains at ambient pressure. The cartridge seat 52 supports the cartridge 54 longitudinally against the force exerted by the seal 64 and piercing pin 68. O-rings 60, 88 and 94 prevent leakage from the passageways from the cartridge 54 to the gauge chamber 122.
As the piercing body 66 and housing 58 slide forward within the lower body to pierce the cartridge 54, the knob 78 moves forward towards the piercing housing nut 76.
With the piercing body 66 fully sealed and engaged against the cartridge 54. The piercing body 66 and housing are in a fully forward position and the back surface of the knob 78 is approximately flush with the back surface of the upper housing 42.
Compressed gas fills the gauge chamber 122, passes through the filters 130 and 132, flows through the port 148 (Fig. 3) and into the upper chamber 34,: of the initia-for valve 144 (Fig. 7). Within the initiator valve 144, the stem collar spring 346 biases the seat ring 340 on the stem collar 342 against the seat neck 350, thereby sealing the upper chamber 344 and preventing the compressed gas from moving forward.
The cartridge 54 contains a saturated propellant gas, such as Co2, in both liquid and gas states, at temperatures near room temperature. The filters 130 and 132 substan-tially prevent any liquid from the cartridge 54 from passing. This allows the device to be used in any orien-tation without affecting injection characteristics.
Without the filters, liquid C02 could pass into the initiator valve 144 and reservoir 168 and flash into gas during actuation of the injector-2D, causing unpredictable injection characteristics.
As compressed gas fills the gauge chamber 122, the Bourdon tube 116 which opens into the gauge chamber 122 is also pressurized. The pressure within the Bourdon tube 116 causes it to spiral outwardly resulting in movement of the pointer 102 to indicate the gas pressure on the gauge label 104 (after the gauge body 106 and gauge base 114 have been properly calibrated). The user can then check the available gas pressure within the injector 20 by looking at the pointer 102 through the lens 98, as shown in Fig. 8.
The ampule 360, plunger 362 and a filling needle may be provided in a sterile package. The filling needle has a fitting to engage the Luer fitting 392 on the ampule.
The ampule may be filled in the same way as a conventional needle and syringe. The filling needle is inserted into a vial of injectant and the injectant is drawn up into the ampule by pulling back on the plunger. Dosage is read by the alignment of the red o-ring 364 with volume gradua-tions on the transparent ampule. The filling needle is removed and safely discarded. The ampule is then ready to be placed into the injector. Variable dosage injections are accordingly achieved by loading the ampule in the same manner as for a needle and syringe. In contrast to other _ ~~.~0772 injectors, the present injector 20 can inject various dosages without adjusting the injector. The ampule 360 may be filled to e.g., 1/3, 1/2, 3/4, etc. of its full volume capacity. Referring to Fig. 10, loading the ampule 5 360 with differing volumes of injectant will cause the plunger 362 to extend from the ampule 360 by varying amounts. However, since the injector 20 can successfully drive the plunger 362 from any plunger starting position, a single size ampule 360 can be used for various dosage 10 injections. Ampules of varying volumes are not required.
With the ampule 360 loaded with the desired dosage and the plunger 362 extending from the ampule 360, the plunger and ampule are installed into the injector 20. The lugs 382 on the ampule 360 are aligned to pass through the lugs 15 25t~ on the front collar 252. The back end of the plunger 362 is passed through the front collar 252, through the return spring 44 and through the clamp piston spring 224:.
Since the teeth or ridges 378 on the plunger 362 extend continuously in between the webs 376 and the back end of 20 the plunger, regardless of the dosage carried by the ampule 360, the teeth 240 of the clamp jaws 236 will over lie the plunger 362.
The back surface 388 of the ampule 360 comes to rest against the pressure plate 2,:8. The lugs 382 on the 25 ampule 360 fit in between the lugs 258 on the indicator ring 250. The user then turns the ampule (clockwise as viewed from the front) through an acute angle e.g., approximately 45°, from an ampule loading position to an ~.
ampule ready position. As the ampule turns, it causes the indicator ring 250 to turn with it as the sides of the ampule lugs 382 push against the sides of the indicator ring lugs 258. A step on each ampule lug prevents the indicator ring and ampule from being turned beyond range.
In addition, as shown in Fig. 13a, the track on which the detent pin 288 acts is deep enough that the detent cannot be forced out of the track. The two ends of the track act as detent stops. As the indicator ring 250 turns and locks into an injection ready position (Fig. 2a), the colored or painted sections on the outside perimeter of the indicator ring 250 moves into view through the view ports 256. This indicates to the user that the ampule is properly installed in the injector 20 and ready for injection.
As the indicator ring 250 turns with the ampule 360 from the ampule loading position to the ready position, a cut out 320 in the indicator ring (Fig. 13) moves into alignment with the hook 264 on the actuator link 262. The trigger 30 can then be pulled back to actuate the injector 20 to provide an injection to a patient.
If the cut out 320 in the indicator ring 250 is not aligned with the hook 264, the actuator link 262 prevents the trigger 30 from moving to actuate the device. There-fore, the injector 20 cannot be actuated unless an ampule is properly installed and aligned in the ready position.
With a cartridge 54 and an ampule 36o properly installed within the injector 20, the nozzle 386 of the ampule 360 WO 94/02188 _ ~ ~ ~ ~ 7 PCT/US93/06940 is placed against the patient's skin and the trigger 30 on the actuator slide block 266 is pulled back by the user's index finger. As the slide block end 272 approaches the initiator valve cam 274, the exhaust valve fork 270 slides the spool valve 286 from -an open position (which allows the reservoir 168 to bleed or exhaust through the exhaust bore to ambient) to a closed position wherein the spool valve 286 substantially seals off the reservoir exhaust bore 290. The reservoir 168 is accordingly sealed off before the slide block end 272 engages the initiator valve cam 274. The spool valve serves as an exhaust control valve.
As the actuator slide block 266 continues to move rearwardly, the slide block end 272 pushes against the initiator valve cam 274 levering the set screw 276 against the initiator valve pin 330.
The sliding movement of the trigger performs three functions: It controls the initiator valve, it controls the spool valve, and it provides an interlock when dis-abled by the actuator link 262.
Referring to Figs. 3 and 7, as the actuator slide block 266 moves against the initiator valve cam 274, the set screw 276 pushes up on the initiator valve pin 330.
The pin socket 332 is driven up against the valve stem 336 causing the stem collar to shift upwardly and separate the seat ring 340 from the seat neck 350, thereby opening the initiator valve 144. Similarly, in the embodiment of Figs. 7a and 7b, the valve poppet spring 157 biases the WO 94/0 ~~ ~ ~ PCT/US93/06940 valve poppet 153 toward the valve seat 155. Gas pressure from the gas inlet 149 drives the poppet 153 into the valve seat 155 creating a gas tight seal. The valve seat 155 is vented on the bottom side 171 to prevent the seat from escaping from the groove 173. The valve seat retain-er 159 retains and vents the valve seal 155. The valve stem 169 is mechanically isolated from the poppet 153 to assure that the poppet closes without interference from the stem.
When the initiator valve 147 is actuated, the valve stem 169 slides up and contacts the valve poppet 153, pushing it away from the valve seat 155. Gas flows from the inlet 149 through a gap between the valve poppet and valve seat, through a side hole 175, around an annulus 177, and out through the outlet 151. When the valve stem is released, the valve stem spring 165 returns the valve stem to the neutral position and the valve poppet 153 also returns to the closed position.
Referring once again to Figs. 3 and 7, with the initiator valve 144 opened, compressed gas flows from the cartridge 54 through the filters and initiator valve 144, through the reservoir port 154 past the dart 160 and into the reservoir 168. Referring to Figs. 3 and 5, as the reservoir 168 fills with compressed gas, gas pressure also builds within the poppet chamber 208, as gas flows from the reservoir 168 through the poppet body supply holes 174.
- WO 94/02188 2 ~. 4 0 7 7 2 PCT/US93/06940 Since the cannula 176 is opened to the reservoir 168, compressed gas flows from the reservoir 168 through the cannula 176 into the clamp piston plenum 216.
Referring to Figs. 2b and 4, as pressure builds within the clamp piston plenum 216, the clamp piston 210 is driven forward compressing the clamp piston spring 224 and driving the clamp jaws 236 together, through the interac-tion of the ramp drive 232 on the clamp piston 210 and the clamp piston ramps 234 on the clamp jaws 236. The teeth 240 on the clamp jaws 236 clamp down and around the plunger 362.
The clamp jaws 236 and their driving mechanism perform two functions: They grab onto the plunger at whatever position the plunger is in, and they transfer driving force from the drive piston to the plunger.
If the ampule 360 is loaded with a maximum volume, the plunger 362 will be fully extended to the rear such that the clamp jaws 236 will engage the plunger 362 close behind the webs 376. On the other hand, if the ampule 360 is loaded with a minimal dosage, the plunger 362 will extend a shorter distance behind the ampule 360 and the clamp jaws 236 will engage the plunger 362 towards the back end of the plunger. However, regardless of the volume of the injectant in the ampule, the clamp jaws 236 securely clamp and engage the plunger 362 with the teeth 240 on the clamp jaws 236 locked into the teeth 378 on the plunger 362. The gas pressure in the clamp piston plenum 216 maintains the engagement of the clamp jaws 236 to the plunger 362 during the injection sequence. As represented in Fig. 12, the clamp jaws clamp onto the plunger before the poppet valve opens.
Referring to Figs. 3, 4 and 5, pressure in the poppet 5 chamber 208 continues to build until it is sufficient to crack the poppet valve 170 open. Specifically, the poppet spring chamber 226 is sealed from the reservoir 168 and the poppet chamber 208 and is vented to ambient pressure.
As pressure increases within the poppet chamber 208, the 10 rearward acting force resulting from the gas pressure acting on the incline surfaces 152 of the poppet body 172 will exceed the forward acting force of the poppet spring 186. When this "cracking point" is reached, the poppet valve 170 snaps open. The poppet body 172 shifts or 15 slides rearwardly. The sealing edge surface 200 separates from its sealing engagement against the conical poppet seat 188 allowing gas from the reservoir 168 to flow through the poppet chamber 208 to the drive bores 194. As the poppet valve 170 begins to open and the poppet body 20 172 moves away from the conical poppet seal 188, the annular front surface 230 of the poppet body 172 is acted on by gas pressure now in the poppet annulus 198. Since the surface areas acted on by the compressed gas are vastly increased with the addition of the front surface 25 230 of the poppet body, the force acting on the poppet body 172 rapidly escalates. The poppet valve 170 there-fore opens with an "over-center" or hard-over action.
When the poppet valve 170 opens and the poppet body 172 shifts rearwardly, the regulation valve 156 closes down via the dart 160 engaging and sealing against the regula-tion seat 158. Thus, additional gas supply to the reser-voir 168 is, at least initially, restricted by the regula-tion valve 156, with substantially only the reservoir 168 then acting as a source of compressed gas.
To maintain at least the minimum pressure on the drive piston throughout the injection, pressure regulation of the reservoir is provided through poppet area ratios and spring forces (which may be readily determined for various capacity injectors by those skilled in the art). During injection of larger dosages, the reservoir pressure reaches a desired minimum pressure. Up to this time, the drive piston plenum has been supplied by a fixed supply of gas from the reservoir. At this point, the spring force, acting forwardly on the poppet body, overcomes the net pressure force, acting rearwardly on the poppet body. As the reservoir pressure drops below this value, the poppet body moves forward, lessening the regulation valve re-striction to incoming flow. Specifically, the dart 160 moves with the poppet body away from the seat 158 to allow commencement or increase of gas flow. Thus, the opening of the regulator valve consequently increases gas flow into the reservoir and increases the reservoir pressure.
As gas pressure then increases above the desired minimum value, the poppet body again moves rearwardly to restrict the incoming flow. Thus the poppet valve and regulator valve act together as a reservoir pressure regulator (and y*
consequently drive piston plenum pressure and ampule pressure). Referring to Fig. 12, regulation movement, when present, occurs generally during the last half of the injection.
The C02 cartridge is filled with saturated CO2. Thus the source pressure is highly dependent on temperature.
The peak ampule pressure is determined by the poppet valve cracking pressure which is independent of source pressure.
The minimum delivery pressure, governed by the pressure regulation is also independent of source pressure. Both of these features are controlled by area ratios and spring rates. Thus the injector is substantially temperature independent.
Fig. 12 illustrates the effect of pressure regulation.
With a smaller dosage of e.g., 1/2 ml or~less, generally there is no pressure regulation. With larger dosages of e.g., over 3/4 ml, pressure regulation occurs. With intermediate range dosages of e.g., between 1/2 and 3/4 ml, some pressure regulation may occur.
The rubber or elastomeric face seal 196 adhered to the back of the drive piston 212 assists to rapidly open the poppet valve 170. The face seal 196 encourages the build up of pressure in the drive bores 194 and poppet annulus 198 before pressurizing the drive plenum 202. According-ly, the rapid pressure increase within the drive bores 194 and poppet annulus 198 shorten the time required for opening the poppet valve 170 providing a quick ampule pressure rise time and a more uniform ampule peak pres-sure. The poppet body supply holes i7~ have a large diameter to minimize pressure drop from the reservoir 168 to the poppet chamber 208.
With the poppet valve 170 open, gas flows through the poppet annulus 198 and drive bores i94 into the drive plenum 202. The gas pressure in the drive plenum 202 acting on the relatively large surface area of the entire back surface of the drive piston 212 generates a large force on the drive piston 212 in the forward direction.
The drive piston 212 accelerates forward with the clamp piston 210 driving the plunger 362 into the ampule 360.
The injectant dose within the ampule chamber 38~ is sprayed out of the ampule nozzle 386 in a high velocity jet which penetrates through the patient's skin. Fig. 2c shows the position of the plunger 362 and piston 212 after injection.
If the trigger 30 is held back for longer than neces-sary for the injection, only a small amount of gas is wasted since all spaces within the injector, except the drive plenum, remain virtually sealed while the trigger is held back. The drive plenum is opened to ambient pres-sure, but only through orifice 282 which severely re-stricts flow. The regulation valve i56 restricts flow while the trigger is held back.
After the injection, the trigger is released. The slide block spring 268 assisted by exhaust gas pressure returns the slide block 266 to its forward position. The initiator valve then closes. Then the exhaust valve fork 1 y.
2140'72 270 moving with the slide block 266 pulls the spool valve 286 forward reconnecting the spool valve bore 302 and spool plenum 300 to the reservoir exhaust bore 290. The spool valve and exhaust passage allow the injector to be quickly and quietly reset for another injection. Gas in the reservoir exhausts out through the reservoir exhaust bore 290 and exhaust passage 296. As this occurs, the exhaust gas pressure in the exhaust passage 296 pushes on the back of the spool valve 286 and helps to return the spool valve and slide block forward to their original ready positions. The slide block spring 268 consequently need only exert a slight force, thereby helping to reduce the finger force necessary to pull the trigger 30.
Immediately after the injection, the drive piston 212 is in the forward position (Fig. 2c), with the plunger shoulder in contact with and exerting a large force on the back end 388 of the ampule 360. The drive piston return spring 244, clamp piston spring 224 and jaw springs 238 are compressed. The jaws 236 are engaged with the plunger and the clamp piston 210 is forward. Each part must then return to the ready position.
Upon release of the trigger 30, the reservoir 168 is able to rapidly vent to atmosphere. Drive piston plenum gas vents into the reservoir, in part, through the poppet body, until the poppet valve closes. Gas also vents into the reservoir through the cannula 176, until the holes in the cannula are sealed by the o-ring 190 contained within the poppet seat 188. This remaining gas, which occupies 2.~~07~2 ~- WO 94/02188 PCT/US93/06940 a relatively small volume, and is at a very low pressure, vents through the bleed orifice 282 connecting the drive piston plenum directly to the atmosphere through the drive plenum exhaust bore 284. Since the orifice 282 is always 5 open, even during the injection, some beneficial drive gas is lost, thus it is a very small, restrictive orifice.
Because the orifice 282 is small, if it was the only vent for drive piston plenum gas (i.e., if there were no cannula side holes), venting and reset time would be 10 unacceptably long.
During venting, the following reset sequence occurs and is controlled by component areas and spring forces, which may be readily determined by those skilled in the art. First, the clamp jaws 236 and clamp piston 2i0 15 release. This must occur before the drive piston is released so that the plunger is not pulled back. The clamp piston spring force overcomes the opposing pressure force. This release occurs when the drive piston 212 is close to a force equilibrium condition. The pressure 20 force must be close to the opposing spring force. If not, then the drive piston 212 will rapidly return (if the spring force is larger) or plunge forward (if pressure force is larger) causing noise and possible damage to the injector. Thus a force balance is established at the 25 point of plunger release, regardless of the dosage.
After the plunger release, the drive piston 2i2 returns as the reservoir bleeds. The drive piston 212 is forced rearward by the drive piston return spring against .
01~
_ 36 the opposing pressure force. Gas exhaust and reset occurs quietly and quickly.
O-ring 222 serves as a seal and a bumper to quiet the clamp piston return.
During the injection, the plunger 362 is driven forward until the collar 374 contacts the back surface 388 of the ampule 360. Accordingly, if the trigger 30 is squeezed once and an injection given, released and squeezed again after some delay (i.e., "second fire") without replacing the ampule, the jaws will grab the plunger with the plunger collar in the forward most position, i.e., in contact with the rear ampule face.
Thus no forward movement of the drive piston will occur.
A second fire does not damage the ampule, plunger or injector.
The cannula 176 is attached to and moves with the drive piston 212. The cannula exhaust hole 190 in the cannula 176 speeds the return stroke of the piston 212.
The poppet valve closes before the drive piston begins its return. Thus a bleed hole in the cannula is required for gas to flow from the drive piston plenum to the reservoir.
During the return stroke, up until the time the cannula exhaust hole 190 passes behind the o-ring 206, gas in the drive plenum 202 flows through the cannula exhaust hole 190 through the cannula 176, back into the reservoir 168 and out through the relatively unobstructed exhaust system of the reservoir exhaust bore 290 and the exhaust passage 296. After the cannula exhaust hole 19o passes behind the ~i~o~~~
o-ring 206, the gas remaining in the now very small volume drive plenum 202, which is a very low pressure, is ex-hausted through the orifice 282 and drive plenum exhaust bore 28~ to ambient. Gas in the clamp piston plenum 216 similarly exhausts through the cannula 176 through the reservoir 168 and out through the reservoir exhaust bore 290 and the exhaust passage 296.
The spent ampule and plunger are turned and removed from the injector 20 which is then prepared for the next injection sequence.
The ampule and plunger are preferably a single use dispos-able unit.
As shown in Figs. 10a and 10b, the plunger may have tapered sections at the front or back which engage a generally cpmplimentary tapered section in the ampule.
During an injection, the injector exerts hundreds of pounds of force on the plunger which drives the tapered section of the plunger of Figs. l0a and lOb into an interference fit with the tapered section of the ampule.
The used and non sterile plunger and ampule cannot easily then be re-used. The tapered sections can also act as a plunger stop, in place of the collar on the plunger of Fig. 10. The taper on the plunger and ampule are slightly mismatched and lock together only with high forces (at the end of an injection) and not at low forces (during filling of the ampule). Fig. lOc shows another non-reusable ampule and plunger having a detent. The detent is dimens-Toned so that only a large force will cause engagement.
WO 94/02188 ~ ~ PCT/US93/06940 The injector can be modified to give multiple sequen-tial injections to the same patient. As shown in Figs. 4a and 4b, a drive piston stop 394 is added; and acts to stop the drive piston, as the plunger shoulder does in variable delivery. When the injector actuates, a small dose is delivered. The jaws then disengage and the injector resets. The plunger will automatically be in a "ready"
position for the next shot, and the injector may be fired again to deliver the same small dosage. This sequence may be repeated to deliver several small dosage injections until the plunger shoulder contacts the ampule. Dosage may be adjusted by rotating the outer ring 396 to the desired value, indicated by graduations 398 on the injec tor housing. A longer ampule can be provided to allow for more sequential shots.
The present method of needleless injection uses a system of an injector and compatible ampules. The injec-for is designed to apply a specific force on the plunger of the ampules. The force applied to the plunger by the injector is varied, forming a force - displacement curve.
At the beginning of the injection, the force applied to the plunger is quite high. As the plunger is advanced, the applied force is reduced substantially linearly until the volume injected reaches approximately 0.5 ml, and thereafter the force is held substantially constant. This force displacement curve is independent of the ampule nozzle size. This force - displacement curve translates directly to an ampule pressure - volume injected curve.
WO 94/02188 ~ O ~ ~ PCT/US93/06940 The injection system employs a singular pressure profile and a family of ampules with various orifice sizes to achieve various depths of penetration. Fig. 17 shows preferred uses of various diameter nozzles with the pressure profile described below.
The traditional approach to measuring pressure profile is to use a pressure - time curve. However, a pressure-volume profile is particularly useful because this pres-sure profile is nearly the same for any size nozzle. In the following discussion, both time and volume will be used as a reference.
Referring to Figs. 15 and 18-20, the preferred pres-sure profile has the following properties: First the pressure rapidly increases from 0 to a value of about 26900-29670 kPa, and preferably about 28290 kPa, (4100 psi) in less than 6 milliseconds (and preferably less than 1 ms). This quick pressure rise avoids "splash-back" and loss of injectant. This pressure range is sufficient to pierce the tissues, but not so high as to cause the excessive pain associated with higher pressures. The pressure is gradually reduced to approximately 8280 -13800 kPa, and preferably 12420 kPa, (1800 psi) in a generally linear (pressure - volume) fashion corresponding with volume discharged of 0.5 ml. In a pressure - time 2'5 framework, the curve forms an exponential decay. At this point, the pressure is held constant until the end of the injection, at which time the pressure abruptly goes to 0 (optimally in less than 5 ms.) Final pressures below 14~4'~ ~ ~
about 8280 kPa tend to result in "leak-back" of the injectant after the injection. The pressure profile is defined as the pressure immediately proximal to the nozzle. The above- described pressure profile covers an 5 injection larger than approximately 0.5 ml. If the injection is less than this amount, the pressure - profile curve is simply truncated at the end of the delivered volume.
Medication viscosity affects penetration of intramus 10 cular injections in a direction contrary to prior art.
Experimental data shows that more viscous medications, in the range of from 0.01 to 0.70 poise, have greater fascia penetrating capability, apparently because of reduced turbulence and lower Reynold s number. Thus, the present 15 invention also includes the appropriate guidelines for selection of nozzle size with viscous medications.
Viscous medications preferably use the same size orifice as for water based medications. Nearly all viscous medications are intramuscular injections. Testing shows 2o that viscous medications have more energy to penetrate the deep fascia than water based medications, but do not go substantially deeper into the muscle. Therefore, the deposition into the muscle is comparable independent of medication viscosity.
25 The present peri-fascial injection is provided by using a nozzle diameter which is smaller than that which would ordinarily be used for an intramuscular injection.
The peri-fascial injection is provided by using a SC
WO 94/02188 _ ~ ~ ~ ~ ~ ~ ~ PCT/US93/06940 nozzle (0.10 mm) at an IM injection site preferably with less than 5 mm adipose. This works well because IM sites tend to have very thin layers of adipose tissue. The SC
nozzle has sufficient penetrating energy to deposit the medication on the deep fascia when injected into a thin layer of adipose. A peri-fascial injection can.also be given at an IM injection site having a 10-15 mm adipose layer using a 0.15 mm diameter nozzle and the above-described pressure profile. As shown in Fig. 16, the injectant 800 in a peri-fascial injection bores through the skin 802 and adipose 804, but not the fascia 806.
Rather, the injectant forms a thin layer 808 over the fascia. The thin layer 808 may provide the same pharmaco-logical effect as an IM injection, without penetrating the muscle.
Claims (5)
1. A method of providing a jet injection by pressurizing a fluid injectant within an ampule, comprising the steps of:
driving a plunger into the ampule with sufficient force to generate a pressure of from 26000-30000 kPa within 6 milliseconds;
reducing the pressure generally linearly until 0.5 ml is expelled and the pressure is 8000-14000 kPa;
maintaining the pressure at 8000-14000 kPa until a desired volume of injectant is expelled from the ampule; and reducing the pressure to about 0.0 kPa within 5.0 milliseconds.
driving a plunger into the ampule with sufficient force to generate a pressure of from 26000-30000 kPa within 6 milliseconds;
reducing the pressure generally linearly until 0.5 ml is expelled and the pressure is 8000-14000 kPa;
maintaining the pressure at 8000-14000 kPa until a desired volume of injectant is expelled from the ampule; and reducing the pressure to about 0.0 kPa within 5.0 milliseconds.
2. The method of claim 1 further comprising the step of adjusting the diameter of the nozzle opening of the ampule to control depth of penetration of the injection.
3. The method of claim 1 or 2 further comprising the step of adjusting the viscosity of the injectant to control depth of penetration.
4. The method of claim 3 wherein the viscosity of the injectant is from 0.01 to 0.70 poise.
5. The method of claim 1 wherein a subcutaneous injection is performed at a standard subcutaneous injection site using a nozzle diameter of from 0.07 to 0.13 mm.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/920,106 US5383851A (en) | 1992-07-24 | 1992-07-24 | Needleless hypodermic injection device |
US07/920,106 | 1992-07-24 | ||
PCT/US1993/006940 WO1994002188A1 (en) | 1992-07-24 | 1993-07-23 | Needleless hypodermic injection methods and device |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2140772A1 CA2140772A1 (en) | 1994-02-03 |
CA2140772C true CA2140772C (en) | 2006-07-11 |
Family
ID=25443171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002140772A Expired - Lifetime CA2140772C (en) | 1992-07-24 | 1993-07-23 | Needleless hypodermic injection methods and device |
Country Status (8)
Country | Link |
---|---|
US (3) | US5383851A (en) |
EP (1) | EP0651663B1 (en) |
JP (2) | JP3633615B2 (en) |
AT (1) | ATE187083T1 (en) |
AU (1) | AU676490B2 (en) |
CA (1) | CA2140772C (en) |
DE (1) | DE69327165T2 (en) |
WO (1) | WO1994002188A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221347B2 (en) | 2004-12-01 | 2012-07-17 | Acushot, Inc. | Needle-free injector |
Families Citing this family (1076)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2689017B1 (en) * | 1992-03-31 | 1994-05-27 | Mtc Medical | MEDICAL OR VETERINARY INJECTION APPARATUS. |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5405333A (en) * | 1992-12-28 | 1995-04-11 | Richmond; Frank M. | Liquid medicament bag with needleless connector fitting using boat assembly |
US6206860B1 (en) | 1993-07-28 | 2001-03-27 | Frank M. Richmond | Spikeless connection and drip chamber with valve |
US5540657A (en) * | 1994-07-15 | 1996-07-30 | Collagen Corporation | Delivery device for injectable materials |
DE19519279A1 (en) * | 1994-12-07 | 1996-08-22 | Wolfgang Dr Med Wagner | Measurement of, esp. glucose level, using suction cup |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
DE29507987U1 (en) * | 1995-05-15 | 1996-09-19 | Ferton Holding | Ejection device for high pressure ejection of a liquid |
US5893397A (en) * | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US5800388A (en) | 1996-02-29 | 1998-09-01 | Medi-Ject Corporation | Plunger/ram assembly adapted for a fluid injector |
US5697917A (en) | 1996-02-29 | 1997-12-16 | Medi-Ject Corporation | Nozzle assembly with adjustable plunger travel gap |
US5722953A (en) | 1996-02-29 | 1998-03-03 | Medi-Ject Corporation | Nozzle assembly for injection device |
US5643211A (en) | 1996-02-29 | 1997-07-01 | Medi-Ject Corporation | Nozzle assembly having a frangible plunger |
US5921967A (en) | 1996-02-29 | 1999-07-13 | Medi-Ject Corporation | Plunger for nozzle assembly |
US5865795A (en) | 1996-02-29 | 1999-02-02 | Medi-Ject Corporation | Safety mechanism for injection devices |
US5785688A (en) * | 1996-05-07 | 1998-07-28 | Ceramatec, Inc. | Fluid delivery apparatus and method |
KR100376646B1 (en) | 1996-07-01 | 2003-03-15 | 파마시아 에이비 | Delivery device and method for its operation |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6106502A (en) * | 1996-12-18 | 2000-08-22 | Richmond; Frank M. | IV sets with needleless fittings and valves |
US5875976A (en) | 1996-12-24 | 1999-03-02 | Medi-Ject Corporation | Locking mechanism for nozzle assembly |
US5993412A (en) * | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
US5911703A (en) * | 1997-05-22 | 1999-06-15 | Avant Drug Delivery Systems, Inc. | Two-stage fluid medicament jet injector |
US5947928A (en) * | 1997-06-19 | 1999-09-07 | Mile Creek Capital, Llc | Drug delivery system |
US5964735A (en) * | 1997-07-01 | 1999-10-12 | Medisys Technologies, Inc. | Fine needle aspiration safety syringe |
EP0888790A1 (en) * | 1997-07-04 | 1999-01-07 | PowderJect Research Limited | Drug particle delivery device |
US6569127B1 (en) * | 1997-07-18 | 2003-05-27 | Liebel-Flarsheim Company | Adapter and syringe for front-loading medical fluid injector |
US6171276B1 (en) | 1997-08-06 | 2001-01-09 | Pharmacia & Upjohn Ab | Automated delivery device and method for its operation |
US6071272A (en) * | 1997-10-28 | 2000-06-06 | Hoffman; Alan S. | Method for treating erectile dysfunctionality |
US6610042B2 (en) | 1997-12-05 | 2003-08-26 | Felton Medical, Inc. | Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof |
US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US5993418A (en) * | 1998-02-24 | 1999-11-30 | Medisys Technologies, Inc. | Safety syringe |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP1071377A1 (en) | 1998-04-14 | 2001-01-31 | Merck & Co., Inc. | Needleless administration of polynucleotide formulations |
ATE342079T1 (en) * | 1998-07-27 | 2006-11-15 | Antares Pharma Inc | INJECTION AUXILIARY TORPEDO FOR A MEDICAL INJECTION SYSTEM |
CN1320050A (en) * | 1998-07-27 | 2001-10-31 | 梅迪-杰克特公司 | Loading mechanism for medical injector assembly |
GB9818110D0 (en) * | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
EP1109594B1 (en) | 1998-08-31 | 2004-10-27 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport device comprising blades |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6783509B1 (en) | 1998-11-18 | 2004-08-31 | Bioject Inc. | Single-use needle-less hypodermic jet injection apparatus and method |
US6383168B1 (en) | 1998-12-08 | 2002-05-07 | Bioject Medical Technologies Inc. | Needleless syringe with prefilled cartridge |
US6132395A (en) * | 1998-12-08 | 2000-10-17 | Bioject, Inc. | Needleless syringe with prefilled cartridge |
US6406455B1 (en) * | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
DE19859137C1 (en) * | 1998-12-21 | 2000-05-18 | Ferton Holding Sa | High pressure medicinal injection unit includes piston advanced into pressure chamber by series of resilient impacts, forcing fluid out in series of impulses for precise low-volume dosing |
US6328714B1 (en) | 1999-01-29 | 2001-12-11 | Powderject Research Limited | Particle delivery device |
US6849060B1 (en) | 1999-01-29 | 2005-02-01 | Powderject Research Limited | Particle delivery device |
WO2000062857A1 (en) | 1999-04-16 | 2000-10-26 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport delivery system comprising internal sensors |
US7060048B1 (en) * | 1999-04-16 | 2006-06-13 | Powerject Research Limited | Needleless syringe |
US6689095B1 (en) | 1999-04-22 | 2004-02-10 | Gilbert Garitano | Needleless permanent makeup and tattoo device |
US6319230B1 (en) | 1999-05-07 | 2001-11-20 | Scimed Life Systems, Inc. | Lateral needle injection apparatus and method |
US6689103B1 (en) | 1999-05-07 | 2004-02-10 | Scimed Life System, Inc. | Injection array apparatus and method |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US7147633B2 (en) * | 1999-06-02 | 2006-12-12 | Boston Scientific Scimed, Inc. | Method and apparatus for treatment of atrial fibrillation |
WO2000072908A1 (en) * | 1999-06-02 | 2000-12-07 | Microheart, Inc. | Devices and methods for delivering a drug |
AU6076200A (en) | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
US6890553B1 (en) | 1999-07-08 | 2005-05-10 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
US6319224B1 (en) * | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
AU7064700A (en) * | 1999-08-20 | 2001-03-19 | Bioject, Inc. | Intramuscular injection system for injecting dna-based injectables into humans |
US20050027239A1 (en) * | 1999-08-20 | 2005-02-03 | Stout Richard R. | Intradermal injection system for injecting DNA-based injectables into humans |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US7133717B2 (en) * | 1999-08-25 | 2006-11-07 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery and diagnostic sampling |
US6626871B1 (en) | 1999-10-11 | 2003-09-30 | Felton International, Inc. | Method and apparatus for removing cap from medical device |
US7074210B2 (en) * | 1999-10-11 | 2006-07-11 | Felton International, Inc. | Universal protector cap with auto-disable features for needle-free injectors |
US6776776B2 (en) * | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US6569123B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
US6843781B2 (en) * | 1999-10-14 | 2005-01-18 | Becton, Dickinson And Company | Intradermal needle |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US7029457B2 (en) * | 1999-11-23 | 2006-04-18 | Felton International, Inc. | Jet injector with hand piece |
US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
DE60029338T2 (en) * | 1999-11-23 | 2007-07-12 | Felton International, Inc., Lenexa | INJECTOR ARRANGEMENT WITH DRIVE AND LOCKING MEANS |
US6770054B1 (en) | 1999-11-23 | 2004-08-03 | Felton International, Inc. | Injector assembly with driving means and locking means |
US6613026B1 (en) | 1999-12-08 | 2003-09-02 | Scimed Life Systems, Inc. | Lateral needle-less injection apparatus and method |
US6344027B1 (en) | 1999-12-08 | 2002-02-05 | Scimed Life Systems, Inc. | Needle-less injection apparatus and method |
EP1296730B2 (en) * | 2000-01-07 | 2014-07-30 | Valeritas, Inc. | Injection device |
IL151097A0 (en) | 2000-02-23 | 2003-04-10 | Smithkline Beecham Biolog | Tumour-specific animal proteins |
FR2805749B1 (en) * | 2000-03-01 | 2002-05-17 | Poudres & Explosifs Ste Nale | NEEDLELESS SYRINGE AT TWO LEVELS OF INJECTION SPEED |
US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
AU2001247721A1 (en) * | 2000-03-23 | 2001-10-03 | Antares Pharma, Inc. | Single use disposable jet injector |
US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
FR2807946B1 (en) * | 2000-04-19 | 2002-06-07 | Poudres & Explosifs Ste Nale | NEEDLELESS SYRINGE OPERATING WITH A TWO-COMPOSITION PYROTECHNIC LOAD |
US6716190B1 (en) * | 2000-04-19 | 2004-04-06 | Scimed Life Systems, Inc. | Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body |
US7404815B2 (en) * | 2000-05-01 | 2008-07-29 | Lifescan, Inc. | Tissue ablation by shear force for sampling biological fluids and delivering active agents |
US6689101B2 (en) * | 2000-05-22 | 2004-02-10 | Pharmacia Ab | Medical arrangement |
US6406456B1 (en) | 2000-06-08 | 2002-06-18 | Avant Drug Delivery Systems, Inc. | Jet injector |
US6645169B1 (en) * | 2000-06-08 | 2003-11-11 | Avant Drug Delivery Systems, Inc. | Air-in-tip jet injector |
DE10029325A1 (en) | 2000-06-20 | 2002-01-03 | Peter Lell | Needle-free injection device with pyrotechnic drive |
JP2004513615A (en) | 2000-06-28 | 2004-05-13 | コリクサ コーポレイション | Compositions and methods for treatment and diagnosis of lung cancer |
US20030180379A1 (en) * | 2000-07-27 | 2003-09-25 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
JP2004505057A (en) | 2000-07-27 | 2004-02-19 | ニュクリスト ファーマシューティカルズ コーポレーション | Treatment of hyperproliferative skin disorders and diseases |
US7001617B2 (en) | 2001-04-23 | 2006-02-21 | Nueryst Pharmaceuticals Corp. | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
US20030206966A1 (en) * | 2000-07-27 | 2003-11-06 | Burrell Robert E. | Methods of inducing apoptosis and modulating metalloproteinases |
US7008647B2 (en) | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
US7427416B2 (en) * | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
US7255881B2 (en) * | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
US6989157B2 (en) * | 2000-07-27 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Dry powders of metal-containing compounds |
US20030185901A1 (en) | 2000-07-27 | 2003-10-02 | Burrell Robert E. | Methods of treating conditions with a metal-containing material |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
CA2324045A1 (en) * | 2000-10-20 | 2002-04-20 | Universite De Sherbrooke | No-needle syringe for the subcutaneous injection of medicated powders |
FR2815544B1 (en) | 2000-10-23 | 2003-02-14 | Poudres & Explosifs Ste Nale | SAFETY NEEDLE SYRINGE WITH COMPACT ARCHITECTURE |
US6652483B2 (en) * | 2000-11-07 | 2003-11-25 | Avant Drug Delivery Systems, Inc. | Needleless jet injector system with separate drug reservoir |
US6626863B1 (en) | 2000-11-22 | 2003-09-30 | Nusaf, L.L.C. | Safety syringe |
US7931614B2 (en) * | 2000-11-30 | 2011-04-26 | Valeritas, Inc. | Injection systems |
GB0100756D0 (en) | 2001-01-11 | 2001-02-21 | Powderject Res Ltd | Needleless syringe |
CN1286536C (en) * | 2001-01-18 | 2006-11-29 | 梅德拉股份有限公司 | Syringe interfaces and adapters for use with medical injectors |
US6758837B2 (en) | 2001-02-08 | 2004-07-06 | Pharmacia Ab | Liquid delivery device and method of use thereof |
DE60239594D1 (en) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION |
US6645170B2 (en) * | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
US6471669B2 (en) | 2001-03-05 | 2002-10-29 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
US20020139088A1 (en) | 2001-03-08 | 2002-10-03 | Archie Woodworth | Polymeric syringe body and stopper |
US20020172615A1 (en) * | 2001-03-08 | 2002-11-21 | Archie Woodworth | Apparatus for and method of manufacturing a prefilled sterile container |
JP2004529754A (en) | 2001-03-14 | 2004-09-30 | ペンジェット・コーポレーション | System and method for removing dissolved gases from a solution |
ZA200200808B (en) | 2001-03-22 | 2002-08-12 | Roche Diagnostics Gmbh | Needleless hypodermic injection system, application device and medication cartridge therefor. |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US7795218B2 (en) | 2001-04-12 | 2010-09-14 | Bioaxone Therapeutique Inc. | ADP-ribosyl transferase fusion variant proteins |
US20050192530A1 (en) * | 2001-04-13 | 2005-09-01 | Penjet Corporation | Method and apparatus for needle-less injection with a degassed fluid |
US6613010B2 (en) * | 2001-04-13 | 2003-09-02 | Penjet Corporation | Modular gas-pressured needle-less injector |
DE60210441T2 (en) | 2001-04-23 | 2006-11-16 | Nucryst Pharmaceuticals Corp., Fort Saskatchewan | MEDICAMENT OR PLASTER CONTAINS A METAL SUCH AS SILVER, GOLD, PLATINUM OR PALLADIUM AS AN ANTIMICROBIAL ACTIVE INGREDIENT AND ITS USE IN THE TREATMENT OF SKIN INFUSION |
WO2002087663A2 (en) | 2001-04-27 | 2002-11-07 | Penjet Corporation | Method and apparatus for filling or refilling a needle-less injector |
WO2002089747A2 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US6648850B2 (en) * | 2001-06-08 | 2003-11-18 | Bioject, Inc. | Durable needle-less jet injector apparatus and method |
US20060018877A1 (en) * | 2001-06-29 | 2006-01-26 | Mikszta John A | Intradermal delivery of vacccines and therapeutic agents |
CN1253220C (en) * | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
US7544188B2 (en) * | 2001-07-19 | 2009-06-09 | Intelliject, Inc. | Medical injector |
US7767872B2 (en) * | 2001-09-06 | 2010-08-03 | Mpg Biotechnologies, Llc | Thimerosal removal device |
US8440791B2 (en) * | 2001-09-06 | 2013-05-14 | Mgp Biotechnologies, Llc | Thimerosal removal device |
US6669664B2 (en) | 2001-09-07 | 2003-12-30 | Avant Drug Delivery Systems, Inc. | Vacuum control cycle for jet injector |
HUP0402259A3 (en) | 2001-09-20 | 2010-01-28 | Glaxo Group Ltd | Vaccines |
US6824526B2 (en) | 2001-10-22 | 2004-11-30 | Penjet Corporation | Engine and diffuser for use with a needle-less injector |
GB0125506D0 (en) * | 2001-10-24 | 2001-12-12 | Weston Medical Ltd | Needle free injection method and apparatus |
PT1443992E (en) * | 2001-11-09 | 2007-02-28 | Alza Corp | Collapsible syringe cartridge |
US6607510B2 (en) | 2001-11-09 | 2003-08-19 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
PT2221076E (en) * | 2001-11-09 | 2013-07-15 | Alza Corp | Pneumatic powered autoinjector |
TWI222370B (en) * | 2001-12-14 | 2004-10-21 | Roche Diagnostics Gmbh | Needleless hypodermic injection device |
CA2476755C (en) | 2001-12-17 | 2014-08-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
AU2003209645A1 (en) * | 2002-03-04 | 2003-09-16 | Nano Pass Technologies Ltd. | Devices and methods for transporting fluid across a biological barrier |
US6912417B1 (en) * | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
CN1324047C (en) | 2002-04-12 | 2007-07-04 | 先灵公司 | G-protein coupled receptor ligands and methods |
DK1503788T3 (en) | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Treatment of alpha-galactosidase A deficiency |
WO2003100008A2 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
US7238167B2 (en) * | 2002-06-04 | 2007-07-03 | Bioject Inc. | Needle-free injection system |
US7156823B2 (en) * | 2002-06-04 | 2007-01-02 | Bioject Inc. | High workload needle-free injection system |
US6676630B2 (en) | 2002-06-04 | 2004-01-13 | Bioject Medical Technologies, Inc. | Needle-free injection system |
US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US6883222B2 (en) * | 2002-10-16 | 2005-04-26 | Bioject Inc. | Drug cartridge assembly and method of manufacture |
SI1558648T1 (en) | 2002-10-17 | 2012-05-31 | Genmab As | Human monoclonal antibodies against cd20 |
CA2500829A1 (en) * | 2002-10-22 | 2004-05-06 | Nucryst Pharmaceuticals Corp. | Prophylactic treatment methods |
DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
AU2003275895B2 (en) | 2002-11-25 | 2009-02-05 | Tecpharma Licensing Ag | Auto-injector comprising a resettable releasing safety device |
RU2389732C2 (en) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Certain aminoalkyl glucosaminide phospahte derivatives and use thereof |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
ES2362424T3 (en) | 2003-01-07 | 2011-07-05 | Dyax Corporation | KUNITZ DOMAIN LIBRARY. |
CA2814767C (en) | 2003-01-31 | 2016-03-15 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
US6935384B2 (en) * | 2003-02-19 | 2005-08-30 | Bioject Inc. | Needle-free injection system |
FR2852517B1 (en) * | 2003-03-21 | 2005-11-11 | INJECTION DEVICE WITHOUT NEEDLE WITH PYROTECHNIC CARTRIDGE AND METHOD FOR ASSEMBLING SUCH A DEVICE | |
JP2006524120A (en) * | 2003-04-21 | 2006-10-26 | ストラテージェント ライフ サイエンシズ | Apparatus and method for repetitively delivering drug by microjet |
US20060184101A1 (en) * | 2003-04-21 | 2006-08-17 | Ravi Srinivasan | Microjet devices and methods for drug delivery |
NZ542988A (en) | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
WO2004110533A1 (en) * | 2003-05-09 | 2004-12-23 | Anges Mg, Inc. | Needleless syringe having medical agent accommodated therein |
AU2004272972A1 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
WO2005034949A1 (en) * | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
IL157981A (en) | 2003-09-17 | 2014-01-30 | Elcam Medical Agricultural Cooperative Ass Ltd | Auto-injector |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
JP4833850B2 (en) | 2003-11-21 | 2011-12-07 | ユセベ ファルマ ソシエテ アノニム | Method for treating multiple sclerosis by inhibiting IL-17 activity |
EA008731B1 (en) * | 2003-11-21 | 2007-08-31 | Чжуншань Ботай Фармасьютик Инструментс Ко., Лтд. | A syringe for powder medicament premixing |
PL1691837T3 (en) | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | Ip-10 antibodies and their uses |
CA2546054C (en) | 2003-12-10 | 2014-05-13 | Medarex, Inc. | Interferon alpha antibodies and their uses |
US20060147946A1 (en) * | 2004-01-27 | 2006-07-06 | Pinchas Akiva | Novel calcium channel variants and methods of use thereof |
EP3466483A1 (en) | 2004-03-08 | 2019-04-10 | Ichor Medical Systems Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
IL160891A0 (en) | 2004-03-16 | 2004-08-31 | Auto-mix needle | |
DE102004024617A1 (en) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentially expressed in tumors gene products and their use |
RU2006138704A (en) * | 2004-05-19 | 2008-06-27 | Вайет (Us) | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
US7717874B2 (en) * | 2004-05-28 | 2010-05-18 | Bioject, Inc. | Needle-free injection system |
CA2570823C (en) | 2004-06-21 | 2015-02-24 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
JP2008515774A (en) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | hK1 binding protein |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US20060040895A1 (en) * | 2004-08-19 | 2006-02-23 | Kipling Thacker | Aesthetic use of hyaluronan |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
EP1793849A2 (en) | 2004-09-22 | 2007-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
WO2007001448A2 (en) * | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
JP2008518629A (en) | 2004-11-08 | 2008-06-05 | シェーリング コーポレイション | Association of MDL-1 with tumor and method thereof |
WO2006050611A1 (en) | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
AU2005306399B2 (en) | 2004-11-19 | 2012-02-09 | Biogen Ma Inc. | Treatment for multiple sclerosis |
US7648483B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US7947017B2 (en) | 2004-11-22 | 2011-05-24 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US7648482B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
CA2586525C (en) * | 2004-11-22 | 2013-01-15 | Intelliject, Llc | Devices, systems, and methods for medicament delivery |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
NZ581497A (en) * | 2004-12-03 | 2012-07-27 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody |
WO2006060419A2 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
US7351226B1 (en) * | 2004-12-07 | 2008-04-01 | Glenn Herskowitz | Medical infusion pump |
EP1841866B1 (en) * | 2005-01-25 | 2009-04-22 | Sky Genetics, Inc. | Nucleic acids for apoptosis of cancer cells |
US20060183893A1 (en) * | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
US8361026B2 (en) | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US7731686B2 (en) | 2005-02-01 | 2010-06-08 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US8206360B2 (en) | 2005-02-01 | 2012-06-26 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
NZ560516A (en) | 2005-02-01 | 2010-12-24 | Intelliject Inc | A delivery system where a medicant is automatically delivered on activation as well as a recorded instruction |
US20090124993A1 (en) | 2005-02-17 | 2009-05-14 | Burkly Linda C | Treating neurological disorders |
US8207303B2 (en) | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
PE20061428A1 (en) | 2005-03-23 | 2007-01-16 | Glaxosmithkline Biolog Sa | VACCINE FORMULATION INCLUDING AN OIL EMULSION ADJUVANT IN WATER AND 3D-MPL |
CN101189023B (en) | 2005-03-31 | 2013-01-30 | 通用医疗公司 | Monitoring and modulating hgf/hgfr activity |
ES2732625T3 (en) | 2005-04-04 | 2019-11-25 | Univ Florida | Desferritiocin polyether analogs |
LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
KR20080025373A (en) | 2005-05-17 | 2008-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
CN102441163A (en) | 2005-05-27 | 2012-05-09 | 比奥根艾迪克Ma公司 | Tweak binding antibodies |
US20060271014A1 (en) * | 2005-05-31 | 2006-11-30 | Mallinckrodt Inc. | Heat retention device for a syringe and methods of use |
US20070118093A1 (en) * | 2005-06-20 | 2007-05-24 | Von Muhlen Marcio G | High-speed jet devices for drug delivery |
CN105330741B (en) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
WO2007016643A2 (en) * | 2005-08-01 | 2007-02-08 | Mount Sinai School Of Medicine Of New York University | A method for extending longevity using npc1l1 antagonists |
EP1919504B1 (en) * | 2005-08-03 | 2013-10-16 | iBio, Inc. | Antibody to bacillus anthracis protective antigen |
US20070055199A1 (en) * | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
EP1934261B1 (en) | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
US20070099246A1 (en) * | 2005-11-03 | 2007-05-03 | Sandy John D | Antibodies, assays and kits to quantitate cartilage destruction |
EP3058972A1 (en) | 2005-11-17 | 2016-08-24 | Zogenix, Inc. | Delivery of viscous formulations by needle-free injection |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EA013338B1 (en) * | 2005-12-05 | 2010-04-30 | Чжуншань Ботай Фармасьютик Инструментс Ко., Лтд. | An automatic syringe |
PT1960434E (en) | 2005-12-08 | 2012-10-02 | Medarex Inc | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
WO2007070682A2 (en) * | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
JO2813B1 (en) | 2005-12-22 | 2014-09-15 | جلاكسو سميث كلاين بايولوجيكالز اس.ايه | Pneumococcal polysaccharide conjugate vaccine |
US20090081157A1 (en) | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
US20070166774A1 (en) * | 2006-01-17 | 2007-07-19 | Groman Ernest V | Functional immunoassay |
DK1986612T3 (en) | 2006-02-07 | 2012-10-29 | Shire Human Genetic Therapies | Stabilized protein compositions with a free thiol moiety |
EP2335754B1 (en) * | 2006-02-09 | 2013-12-18 | DEKA Products Limited Partnership | Patch-sized fluid delivery systems |
JP2009526526A (en) * | 2006-02-13 | 2009-07-23 | フラウンホーファー ユーエスエー, インコーポレイテッド | Influenza antigens, vaccine compositions, and related methods |
US20080279877A1 (en) * | 2006-02-13 | 2008-11-13 | Fraunhofer U.S.A. Inc. | HPV antigens, vaccine compositions, and related methods |
US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
CA2642540C (en) * | 2006-02-17 | 2015-11-24 | Alan L. Buchman | Catheter cleaning devices |
EP1998684A4 (en) * | 2006-03-10 | 2014-09-17 | Massachusetts Inst Technology | Triggered self-assembly conjugates and nanosystems |
US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
US20080045471A1 (en) * | 2006-03-27 | 2008-02-21 | North Don A | Nucleic Acids For Apoptosis Of Cancer Cells |
MX337528B (en) | 2006-03-30 | 2016-03-09 | Glaxosmithkline Biolog Sa | Immunogenic composition. |
ES2776100T3 (en) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | System for targeted delivery of therapeutic agents |
WO2007120638A2 (en) * | 2006-04-12 | 2007-10-25 | President And Fellows Of Harvard College | Methods and compositions for modulating glycosylation |
EP2021030A2 (en) * | 2006-04-21 | 2009-02-11 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
US20070258941A1 (en) * | 2006-05-02 | 2007-11-08 | Pfister Brian E | Methods and compositions for remediation of disc herniation by modifying structure |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
US10119979B2 (en) | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
WO2007143574A1 (en) * | 2006-06-02 | 2007-12-13 | President And Fellows Of Harvard College | Protein surface remodeling |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
EP2032989B2 (en) | 2006-06-30 | 2015-10-28 | Merck Sharp & Dohme Corp. | Igfbp2 biomarker |
EP2046383B1 (en) | 2006-07-04 | 2014-11-19 | Genmab A/S | Cd20 binding molecules for the treatment of copd |
SI2422810T1 (en) | 2006-07-17 | 2015-01-30 | Glaxosmithkline Biologicals S.A. | Influenza vaccine |
US20080033347A1 (en) * | 2006-08-03 | 2008-02-07 | Becton, Dickinson And Company | Detachable needle syringe having reduced dead space |
US7618396B2 (en) * | 2006-08-09 | 2009-11-17 | Avant Medical Corp. | Injection system with hidden needles |
WO2008018641A1 (en) | 2006-08-11 | 2008-02-14 | Ono Pharmaceutical Co., Ltd. | Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
US9115358B2 (en) * | 2006-08-11 | 2015-08-25 | President And Fellows Of Harvard College | Moenomycin biosynthesis-related compositions and methods of use thereof |
US20090269342A1 (en) * | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
KR20090050056A (en) * | 2006-08-14 | 2009-05-19 | 메사츄세츠 인스티튜트 어브 테크놀로지 | Hemagglutinin polypeptides, and reagents and methods |
US20110182904A1 (en) | 2006-09-05 | 2011-07-28 | Deborah Zimmerman | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
US7942845B2 (en) * | 2006-09-19 | 2011-05-17 | Bioject, Inc. | Needle-free injector and process for providing serial injections |
SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
US7547293B2 (en) | 2006-10-06 | 2009-06-16 | Bioject, Inc. | Triggering mechanism for needle-free injector |
EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
JO3598B1 (en) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
BRPI0717219B8 (en) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | immunogenic composition, and, use of an immunogenic composition |
ES2388567T3 (en) | 2006-10-19 | 2012-10-16 | Csl Limited | Anti-il-13r alpha 1 antibodies and uses thereof |
EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
EP2311481A3 (en) | 2006-10-20 | 2013-10-16 | Biogen Idec MA Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
US20090124996A1 (en) * | 2006-11-03 | 2009-05-14 | Scott Heneveld | Apparatus and methods for injecting high viscosity dermal fillers |
MX2009005189A (en) | 2006-11-15 | 2009-06-30 | Medarex Inc | Human monoclonal antibodies to btla and methods of use. |
US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
CN101848702B (en) | 2006-12-01 | 2013-07-17 | 安特里奥公司 | Amphiphilic entity nanoparticles |
MX2009005776A (en) | 2006-12-01 | 2009-06-10 | Medarex Inc | Human antibodies that bind cd22 and uses thereof. |
WO2008073856A2 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
WO2008074004A2 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
CA2790018C (en) * | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
CN110003079A (en) | 2006-12-26 | 2019-07-12 | 兰休斯医疗成像公司 | For making the ligand of imaging cardiac innervation |
EP2104525A4 (en) * | 2006-12-29 | 2010-12-29 | Amir Genosar | Hypodermic drug delivery reservoir and apparatus |
EP2125075A2 (en) | 2007-01-22 | 2009-12-02 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
AU2008210434C8 (en) | 2007-01-31 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
US9217129B2 (en) * | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
PL2716301T3 (en) | 2007-02-16 | 2017-10-31 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
WO2008103997A2 (en) * | 2007-02-23 | 2008-08-28 | Bioject Inc. | Needle-free injection devices and drug delivery systems therefor |
EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
AU2008229472B2 (en) | 2007-03-15 | 2013-03-14 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
JP5779350B2 (en) | 2007-03-27 | 2015-09-16 | シー レーン バイオテクノロジーズ, エルエルシー | Constructs and libraries containing antibody surrogate light chain sequences |
BRPI0809366B8 (en) | 2007-03-28 | 2021-05-25 | Harvard College | substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition |
JP2010523595A (en) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | Poly (amino acid) targeting part |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
WO2008134643A2 (en) * | 2007-04-28 | 2008-11-06 | Fraunhofer Usa, Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
GB0708758D0 (en) | 2007-05-04 | 2007-06-13 | Powderject Res Ltd | Particle cassettes and process thereof |
WO2008148057A2 (en) | 2007-05-23 | 2008-12-04 | Vical Incorporated | Cationic lipids compositions and methods for enhancing immune responses to vaccines |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
WO2008153926A2 (en) | 2007-06-05 | 2008-12-18 | Yale University | Inhibitors of receptor tyrosine kinases and methods of use thereof |
CN103977404A (en) * | 2007-06-14 | 2014-08-13 | 比奥根艾迪克Ma公司 | Antibody formulations |
CN101754770B (en) * | 2007-06-14 | 2015-05-20 | 克鲁塞尔瑞士股份公司 | Intradermal influenza vaccine |
WO2008156676A1 (en) | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
PT2167121E (en) | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2009009759A2 (en) | 2007-07-11 | 2009-01-15 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
DE102007034871A1 (en) * | 2007-07-24 | 2009-01-29 | Lts Lohmann Therapie-Systeme Ag | Disposable injector with manually operated piston |
US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
US20110059130A1 (en) * | 2007-08-20 | 2011-03-10 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods |
US8415455B2 (en) | 2007-09-04 | 2013-04-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
WO2009046314A2 (en) * | 2007-10-04 | 2009-04-09 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
EP2215269B1 (en) * | 2007-10-15 | 2017-12-13 | Admedus Vaccines Pty Limited | Construct system and uses therefor |
DK2567709T3 (en) | 2007-11-02 | 2018-03-12 | Novartis Ag | Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) |
NZ585556A (en) | 2007-11-07 | 2012-07-27 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
US8617099B2 (en) * | 2007-11-26 | 2013-12-31 | Bioject Inc. | Injection device plunger auto-disable |
US20090137949A1 (en) * | 2007-11-26 | 2009-05-28 | Bioject Inc. | Needle-free injection device with nozzle auto-disable |
EP2231705A2 (en) | 2007-12-17 | 2010-09-29 | Pfizer Limited | Treatment of interstitial cystitis |
WO2009086250A1 (en) | 2007-12-21 | 2009-07-09 | Aesthetic Sciences Corporation | Self-contained pressurized injection device |
CN101951988A (en) | 2007-12-28 | 2011-01-19 | 阿克蒂弗派克股份有限公司 | Dispenser and therapeutic package suitable for administering a therapeutic substance to a subject |
DE102008011873A1 (en) | 2007-12-30 | 2009-07-09 | Idelevich, Evgeny | Application device for automatically dispensing medicine during blood pressure lowering, has medicine cylinders filled with antidote, where liquid medicine in muscle tissue is injected with help of electro-hydraulical injector |
CN101951927A (en) * | 2008-01-03 | 2011-01-19 | 麻省理工学院 | Decoy influenza therapies |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101588309B1 (en) | 2008-01-22 | 2016-01-25 | 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 | Peptides, compositions, and uses thereof |
US8039596B2 (en) | 2008-02-05 | 2011-10-18 | Bristol-Myers Squibb Company | Alpha 5-beta 1 antibodies and their uses |
CN101952454B (en) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | Anti-IFNAR1 antibodies with reduced Fc ligand affinity |
AR072249A1 (en) * | 2008-04-09 | 2010-08-18 | Infinity Pharmaceuticals Inc | INHIBITORS OF AMIDA HYDROLASS ACID FAT. APPLICATIONS. METHODS |
AU2009237647A1 (en) | 2008-04-16 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Vaccine |
EP2829265B1 (en) * | 2008-04-28 | 2016-08-24 | Zogenix, Inc. | Novel formulations for treatment of migraine |
AU2009243187C1 (en) * | 2008-04-28 | 2015-12-24 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US8021344B2 (en) | 2008-07-28 | 2011-09-20 | Intelliject, Inc. | Medicament delivery device configured to produce an audible output |
CA2725911A1 (en) | 2008-05-30 | 2009-12-23 | Dana-Farber Cancer Institute, Inc. | Methods of treating a meiotic kinesin-associated disease |
JP2011521744A (en) * | 2008-05-30 | 2011-07-28 | アラーガン、インコーポレイテッド | Injection device for injecting soft tissue enhancing fillers, bioactive agents and other biocompatible materials in liquid or gel form |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
JP6146949B2 (en) | 2008-06-20 | 2017-06-21 | ノバルティス アーゲー | Immunoglobulin with reduced aggregation |
BRPI0914630A2 (en) | 2008-06-26 | 2019-09-24 | Anterios Inc | dermal release |
JP5986745B2 (en) | 2008-07-15 | 2016-09-06 | アカデミア シニカAcademia Sinica | Glycan arrays on PTFE-like aluminum-coated glass slides and related methods |
AU2009274571A1 (en) * | 2008-07-23 | 2010-01-28 | Massachusetts Institute Of Technology | Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival |
EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | Ligation of stapled polypeptides |
EP2316030B1 (en) | 2008-07-25 | 2019-08-21 | Wagner, Richard W. | Protein screeing methods |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
ES2824839T3 (en) * | 2008-09-18 | 2021-05-13 | Becton Dickinson Co | Slide Sleeve Activation Medical Injector |
ES2592216T3 (en) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1 and PD-L2 antibodies and their uses |
WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
KR101581986B1 (en) | 2008-10-29 | 2016-01-04 | 아블린쓰 엔.브이. | Formulations of single domain antigen binding molecules |
WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
US9545483B2 (en) * | 2008-12-02 | 2017-01-17 | Sanofi-Aventis Deutschland Gmbh | Drive assembly suitable for use in a medication delivery device and medication delivery device |
CA2743583C (en) | 2008-12-02 | 2016-11-15 | Allergan, Inc. | Injection device |
AU2009325878B2 (en) | 2008-12-08 | 2014-01-16 | Compugen Ltd. | TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
WO2010067345A1 (en) * | 2008-12-08 | 2010-06-17 | Perf-Action Technologies Ltd. | Erosion prevention for o-rings in a high pressure injection device |
EP2376619A4 (en) | 2008-12-15 | 2012-07-04 | Greenlight Biosciences Inc | Methods for control of flux in metabolic pathways |
WO2010069605A2 (en) | 2008-12-19 | 2010-06-24 | Medirista Biotechnologies Ab | Oxidized cardiolipin as a novel pro-inflammatory factor |
CN105132387A (en) * | 2008-12-22 | 2015-12-09 | 绿光生物科学公司 | Compositions and methods for the production of a compound |
BRPI1009232B1 (en) | 2009-03-05 | 2022-05-03 | E.R. Squibb & Sons, Llc. | Isolated monoclonal antibody or an antigen-binding portion thereof, or an antibody fragment, composition comprising them, nucleic acid molecule, hybridoma and methods for preparing an anti-cadm1 antibody |
GB0904540D0 (en) | 2009-03-17 | 2009-04-29 | Biotica Tech Ltd | Novel compounds and methods for their production |
AU2010234449A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
EP2416660B1 (en) | 2009-04-07 | 2014-07-02 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
CN102625661B (en) | 2009-04-09 | 2015-05-27 | 阿米库斯治疗学公司 | Methods for preventing and/or treating lysosomal storage disorders |
AU2010236257A1 (en) * | 2009-04-17 | 2011-11-03 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
EP2243505B1 (en) * | 2009-04-23 | 2018-02-14 | Bayer Healthcare LLC | Syringe assemblies, methods of forming syringe assemblies |
JP5766179B2 (en) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | Compositions and methods for increasing muscle growth |
MX2011011338A (en) | 2009-04-27 | 2012-04-19 | Novartis Ag | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit. |
US9221886B2 (en) | 2009-04-28 | 2015-12-29 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
UY32608A (en) | 2009-05-04 | 2010-12-31 | Pangenetics 110 B V | ANTIBODIES AGAINST THE NERVOUS GROWTH FACTOR (NGF) WITH IMPROVED LIVE STABILITY |
US20120128671A1 (en) | 2009-05-13 | 2012-05-24 | Lawrence Horowitz | Neutralizing molecules to influenza viruses |
US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
EP2438046A4 (en) | 2009-06-01 | 2013-04-17 | Harvard College | O-glcnac transferase inhibitors and uses thereof |
WO2010141430A2 (en) | 2009-06-01 | 2010-12-09 | Shriners Hospitals For Children | A cloned transmembrane receptor for 24-hydroxylated vitamin d compounds and uses thereof |
US8974423B2 (en) * | 2009-06-01 | 2015-03-10 | Sanofi-Aventis Deutschland Gmbh | Resettable drug delivery device |
EP3248619A3 (en) | 2009-06-04 | 2018-03-07 | Novartis AG | Methods for identification of sites for igg conjugation |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
KR20120090037A (en) | 2009-07-31 | 2012-08-16 | 메다렉스, 인코포레이티드 | Fully human antibodies to btla |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0914589D0 (en) | 2009-08-20 | 2009-09-30 | Biotica Tech Ltd | Novel compounds and methods for their production |
WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
GB0916630D0 (en) | 2009-09-22 | 2009-11-04 | Secr Defence | Antibody |
EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
EP2488199A1 (en) | 2009-10-14 | 2012-08-22 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
JP5805649B2 (en) | 2009-10-19 | 2015-11-04 | アミカス セラピューティックス インコーポレイテッド | Novel composition for preventing and / or treating degenerative disorders of the central nervous system |
RU2016103139A (en) | 2009-10-19 | 2018-11-22 | Амикус Терапьютикс, Инк. | NEW COMPOSITIONS FOR PREVENTING AND / OR TREATING LYSOSOMAL ACCUMULATION DISEASES |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
EP2496944A2 (en) | 2009-11-05 | 2012-09-12 | Novartis AG | Biomarkers predictive of progression of fibrosis |
US9428586B2 (en) | 2009-12-01 | 2016-08-30 | Compugen Ltd | Heparanase splice variant |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US20110137260A1 (en) | 2009-12-07 | 2011-06-09 | Allergan, Inc. | Slotted syringe |
US8293718B2 (en) | 2009-12-18 | 2012-10-23 | Novartis Ag | Organic compositions to treat HSF1-related diseases |
CA2785139A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2528615B1 (en) | 2010-01-27 | 2020-05-13 | Massachusetts Institute of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
CN102834401B (en) | 2010-02-03 | 2016-08-24 | 无限药品股份有限公司 | Inhibitors of fatty acid amide hydrolase |
MX2012009318A (en) | 2010-02-10 | 2012-09-07 | Novartis Ag | Methods and compounds for muscle growth. |
CN102844023B (en) | 2010-03-08 | 2016-01-20 | 索隆-基特林癌症研究协会 | CDC7 inhibitors of kinases with and uses thereof |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
US20110256135A1 (en) | 2010-03-17 | 2011-10-20 | Wolfgang Fraunhofer | Anti-nerve growth factor (ngf) antibody compositions |
US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US9631018B2 (en) | 2010-03-26 | 2017-04-25 | The Trustees Of Dartmouth College | Vista regulatory T cell mediator protein, vista binding agents and use thereof |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
BR112012026227A2 (en) | 2010-04-13 | 2020-08-04 | Celldex Therapeutics, Inc. | human or humanized monoclonal antibody, bispecific molecule, expression vector, transformed cell, composition, and, uses of an antibody |
SG10201502967RA (en) | 2010-04-16 | 2015-05-28 | Biogen Ma Inc | Anti-vla-4 antibodies |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
KR20220008383A (en) | 2010-04-23 | 2022-01-20 | 애로우헤드 파마슈티컬스 인코포레이티드 | ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES |
MX2012012441A (en) | 2010-05-04 | 2013-02-26 | Merrimack Pharmaceuticals Inc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof. |
WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
WO2011140516A2 (en) | 2010-05-07 | 2011-11-10 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through enzyme relocation |
BR122020018186B1 (en) | 2010-05-11 | 2021-07-27 | Lantheus Medical Imaging, Inc | USE OF IMAGING AGENTS TO PREPARE A COMPOSITION FOR DETECTION OF THE NOREPINEPHRIN CONVEYOR (NET) AND METHOD FOR THE DETECTION OF NET |
ES2587180T3 (en) | 2010-05-19 | 2016-10-21 | Allergan, Inc. | Modular injection device |
ES2664872T3 (en) | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | PRPK-TPRKB modulators and their uses |
WO2016030888A1 (en) | 2014-08-26 | 2016-03-03 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
CN107441480A (en) | 2010-06-30 | 2017-12-08 | 卡姆普根有限公司 | Polypeptide and its purposes as the medicine for treating multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
CA2804154C (en) | 2010-07-01 | 2021-06-01 | The Texas A&M University System | Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
WO2012007880A2 (en) | 2010-07-16 | 2012-01-19 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US8859723B2 (en) | 2010-08-13 | 2014-10-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
US8916358B2 (en) | 2010-08-31 | 2014-12-23 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through protease manipulation |
JP5856621B2 (en) | 2010-09-15 | 2016-02-10 | ゾゲニクス インコーポレーティッド | Needleless syringe and its design parameters to optimize injection performance |
WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
EP2640405A4 (en) | 2010-09-21 | 2015-04-15 | Massachusetts Inst Technology | Human-adapted ha polypeptides, vaccines, and influenza treatment |
US8957026B2 (en) | 2010-09-22 | 2015-02-17 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
EP2621514B1 (en) | 2010-09-28 | 2016-09-21 | KAHR Medical (2005) Ltd | Compositions and methods for treatment of hematological malignancies |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
NZ608630A (en) | 2010-10-01 | 2015-03-27 | Biogen Idec Inc | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2011312178B2 (en) | 2010-10-04 | 2016-05-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
CN103154037A (en) | 2010-10-05 | 2013-06-12 | 诺瓦提斯公司 | Anti-IL 12 Rbeta 1 antibodies and their use in treating autoimmune and inflammatory disorders |
EP2635317B1 (en) | 2010-11-03 | 2023-03-08 | Construct Medical Pty Ltd | Portable vacuum device |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2011333685A1 (en) | 2010-11-24 | 2013-06-27 | Glykos Finland Oy | Fusion enzymes having N-acetylglucosaminyltransferase activity |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9089579B2 (en) | 2011-01-19 | 2015-07-28 | Topokine Therapeutics, Inc. | Methods and compositions for treating metabolic syndrome |
AU2012209274A1 (en) | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
TR201905477T4 (en) | 2011-01-24 | 2019-05-21 | Anterios Inc | Nano-particle compositions. |
EP2667945A1 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Oil compositions |
US9084849B2 (en) | 2011-01-26 | 2015-07-21 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
CN103889219A (en) | 2011-03-03 | 2014-06-25 | 特萨斯制药有限责任公司 | Compositions and methods comprising c16:1n7-palmitoleate |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
US20130281932A1 (en) * | 2011-03-30 | 2013-10-24 | Ziv Harish | Palm-based injector actuation and safety surfaces |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2012140627A1 (en) | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
CN103608065A (en) * | 2011-04-19 | 2014-02-26 | 因维希德姆有限责任公司 | Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof |
US20140072622A1 (en) | 2011-05-17 | 2014-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
JP2014519338A (en) | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | Soluble proteins used as therapeutic agents |
WO2012177595A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
PE20140756A1 (en) | 2011-06-28 | 2014-07-04 | Oxford Biotherapeutics Ltd | ANTIBODIES THAT JOIN BST1 |
AU2012277376B2 (en) | 2011-06-30 | 2016-11-24 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
ES2692519T3 (en) | 2011-07-01 | 2018-12-04 | Novartis Ag | Method to treat metabolic disorders |
AR088218A1 (en) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2842524C (en) | 2011-07-22 | 2020-07-14 | Massachusetts Institute Of Technology | Activators of class i histone deacetylases (hdacs) and uses thereof |
EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013030778A2 (en) | 2011-09-02 | 2013-03-07 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
WO2013036787A2 (en) | 2011-09-09 | 2013-03-14 | Greenlight Biosciences, Inc. | Cell-free preparation of carbapenems |
CA2848147C (en) | 2011-09-09 | 2021-08-24 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
MX353958B (en) | 2011-09-22 | 2018-02-07 | Amgen Inc | Cd27l antigen binding proteins. |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
RU2474437C1 (en) * | 2011-10-13 | 2013-02-10 | Борис Владимирович Смоляров | Needle-free injection technique |
US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
CN108929375A (en) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | Peptidomimetic macrocyclic compound |
EA026153B1 (en) | 2011-11-09 | 2017-03-31 | Бристол-Майерс Сквибб Компани | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
US8603028B2 (en) | 2011-11-18 | 2013-12-10 | Allergan, Inc. | Injection device having an angled tip portion |
GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
KR20140102759A (en) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleoside, nucleotide, and nucleic acid compositions |
CN113398126A (en) | 2011-12-16 | 2021-09-17 | 佛罗里达大学研究基金会 | Use of 4' -deferthionin analogues |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
EP2793940B1 (en) | 2011-12-22 | 2018-11-14 | i2 Pharmaceuticals, Inc. | Surrogate binding proteins |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
CA2861697C (en) | 2012-01-05 | 2022-03-15 | Novartis Ag | Protease deficient filamentous fungal cells and methods of use thereof |
US10023862B2 (en) | 2012-01-09 | 2018-07-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-catenin-related diseases |
US10130800B2 (en) | 2012-01-27 | 2018-11-20 | Invisiderm, Llc | Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof |
AU2013216320A1 (en) | 2012-02-01 | 2014-04-03 | Compugen Ltd. | C10RF32 antibodies, and uses thereof for treatment of cancer |
MX350539B (en) | 2012-02-13 | 2017-09-08 | Bristol Myers Squibb Co | Enediyne compounds, conjugates thereof, and uses and methods therefor. |
US8927500B2 (en) | 2012-02-15 | 2015-01-06 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
MX354127B (en) | 2012-03-27 | 2018-02-14 | Amicus Therapeutics Inc | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. |
WO2013144758A1 (en) | 2012-03-27 | 2013-10-03 | Novartis Ag | Treatment of fibrosis |
WO2013152279A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Chemoenzymatic methods for synthesizing moenomycin analogs |
US9273084B2 (en) | 2012-04-06 | 2016-03-01 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
WO2013151697A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Methods and compounds for identifying glycosyltransferase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US20130304017A1 (en) * | 2012-05-09 | 2013-11-14 | Bioject, Inc. | Peformance of needle-free injection according to known relationships |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
MX2014013678A (en) | 2012-05-10 | 2015-02-04 | Massachusetts Inst Technology | Agents for influenza neutralization. |
US9399672B2 (en) | 2012-05-17 | 2016-07-26 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Hepatitis C virus neutralizing antibody |
JO3623B1 (en) | 2012-05-18 | 2020-08-27 | Amgen Inc | St2 antigen binding proteins |
US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
US9695454B2 (en) | 2012-05-23 | 2017-07-04 | Glykos Finland Oy | Production of fucosylated glycoproteins |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
CA2875683A1 (en) | 2012-06-05 | 2013-12-12 | The Australian National University | Vaccination with interleukin-4 antagonists |
GB201210082D0 (en) * | 2012-06-07 | 2012-07-25 | Consort Medical Plc | Improved syringe |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2014039983A1 (en) | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP2015525794A (en) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Method for eliciting an immune response against RSV and Bordetella pertussis in infants |
AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
US10309430B2 (en) * | 2012-08-10 | 2019-06-04 | Confluent Surgical, Inc. | Pneumatic actuation assembly |
WO2014028463A1 (en) | 2012-08-14 | 2014-02-20 | Allergan, Inc. | Syringe for mixing and dispensing adipose tissue |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
HUE054444T2 (en) | 2012-09-26 | 2021-09-28 | Harvard College | Proline-locked stapled peptides and uses thereof |
US20150225471A1 (en) | 2012-10-01 | 2015-08-13 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
JP6321662B2 (en) | 2012-10-12 | 2018-05-09 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | GSK3 inhibitor and method of use thereof |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
US20140114248A1 (en) | 2012-10-24 | 2014-04-24 | Nuance Designs, LLC | Power pack for an autoinjector |
WO2014065822A1 (en) | 2012-10-26 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hepatitis c virus neutralizing epitopes, antibodies, and methods |
PT2914296T (en) | 2012-11-01 | 2018-10-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
JP6526563B2 (en) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | Disubstituted amino acids and methods for their preparation and use |
US9567301B2 (en) | 2012-11-02 | 2017-02-14 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors |
CN104936632B (en) * | 2012-11-13 | 2017-08-04 | 康斯特鲁科特医疗有限公司 | Portable aspirator |
CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
JP6408478B2 (en) | 2012-11-26 | 2018-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Trioxacalcin, trioxacalcin-antibody complex and use thereof |
JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
ES2780398T3 (en) | 2012-12-10 | 2020-08-25 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibody and use thereof |
SI2935320T1 (en) | 2012-12-18 | 2019-12-31 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US8906900B2 (en) | 2012-12-21 | 2014-12-09 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
JP6678455B2 (en) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | PRMT5 inhibitors and uses thereof |
WO2014106056A2 (en) | 2012-12-27 | 2014-07-03 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
CA2897941A1 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
JP6518597B2 (en) | 2013-02-07 | 2019-05-22 | マサチューセッツ インスティテュート オブ テクノロジー | Human adaptation of H5 influenza |
SI2953969T1 (en) | 2013-02-08 | 2020-01-31 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
RS56169B1 (en) | 2013-02-14 | 2017-11-30 | Bristol Myers Squibb Co | Tubulysin compounds, methods of making and use |
CA2902068C (en) | 2013-02-28 | 2023-10-03 | Caprion Proteomics Inc. | Tuberculosis biomarkers and uses thereof |
KR20150131244A (en) | 2013-03-13 | 2015-11-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Stapled and stitched polypeptides and uses thereof |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
SG11201504260UA (en) | 2013-03-14 | 2015-10-29 | Abbvie Inc | Low acidic species compositions and methods for producing and using the same |
WO2014159554A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
AR095596A1 (en) | 2013-03-15 | 2015-10-28 | Amgen Res (Munich) Gmbh | UNIQUE CHAIN UNION MOLECULES UNDERSTANDING N-TERMINAL ABP |
AU2014248090B2 (en) | 2013-04-03 | 2018-08-02 | N-Fold Llc | Novel nanoparticle compositions |
CN111825733A (en) | 2013-04-04 | 2020-10-27 | 哈佛大学的校长及成员们 | Macrolides and methods of making and using the same |
ES2774330T3 (en) | 2013-04-09 | 2020-07-20 | Massachusetts Inst Technology | Drug supply polymer and uses thereof |
WO2014179464A1 (en) | 2013-04-30 | 2014-11-06 | Massachusetts Institute Of Technology | Human adaptation of h3 influenza |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
US20140350518A1 (en) | 2013-05-23 | 2014-11-27 | Allergan, Inc. | Syringe extrusion accessory |
US20140350516A1 (en) | 2013-05-23 | 2014-11-27 | Allergan, Inc. | Mechanical syringe accessory |
EA201592285A1 (en) | 2013-05-30 | 2016-05-31 | Байоджен Ма Инк. | ANTIGENSYCLING PROTEINS TO ONCOSTATIN M RECEPTOR |
DK3003309T3 (en) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Treatment of cancer with PI3 kinase isoform modulators |
WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
EP3030239A4 (en) | 2013-06-11 | 2017-03-08 | Kala Pharmaceuticals, Inc. | Urea derivatives and uses thereof |
CN105492460A (en) | 2013-06-14 | 2016-04-13 | 哈佛大学的校长及成员们 | Stabilized polypeptide insulin receptor modulators |
EP3013818B1 (en) | 2013-06-26 | 2021-12-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for treating cancer |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
BR112016001457A2 (en) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES |
CA2919773A1 (en) | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
BR112016002494A2 (en) | 2013-08-05 | 2017-09-05 | Greenlight Biosciences Inc | PROTEINS CONSTRUCTED WITH A PROTEASE CLEAVAGE SITE, NUCLEIC ACID, VECTOR, CELL AND PROCESS ENGINEERING A RECOMBINANT PROTEIN AND A LARGE NUMBER OF NUCLEIC ACID VARIANTS THAT ENCODE RECOMBINANT PROTEINS |
TWI532511B (en) * | 2013-08-16 | 2016-05-11 | 京華堂實業股份有限公司 | A needleless drug-injecting system and a drug-injecting method thereof |
CN105682666B (en) | 2013-09-06 | 2021-06-01 | 中央研究院 | Activation of human iNKT cells using glycolipids |
AR097648A1 (en) | 2013-09-13 | 2016-04-06 | Amgen Inc | COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
CN105792839A (en) | 2013-10-02 | 2016-07-20 | 诺华股份有限公司 | Insulin-like growth factor mimetics for use in therapy |
WO2015051234A2 (en) | 2013-10-04 | 2015-04-09 | Biogen Idec Ma Inc. | Tweak antagonists for treating lupus nephritis and muscle atrophy |
PE20160685A1 (en) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PT3055331T (en) | 2013-10-11 | 2021-04-05 | Oxford Bio Therapeutics Ltd | Conjugated antibodies against ly75 for the treatment of cancer |
US9982009B2 (en) | 2013-10-15 | 2018-05-29 | Massachusetts Institute Of Technology | Methods for treating polycystic kidney disease and polycystic liver disease |
WO2015057958A2 (en) | 2013-10-16 | 2015-04-23 | Massachusetts Institute Of Technology | Enterobactin conjugates and uses thereof |
ES2676734T3 (en) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Heteroatomic compounds useful for the treatment of proliferative diseases |
JP6491202B2 (en) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7) |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6426194B2 (en) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | Crystalline forms of therapeutic compounds and uses thereof |
UY35874A (en) | 2013-12-12 | 2015-07-31 | Novartis Ag | A PROCESS FOR THE PREPARATION OF A COMPOSITION OF PEGILATED PROTEINS |
CN113402609B (en) | 2013-12-20 | 2023-12-05 | 英特维特国际股份有限公司 | Canine antibodies with modified CH2-CH3 sequences |
TWI728373B (en) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | Antibodies and methods of use |
PL3712174T3 (en) | 2013-12-24 | 2022-07-04 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
EA201891279A1 (en) | 2013-12-24 | 2019-01-31 | Президент Энд Феллоус Оф Гарвард Колледж | ANALOGUES OF CORTISTATIN, THEIR SYNTHESIS AND APPLICATIONS |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US9982041B2 (en) | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
JP2017504651A (en) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Use of diazepan derivatives |
WO2015123385A1 (en) | 2014-02-12 | 2015-08-20 | Amicus Therapeutics, Inc. | Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of mps iiic |
JP6625071B2 (en) | 2014-03-07 | 2019-12-25 | ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Non-drug CRMP2 peptides targeting sodium channels for chronic pain |
SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
TWI687428B (en) | 2014-03-27 | 2020-03-11 | 中央研究院 | Reactive labelling compounds and uses thereof |
ES2868305T3 (en) | 2014-03-28 | 2021-10-21 | Univ Washington Through Its Center For Commercialization | Vaccines against breast and ovarian cancer |
US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
WO2015168380A1 (en) | 2014-04-30 | 2015-11-05 | Massachusetts Institute Of Technology | Siderophore-based immunization against gram-negative bacteria |
US10029048B2 (en) | 2014-05-13 | 2018-07-24 | Allergan, Inc. | High force injection devices |
CN106573032B (en) | 2014-05-21 | 2022-03-18 | 哈佛大学的校长及成员们 | RAS inhibitory peptides and uses thereof |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
CN106573971A (en) | 2014-05-27 | 2017-04-19 | 中央研究院 | Anti-CD20 glycoantibodies and uses thereof |
EP3149161B1 (en) | 2014-05-27 | 2021-07-28 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
JP6612017B2 (en) * | 2014-06-03 | 2019-11-27 | 株式会社ダイセル | Needleless syringe injection system |
EA037006B1 (en) | 2014-06-06 | 2021-01-26 | Бристол-Майерс Сквибб Компани | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
MX2016016310A (en) | 2014-06-11 | 2017-10-20 | A Green Kathy | Use of vista agonists and antagonists to suppress or enhance humoral immunity. |
EP3154576A1 (en) | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
SI3157916T1 (en) | 2014-06-19 | 2019-05-31 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
EP2959931A1 (en) | 2014-06-24 | 2015-12-30 | LTS LOHMANN Therapie-Systeme AG | Needle-free injection device |
EP3161001A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
WO2016004197A1 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
US20160185848A1 (en) | 2014-07-09 | 2016-06-30 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using sugars |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
WO2016016415A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
JP6749312B2 (en) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Optimized interspecific bispecific single chain antibody constructs |
EP2979714A1 (en) | 2014-08-02 | 2016-02-03 | LTS LOHMANN Therapie-Systeme AG | Needleless injection device with a membrane |
WO2016025331A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
US10736966B2 (en) | 2014-08-12 | 2020-08-11 | Massachusetts Institute Of Technology | Brush-poly (glycoamidoamine)-lipids and uses thereof |
IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
EP2993174A1 (en) | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
US10226585B2 (en) | 2014-10-01 | 2019-03-12 | Allergan, Inc. | Devices for injection and dosing |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
AU2015327819B2 (en) | 2014-10-03 | 2021-07-01 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
TN2017000157A1 (en) | 2014-10-21 | 2018-10-19 | Ariad Pharma Inc | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine |
EP3011988A1 (en) | 2014-10-22 | 2016-04-27 | LTS LOHMANN Therapie-Systeme AG | Needle-free injection device with a gel and a membrane |
US20180015101A1 (en) | 2014-10-28 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for antigen-specific tolerance |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
US10647687B2 (en) | 2014-11-10 | 2020-05-12 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
RS60631B1 (en) | 2014-11-21 | 2020-09-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
EP3221346B1 (en) | 2014-11-21 | 2020-09-02 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
EP3227341A1 (en) | 2014-12-02 | 2017-10-11 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
EP3226900A4 (en) | 2014-12-05 | 2018-09-19 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
EP3230272B1 (en) | 2014-12-10 | 2020-08-19 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
PT3233912T (en) | 2014-12-19 | 2021-08-09 | Regenesance B V | Antibodies that bind human c6 and uses thereof |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
AU2015369707B2 (en) | 2014-12-23 | 2020-07-23 | Sloan-Kettering Institute For Cancer Research | Polymorph of granaticin B |
TWI708786B (en) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | Antibodies to tigit |
AU2016206191B2 (en) | 2015-01-09 | 2017-08-03 | Adalta Limited | CXCR4 binding molecules |
WO2016115201A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3248005B1 (en) | 2015-01-24 | 2020-12-09 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
BR112017019272A2 (en) | 2015-03-10 | 2018-05-02 | Allergan Pharmaceuticals Holdings Ireland Unlimited Company | multiple needle injector |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
MX2017011834A (en) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
AU2016235054B2 (en) | 2015-03-24 | 2020-07-16 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
MX2017012665A (en) | 2015-03-30 | 2018-04-24 | Greenlight Biosciences Inc | Cell-free production of ribonucleic acid. |
DK3277722T3 (en) | 2015-04-02 | 2021-10-11 | Intervet Int Bv | ANTIBODIES TO CANIN INTERLEUKIN-4 RECEPTOR ALPHA |
MX2017012966A (en) | 2015-04-10 | 2018-06-06 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells. |
WO2016162405A1 (en) | 2015-04-10 | 2016-10-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Pyrone derivatives for use as antiviral agents |
EP4276116A3 (en) | 2015-04-17 | 2024-01-17 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
US10570104B2 (en) | 2015-04-27 | 2020-02-25 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
TW201702271A (en) | 2015-04-30 | 2017-01-16 | 哈佛大學校長及研究員協會 | Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
US10568852B2 (en) | 2015-05-22 | 2020-02-25 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Combination compositions and their use in methods for treating obesity and obesity-related disorders |
EA039951B1 (en) | 2015-05-27 | 2022-03-31 | Юсб Биофарма Спрл | Inhibitor of csf-1r activity for use in the treatment or prophylaxis of epilepsy or parkinson's disease and pharmaceutical composition thereof |
US11078259B2 (en) * | 2015-06-05 | 2021-08-03 | Joslin Diabetes Center, Inc. | Methods and compositions for promoting thermogenic potential |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
EP3307348A2 (en) * | 2015-06-15 | 2018-04-18 | Nuance Designs of CT, LLC | Gas-propelled autoinjector with gas flow regulator |
JP2017000667A (en) | 2015-06-16 | 2017-01-05 | 国立大学法人三重大学 | Needle-free injector and method for introducing dna to injection target area using the same |
US10201618B2 (en) | 2015-06-19 | 2019-02-12 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof |
JP7026509B2 (en) | 2015-06-24 | 2022-02-28 | ヤンセン ファーマシューティカ エヌブイ | Anti-VISTA antibody and fragment |
JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
JP6830067B2 (en) | 2015-06-30 | 2021-02-17 | カレオ,インコーポレイテッド | Automatic syringe that administers medication in a prefilled syringe |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CA2991980A1 (en) | 2015-07-13 | 2017-01-19 | Compugen Ltd. | Hide1 compositions and methods |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
JO3620B1 (en) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers |
US10179128B2 (en) | 2015-08-31 | 2019-01-15 | Amicus Therapeutics, Inc. | Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of mcl-1 |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US20180256750A1 (en) | 2015-09-17 | 2018-09-13 | Moderna Therapeutics, Inc. | Polynucleotides containing a stabilizing tail region |
RU2638457C2 (en) | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production |
WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
AU2016330772A1 (en) | 2015-09-30 | 2018-04-19 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
WO2017059389A1 (en) | 2015-10-01 | 2017-04-06 | Kythera Biopharmaceuticals, Inc. | Compositions comprising a statin for use in methods of adipolysis |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
JP6998869B2 (en) | 2015-11-08 | 2022-02-04 | ジェネンテック, インコーポレイテッド | Screening method for multispecific antibody |
US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
AR108824A1 (en) | 2015-11-21 | 2018-10-03 | Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa | DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY |
WO2017095875A1 (en) | 2015-11-30 | 2017-06-08 | Bristol-Myers Squibb Company | Anti human ip-10 antibodies and their uses |
CA3006759A1 (en) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
US10596248B2 (en) | 2015-12-09 | 2020-03-24 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
PL3394030T3 (en) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
CN108884169B (en) | 2016-01-22 | 2022-03-22 | 默沙东公司 | Anti-coagulation factor XI antibodies |
JOP20170017B1 (en) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | Pharmaceutical composition comprising bispecific antibody constructs |
EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
KR20180103084A (en) | 2016-02-03 | 2018-09-18 | 암젠 리서치 (뮌헨) 게엠베하 | BCMA and CD3 bispecific T cell engrafting antibody constructs |
CN116920085A (en) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | anti-VISTA (B7H 5) antibodies |
RU2018131123A (en) | 2016-02-17 | 2020-03-17 | Новартис Аг | ANTIBODIES TO TGF-BETA2 |
JP7104629B2 (en) | 2016-02-24 | 2022-07-21 | ビステラ, インコーポレイテッド | Preparation of antibody molecule against influenza virus |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
SG11201807677YA (en) | 2016-03-04 | 2018-10-30 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity |
EA201891983A8 (en) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | COMBINED THERAPY BY ANTIBODIES TO CD73 |
TW201808978A (en) | 2016-03-08 | 2018-03-16 | 中央研究院 | Methods for modular synthesis of N-glycans and arrays thereof |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
KR102535764B1 (en) | 2016-03-28 | 2023-05-30 | 아이커 메디칼 시스템스 인코포레이티드 | Apparatus for delivery of therapeutic agents |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
EP4293104A3 (en) | 2016-04-06 | 2024-04-24 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
CA3020146A1 (en) | 2016-04-08 | 2017-10-12 | Allergan, Inc. | Aspiration and injection device |
RU2021111187A (en) | 2016-04-15 | 2021-04-29 | Янссен Фармасьютикалз, Инк. | ANTIBODIES AGAINST HUMAN VISTA AND THEIR APPLICATION |
WO2017184586A1 (en) | 2016-04-18 | 2017-10-26 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
MA44723A (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
SI3445850T1 (en) | 2016-04-22 | 2021-12-31 | BioNTech SE | Methods for providing single-stranded rna |
ES2886966T3 (en) * | 2016-04-29 | 2021-12-21 | Altaviz Llc | self-powered syringe |
KR20180133198A (en) | 2016-05-04 | 2018-12-13 | 암젠 인크 | Interleukin-2 mutein for proliferation of T-regulatory cells |
EP3455256A1 (en) | 2016-05-09 | 2019-03-20 | Bristol-Myers Squibb Company | Tl1a antibodies and uses thereof |
TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
SG10201913650WA (en) | 2016-06-03 | 2020-03-30 | Sanofi Pasteur Inc | Modification of engineered influenza hemagglutinin polypeptides |
US10105449B2 (en) | 2016-06-07 | 2018-10-23 | Massachusetts Institute Of Technology | Drug delivery polymers and uses thereof |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2017286606A1 (en) | 2016-06-14 | 2018-12-13 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
AU2017286432B2 (en) | 2016-06-14 | 2020-09-24 | Adimab, Llc | Anti-coagulation factor XI antibodies |
US20180002417A1 (en) | 2016-06-15 | 2018-01-04 | Celimmune Llc | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
US10328205B2 (en) * | 2016-07-07 | 2019-06-25 | Shl Medical Ag | Drug delivery device with pneumatic power pack |
JP7027401B2 (en) | 2016-07-14 | 2022-03-01 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies to TIM3 and its use |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
US20180028755A1 (en) * | 2016-07-28 | 2018-02-01 | Portal Instruments, Inc. | Connected health platform including needle-free injector system |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
WO2018027042A1 (en) | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy |
CN109862908B (en) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2019001341A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
KR102493853B1 (en) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use |
JP7213549B2 (en) | 2016-08-22 | 2023-01-27 | シーエイチオー ファーマ インコーポレイテッド | Antibodies, Binding Fragments, and Methods of Use |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
EP3305781A1 (en) | 2016-10-07 | 2018-04-11 | Deutsches Krebsforschungszentrum | Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6) |
WO2018071822A2 (en) | 2016-10-13 | 2018-04-19 | Massachusetts Institute Of Technology | Antibodies that bind zika virus envelope protein and uses thereof |
WO2018081578A1 (en) | 2016-10-28 | 2018-05-03 | Astute Medical, Inc. | Use of antibodies to timp-2 for the improvement of renal function |
CN110267971B (en) | 2016-11-07 | 2023-12-19 | 百时美施贵宝公司 | Immunomodulators |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11434301B2 (en) | 2016-11-11 | 2022-09-06 | The Regents Of The University Of California | Anti-CD46 antibodies and methods of use |
CN110062626A (en) | 2016-11-18 | 2019-07-26 | 纽维制药有限公司 | Purposes of the sanglifehrin Macrocyclic analogs as anticancer compound |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
KR20190096409A (en) | 2016-12-21 | 2019-08-19 | 메레오 바이오파마 3 리미티드 | Use of anti-sclerostine antibodies in the treatment of incomplete osteoplasia |
WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
EP3559047A1 (en) | 2016-12-23 | 2019-10-30 | Novartis AG | Factor xi antibodies and methods of use |
AU2017379094B2 (en) | 2016-12-23 | 2023-08-24 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
KR20240031326A (en) | 2016-12-31 | 2024-03-07 | 바이오엑셀 테라퓨틱스 인코포레이티드 | Use of Sublingual Dexmedetomidine for the treatment of Agitation |
US11702458B2 (en) | 2017-01-05 | 2023-07-18 | Kahr Medical Ltd. | PD1-41BBL fusion protein and methods of use thereof |
SI3565828T1 (en) | 2017-01-05 | 2022-04-29 | Kahr Medical Ltd. | A sirp1 alpha-41bbl fusion protein and methods of use thereof |
US20180244785A1 (en) | 2017-01-09 | 2018-08-30 | Merrimack Pharmaceuticals, Inc. | Anti-fgfr antibodies and methods of use |
US10332623B2 (en) | 2017-01-17 | 2019-06-25 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and event detection |
US11377497B2 (en) | 2017-01-23 | 2022-07-05 | Suzhou Alphamab Co., Ltd. | PD-L1 binding polypeptide or composite |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
GB2559553B (en) * | 2017-02-06 | 2021-10-13 | Consort Medical Plc | A medicament delivery device |
GB201702144D0 (en) | 2017-02-09 | 2017-03-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
CN110603038A (en) | 2017-02-10 | 2019-12-20 | 塔姆山治疗公司 | Rapamycin analogs |
EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
HUE060693T2 (en) | 2017-03-15 | 2023-04-28 | Modernatx Inc | Compound and compositions for intracellular delivery of therapeutic agents |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
USD867582S1 (en) | 2017-03-24 | 2019-11-19 | Allergan, Inc. | Syringe device |
JP7157075B2 (en) | 2017-04-05 | 2022-10-19 | ザ ブロード インスティテュート,インコーポレーテッド | Tricyclic compounds and their use as glycogen synthase kinase 3 (GSK3) inhibitors |
TWI796329B (en) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | Anti-ilt4 antibodies and antigen-binding fragments |
TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
KR20190134807A (en) | 2017-04-25 | 2019-12-04 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Novel compositions for preventing and / or treating degenerative diseases and / or lysosomal reservoirs of the central nervous system |
WO2018204907A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
AU2018266847A1 (en) | 2017-05-10 | 2019-11-28 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual HIV antiviral and immunomodulatory activity |
CN111094335B (en) | 2017-05-15 | 2022-08-23 | 罗切斯特大学 | Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof |
KR20220167342A (en) | 2017-05-25 | 2022-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies comprising modified heavy constant regions |
US20210198200A1 (en) | 2017-06-14 | 2021-07-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2018233333A1 (en) | 2017-06-23 | 2018-12-27 | 苏州博聚华生物医药科技有限公司 | Monoclonal antibody of targeted human tumor stem cells and application of monoclonal antibody |
KR20200020858A (en) | 2017-06-23 | 2020-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Immunomodulators Acting as Antagonists of PD-1 |
US11612647B2 (en) | 2017-06-23 | 2023-03-28 | University Of Maryland, Baltimore | Immunogenic compositions |
WO2019013789A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds |
WO2019013790A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds and uses thereof |
MX2020001851A (en) | 2017-08-22 | 2020-08-20 | Biogen Ma Inc | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies. |
MX2020002351A (en) | 2017-08-28 | 2021-02-26 | Shanghai Yile Biotechnology Co Ltd | Polypeptide and antibody bound to polypeptide. |
US11414450B1 (en) | 2017-08-28 | 2022-08-16 | Revagenix, Inc. | Aminoglycosides and uses thereof |
JP7275111B2 (en) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | Method for producing lipid nanoparticles |
US11492375B2 (en) | 2017-10-03 | 2022-11-08 | Bristol-Myers Squibb Company | Cyclic peptide immunomodulators |
SG11202003114UA (en) | 2017-10-04 | 2020-05-28 | Amgen Inc | Transthyretin immunoglobulin fusions |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
AU2018347405B2 (en) | 2017-10-11 | 2022-02-03 | Greenlight Biosciences, Inc. | Methods and compositions for nucleoside triphosphate and ribonucleic acid production |
EP3700938A1 (en) | 2017-10-26 | 2020-09-02 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. | Novel recombinant fusion proteins, preparation and use thereof |
WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
KR102478433B1 (en) | 2017-11-17 | 2022-12-15 | 머크 샤프 앤드 돔 엘엘씨 | Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof |
US11786477B2 (en) | 2017-12-01 | 2023-10-17 | North Carolina State University | Fibrin particles and methods of making the same |
EP3724229A1 (en) | 2017-12-11 | 2020-10-21 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
SG11202004966PA (en) | 2017-12-21 | 2020-06-29 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
CN111432801A (en) * | 2017-12-21 | 2020-07-17 | 台湾微脂体股份有限公司 | Sustained release triptan compositions and methods of using same via subcutaneous or similar routes |
SG11202004971YA (en) | 2017-12-21 | 2020-06-29 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
JP7358361B2 (en) | 2018-01-12 | 2023-10-10 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies against TIM3 and their uses |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
CN111868082A (en) | 2018-02-02 | 2020-10-30 | 博奥泰克尼公司 | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using the same |
KR101859735B1 (en) * | 2018-02-07 | 2018-05-21 | 주식회사 피테크 | Painless injection device |
CA3089906A1 (en) | 2018-02-08 | 2019-08-15 | Amgen Inc. | Low ph pharmaceutical antibody formulation |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
US20210363172A1 (en) | 2018-03-15 | 2021-11-25 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing rna, expressing proteins in therapy |
TW202003565A (en) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | Antibodies against MICA and/or MICB and uses thereof |
EP3777889A4 (en) | 2018-03-26 | 2022-01-26 | Shanghai Yile Biotechnology Co., Ltd. | Use of probdnf regulator in b cell-related diseases |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
WO2019194858A1 (en) | 2018-04-03 | 2019-10-10 | Achaogen, Inc. | Modular synthesis of aminoglycosides |
AU2019249255A1 (en) | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
CA3096674A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
KR20210011919A (en) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | Anti-CD27 antibody and anti-PD-L1 antibody and bispecific construct |
WO2019202160A2 (en) | 2018-04-20 | 2019-10-24 | Iomx Therapeutics Ag | A 5-thiazolecarboxamide kinase inhibitor and uses thereof |
KR102104080B1 (en) * | 2018-05-02 | 2020-04-23 | 주식회사 피테크 | Sonic vibration device for painless syringe and painless sylinge having the same |
KR102107578B1 (en) * | 2018-05-02 | 2020-05-07 | 주식회사 피테크 | Constant velocity infusion device for painless syringe and painless sylinge having the same |
KR101907552B1 (en) * | 2018-05-03 | 2018-10-12 | 주식회사 피테크 | Painless injection device without needle |
CA3096703A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
CA3101364A1 (en) | 2018-05-25 | 2019-11-28 | Primmune Therapeutics, Inc. | Tlr7 agonists |
EP3800999A4 (en) | 2018-06-04 | 2022-06-01 | Biogen MA Inc. | Anti-vla-4 antibodies having reduced effector function |
US11951286B2 (en) * | 2018-06-12 | 2024-04-09 | Banza Stamping Industry Corp. | Automatic injection device for fluid |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
EA202190092A1 (en) | 2018-06-21 | 2021-05-18 | Юманити Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS |
CA3103431A1 (en) | 2018-06-27 | 2020-01-02 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
MX2021000263A (en) | 2018-07-11 | 2021-05-12 | Kahr Medical Ltd | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF. |
US11929160B2 (en) | 2018-07-16 | 2024-03-12 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and compliance detection |
JP2021532140A (en) | 2018-07-30 | 2021-11-25 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Long-term administration of bispecific antibody constructs that bind to CD33 and CD3 |
MA53333A (en) | 2018-07-31 | 2021-11-03 | Amgen Inc | PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES |
EP3830122A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Research (Munich) GmbH | Dosing regimen for bcma-cd3 bispecific antibodies |
MA53330A (en) | 2018-08-03 | 2021-06-09 | Amgen Inc | ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3 |
JP7193058B2 (en) | 2018-08-08 | 2022-12-20 | イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド | Recombinant bifunctional protein targeting CD47 and HER2 |
WO2020049208A1 (en) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora kinase as target for treating, preventing or curing hiv infection or aids |
WO2020061210A1 (en) | 2018-09-18 | 2020-03-26 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
KR102199724B1 (en) * | 2018-10-05 | 2021-01-07 | 주식회사 피테크 | Painless injection device without needle |
JP2022504839A (en) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | Anti-LAP antibody mutants and their use |
JP2022512636A (en) | 2018-10-11 | 2022-02-07 | アムジエン・インコーポレーテツド | Downstream processing of bispecific antibody constructs |
EP3643713A1 (en) | 2018-10-23 | 2020-04-29 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
US20220024944A1 (en) | 2018-10-23 | 2022-01-27 | Myelopro Diagnostics And Research Gmbh | Compounds targeting mutant calreticulin |
US11160791B2 (en) | 2018-11-01 | 2021-11-02 | Medefil, Inc. | Dexmedetomidine injection premix formulation in ready to use (RTU) bags |
US11827670B2 (en) | 2018-11-09 | 2023-11-28 | University Of Massachusetts | Anti-CfaE antibodies and methods of use |
PE20211284A1 (en) | 2018-11-16 | 2021-07-19 | Bristol Myers Squibb Co | ANTI-NKG2A ANTIBODIES AND USES OF THEM |
JP2022513653A (en) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies containing modified heavy chain constant regions |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
CN113195532A (en) | 2018-12-18 | 2021-07-30 | 瑞泽恩制药公司 | Compositions and methods for increasing body weight and lean muscle mass using antagonists against leptin receptor, GDF8, and activin A |
WO2020128863A1 (en) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anti-tnf-alpha antibodies |
WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
WO2020144535A1 (en) | 2019-01-08 | 2020-07-16 | Aduro Biotech Holdings, Europe B.V. | Methods and compositions for treatment of multiple myeloma |
CN113924292A (en) | 2019-01-16 | 2022-01-11 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
CN113825748A (en) | 2019-01-16 | 2021-12-21 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
CN109762067B (en) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
CA3127236A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
JP7061236B2 (en) | 2019-01-22 | 2022-04-27 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC Modulator and Its Use |
WO2020154405A2 (en) | 2019-01-22 | 2020-07-30 | Genentech, Inc. | Immunoglobulin a antibodies and methods of production and use |
CA3128215A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020168466A1 (en) | 2019-02-19 | 2020-08-27 | Stemirna Therapeutics Co., Ltd. | Modified nucleoside and synthetic methods thereof |
CA3131953A1 (en) | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
BR112021017644A2 (en) | 2019-03-11 | 2021-11-16 | Biogen Ma Inc | Pharmaceutical compositions containing anti-lingo-1 antibodies |
AU2020248404A1 (en) | 2019-03-25 | 2021-09-30 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
MX2021012160A (en) | 2019-04-08 | 2022-01-06 | Biogen Ma Inc | Anti-integrin antibodies and uses thereof. |
JP2022533233A (en) | 2019-05-21 | 2022-07-21 | ブリストル-マイヤーズ スクイブ カンパニー | Immunomodulator |
CA3140075A1 (en) | 2019-06-11 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
TW202045711A (en) | 2019-06-13 | 2020-12-16 | 美商安進公司 | Automated biomass-based perfusion control in the manufacturing of biologics |
CN114127125A (en) | 2019-07-08 | 2022-03-01 | 安进公司 | Multispecific thyroxin transporter immunoglobulin fusions |
MX2022000367A (en) | 2019-07-11 | 2022-07-13 | Kahr Medical Ltd | Heterodimers and methods of use thereof. |
EP3999538A1 (en) | 2019-07-15 | 2022-05-25 | Intervet International B.V. | Caninized antibodies against canine ctla-4 |
EP3999543A1 (en) | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
WO2021011681A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
AU2020312687A1 (en) | 2019-07-15 | 2022-01-27 | Intervet International B.V. | Caninized antibodies to human and canine CTLA-4 |
CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
EP4003296A1 (en) | 2019-07-31 | 2022-06-01 | ModernaTX, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
WO2021021729A1 (en) | 2019-07-31 | 2021-02-04 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
CA3145580A1 (en) | 2019-08-09 | 2021-02-18 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
MX2022001866A (en) | 2019-08-13 | 2022-03-11 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells. |
KR20220079857A (en) | 2019-09-13 | 2022-06-14 | 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 | AAV-compatible laminin-linker polymeric protein |
KR20220088868A (en) | 2019-10-30 | 2022-06-28 | 브리스톨-마이어스 스큅 컴퍼니 | immunomodulators |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
AU2020384885A1 (en) | 2019-11-13 | 2022-06-09 | Curza Global, Llc | Antimicrobial compounds and methods |
CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
WO2021102143A1 (en) | 2019-11-19 | 2021-05-27 | Bristol-Myers Squibb Company | Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases |
BR112022011350A2 (en) | 2019-12-11 | 2022-08-23 | Visterra Inc | COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT AND PREVENTION |
JP2023507115A (en) | 2019-12-17 | 2023-02-21 | アムジエン・インコーポレーテツド | Dual interleukin-2/TNF receptor agonist for use in therapy |
MX2022007636A (en) | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis. |
MX2022007672A (en) | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Canine interleukin-4 receptor alpha antibodies. |
UY38995A (en) | 2019-12-20 | 2021-06-30 | Amgen Inc | MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS |
CN114929714A (en) | 2020-01-06 | 2022-08-19 | 百时美施贵宝公司 | Macrocyclic peptides as PD-L1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases |
JP2023510737A (en) | 2020-01-06 | 2023-03-15 | ブリストル-マイヤーズ スクイブ カンパニー | Immunomodulator |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
CA3169669A1 (en) | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
US20230105029A1 (en) | 2020-02-27 | 2023-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding il4r and uses thereof |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
US20230140384A1 (en) | 2020-03-09 | 2023-05-04 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
US20230183292A1 (en) | 2020-03-16 | 2023-06-15 | Bristol-Myers Squibb Company | Immunomodulators |
KR20220155338A (en) | 2020-03-19 | 2022-11-22 | 암젠 인크 | Antibodies to mucin 17 and uses thereof |
WO2021195089A1 (en) | 2020-03-23 | 2021-09-30 | Sorrento Therapeutics, Inc. | Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof |
KR20220161407A (en) | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | immunomodulator |
CA3170570A1 (en) | 2020-04-01 | 2021-10-07 | James J. KOBIE | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
CA3168737A1 (en) | 2020-04-21 | 2021-10-28 | Jiaxi WU | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
EP3901151A1 (en) | 2020-04-21 | 2021-10-27 | iOmx Therapeutics AG | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
WO2021219731A2 (en) | 2020-04-28 | 2021-11-04 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and uses thereof |
AU2021263813A1 (en) | 2020-04-29 | 2022-10-27 | Amgen Inc. | Pharmaceutical formulation |
US20230167176A1 (en) | 2020-04-29 | 2023-06-01 | Amgen Inc. | Pharmaceutical formulation |
BR112022022045A2 (en) | 2020-04-30 | 2023-01-10 | Sairopa B V | ANTIGEN-BINDING ANTIBODY OR FRAGMENT OF THE SAME WHICH BINDS HUMAN CD103, ONE OR MORE NUCLEIC ACIDS, EXPRESSION SYSTEM, HOST CELL, COMPOSITION, METHODS OF PRODUCTION OF AN ANTIBODY OR ANTIGEN-BINDING FRAGMENT, TO DETECT THE PRESENCE OF CD103 IN A BIOLOGICAL SAMPLE, TO TREAT OR PREVENT A CONDITION MEDIATED BY CD103 SIGNALING IN AN INDIVIDUAL IN NEED, TO INHIBIT CD103 SIGNALING IN A CELL, TO INHIBIT THE BINDING OF CD103 TO E-CADHERIN PRESENT IN A CELL, TO REMOVE THE CD103-EXPRESSING CELLS IN AN INDIVIDUAL, TO TREAT OR PREVENT A DISEASE AND IMAGING AGENT |
CN115916340A (en) | 2020-05-08 | 2023-04-04 | 百时美施贵宝公司 | Immunomodulator |
WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
MX2022014636A (en) | 2020-05-19 | 2023-02-23 | Amgen Inc | Mageb2 binding constructs. |
US20230277524A1 (en) | 2020-05-22 | 2023-09-07 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
JP2023527972A (en) | 2020-05-29 | 2023-07-03 | アムジエン・インコーポレーテツド | Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3 |
WO2021252708A1 (en) | 2020-06-11 | 2021-12-16 | President And Fellows Of Harvard College | Stabilized trioxacarcin antibody drug conjugates and uses thereof |
FR3112939B1 (en) | 2020-07-31 | 2024-01-05 | Univ Montpellier | Universal cell therapy product and its use |
EP4192511A1 (en) | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugates targeting cd46 and methods of use thereof |
KR20230058432A (en) | 2020-08-24 | 2023-05-03 | 암젠 인크 | pharmaceutical formulation |
US20230365627A1 (en) | 2020-10-02 | 2023-11-16 | Bristol-Myers Squibb Company | Macrocyclic peptide boronate immunomodulators |
JP2023546020A (en) | 2020-10-08 | 2023-11-01 | ブリストル-マイヤーズ スクイブ カンパニー | Novel dimeric immunomodulator |
CN116323640A (en) | 2020-10-09 | 2023-06-23 | 百时美施贵宝公司 | Macrocyclic immunomodulators |
MX2023004438A (en) | 2020-10-15 | 2023-05-08 | Intervet Int Bv | CANINIZED RAT ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR <i>ALPHA. |
WO2022092294A1 (en) | 2020-10-30 | 2022-05-05 | 学校法人慶應義塾 | Novel treatment and prevention of sarcopenia-related diseases |
JPWO2022092295A1 (en) | 2020-10-30 | 2022-05-05 | ||
AR123997A1 (en) | 2020-11-04 | 2023-02-01 | Univ Rockefeller | NEUTRALIZING ANTIBODIES AGAINST SARS-CoV-2 |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
BR112023008670A2 (en) | 2020-11-06 | 2024-02-06 | Amgen Inc | POLYPEPTIDE CONSTRUCTS LINKED TO CD3 |
JP2023547662A (en) | 2020-11-06 | 2023-11-13 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Polypeptide constructs that selectively bind to CLDN6 and CD3 |
AU2021374839A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
TW202233682A (en) | 2020-11-10 | 2022-09-01 | 美商安進公司 | Methods for administering a bcmaxcd3 binding molecule |
CN116547305A (en) | 2020-11-11 | 2023-08-04 | 生物技术公司 | Monoclonal antibodies against programmed death-1 proteins and their use in medicine |
AR124267A1 (en) | 2020-12-09 | 2023-03-01 | Genentech Inc | HIGH THROUGH METHODS FOR PREPARING LIPID NANOPARTICLES AND THEIR USES |
DE102020134181A1 (en) | 2020-12-18 | 2022-06-23 | Henke-Sass, Wolf Gmbh | Device for applying a fluid |
CN114685669A (en) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | Antibodies that bind TROP2 and uses thereof |
US20220227844A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
EP4305088A1 (en) | 2021-03-09 | 2024-01-17 | Massachusetts Institute of Technology | Branched poly(-amino esters) for the delivery of nucleic acids |
JP2024510207A (en) | 2021-03-12 | 2024-03-06 | ブリストル-マイヤーズ スクイブ カンパニー | KRAS inhibitor |
WO2022204412A1 (en) | 2021-03-24 | 2022-09-29 | Bristol-Myers Squibb Company | Immunomodulators |
BR112023020303A2 (en) | 2021-04-09 | 2023-11-14 | Celldex Therapeutics Inc | ANTIBODIES AGAINST ILT4, BISPECIFIC ANTI-ILT4/PD-L1 ANTIBODY AND THEIR USES |
KR20230169230A (en) | 2021-04-12 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | Cyclic peptide immunomodulator |
EP4333805A1 (en) | 2021-05-06 | 2024-03-13 | Amgen Inc. | Etelcalcetide formulations |
EP4334358A1 (en) | 2021-05-06 | 2024-03-13 | Amgen Research (Munich) GmbH | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
WO2022235867A2 (en) | 2021-05-06 | 2022-11-10 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
KR20240017813A (en) | 2021-05-10 | 2024-02-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | Pharmaceutical composition for treating neurological diseases |
IL308545A (en) | 2021-05-26 | 2024-01-01 | Oxford Biotherapeutics Ltd | Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor |
TW202313065A (en) | 2021-05-28 | 2023-04-01 | 美商季卡尼醫療公司 | Compounds for treating genetic diseases |
EP4352077A1 (en) | 2021-06-09 | 2024-04-17 | Bristol-Myers Squibb Company | Cyclic peptide immunomodulators |
WO2022258792A1 (en) | 2021-06-09 | 2022-12-15 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel anti-fibrotic drugs |
CA3220933A1 (en) | 2021-06-30 | 2023-01-05 | Amgen Inc. | Method of reconstituting lyophilized formulation |
WO2023288213A1 (en) | 2021-07-12 | 2023-01-19 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
KR20240035843A (en) | 2021-07-19 | 2024-03-18 | 브리스톨-마이어스 스큅 컴퍼니 | Macrocyclic immunomodulators |
IL309799A (en) | 2021-07-20 | 2024-02-01 | Regeneron Pharma | Butyrophilin-like 2 agents for treating inflammatory disorders |
CN113398365B (en) * | 2021-07-21 | 2022-10-28 | 南京瑞淇卓越医疗美容诊所有限公司 | Clinical radiography injection device and injection method for cardiovascular medicine |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
AU2022329459A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
AU2022331810A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Fusion proteins for treating atopic dermatitis |
WO2023039108A1 (en) | 2021-09-08 | 2023-03-16 | Affinivax, Inc. | Coronavirus vaccine |
CN113773401B (en) | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof |
CA3233926A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
CN113754769B (en) | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术(上海)股份有限公司 | CD 70-targeting antibodies, their preparation and use |
CN113831412B (en) | 2021-10-13 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | Antibodies targeting CD24, their preparation and use |
CN113956363B (en) | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术(上海)股份有限公司 | Recombinant fusion protein targeting CD47 and CD24 and preparation and application thereof |
WO2023069994A1 (en) | 2021-10-20 | 2023-04-27 | Bristol-Myers Squibb Company | Immunomodulators |
CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
WO2023096904A2 (en) | 2021-11-24 | 2023-06-01 | President And Fellows Of Harvard College | C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof |
WO2023102507A1 (en) | 2021-12-03 | 2023-06-08 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
WO2023105281A1 (en) | 2021-12-11 | 2023-06-15 | Fundaciò Privada Institut De Recerca De La Sida-Caixa | Soluble tigit recombinant proteins |
WO2023114884A2 (en) | 2021-12-15 | 2023-06-22 | Interius Biotherapeutics, Inc. | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
WO2023111157A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized and felinized antibodies to human ngf |
WO2023114889A1 (en) | 2021-12-16 | 2023-06-22 | Modernatx, Inc. | Processes for preparing lipid nanoparticles |
WO2023111148A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha 1 |
WO2023129963A1 (en) | 2021-12-30 | 2023-07-06 | Curza Global, Llc | Antimicrobial compounds and methods |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023166488A1 (en) | 2022-03-04 | 2023-09-07 | Revagenix, Inc. | Broad spectrum aminoglycosides and uses thereof |
WO2023177579A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
WO2023192873A1 (en) | 2022-03-28 | 2023-10-05 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
WO2023193002A1 (en) | 2022-04-01 | 2023-10-05 | Modernatx, Inc. | Cross mixers for lipid nanoparticle production, and methods of operating the same |
EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
WO2023212559A1 (en) | 2022-04-26 | 2023-11-02 | Amgen Inc. | Lyophilization method |
US11932693B2 (en) | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
GB202207263D0 (en) | 2022-05-18 | 2022-06-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
WO2023225661A1 (en) | 2022-05-20 | 2023-11-23 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
WO2023235380A1 (en) | 2022-06-01 | 2023-12-07 | Zikani Therapeutics, Inc. | Macrolides for treating genetic diseases |
WO2023240188A1 (en) | 2022-06-10 | 2023-12-14 | Bristol-Myers Squibb Company | Pyrido[4,3-d]pyrimidine derivatives as kras inhibitors |
WO2023240189A1 (en) | 2022-06-10 | 2023-12-14 | Bristol-Myers Squibb Company | Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors |
WO2023250513A1 (en) | 2022-06-24 | 2023-12-28 | Zikani Therapeutics, Inc. | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation |
WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
WO2024036270A1 (en) | 2022-08-11 | 2024-02-15 | Bristol-Myers Squibb Company | Kras inhibitors |
WO2024040109A2 (en) | 2022-08-16 | 2024-02-22 | Bristol-Myers Squibb Company | Kras inhibitors |
WO2024049994A1 (en) | 2022-09-01 | 2024-03-07 | Zikani Therapeutics, Inc. | Treatment of familial adenomatous polyopsis using a 13-membered macrolide |
WO2024054926A1 (en) | 2022-09-07 | 2024-03-14 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
WO2024059472A1 (en) | 2022-09-12 | 2024-03-21 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2704543A (en) * | 1955-03-22 | Hypo jet injector | ||
US2101140A (en) * | 1935-03-23 | 1937-12-07 | Raymond W Hege | Automatic injecting syringe device |
US2380534A (en) * | 1941-04-26 | 1945-07-31 | Marshall L Lockhart | Hypodermic injector |
US2605763A (en) * | 1948-01-31 | 1952-08-05 | Becton Dickinson Co | Injection device |
US2547099A (en) * | 1948-03-11 | 1951-04-03 | Becton Dickinson Co | Injection device and ampoule |
US2680439A (en) * | 1948-09-08 | 1954-06-08 | Arnold K Sutermeister | High-pressure injection device |
US2670121A (en) * | 1951-01-31 | 1954-02-23 | Scherer Corp R P | Flexible follower for metal ampoules |
US2816543A (en) * | 1954-07-12 | 1957-12-17 | Scherer Corp R P | Hypodermic injector |
NL268186A (en) * | 1960-08-15 | |||
US3292621A (en) * | 1963-07-19 | 1966-12-20 | Oscar H Banker | Jet type protable inoculator |
US3292622A (en) * | 1964-09-21 | 1966-12-20 | Oscar H Banker | Power operated inoculator |
US3424154A (en) * | 1965-11-08 | 1969-01-28 | Charles W Kinsley | Injection system |
US3561443A (en) * | 1968-09-06 | 1971-02-09 | Oscar H Banker | Inoculator gun with delayed action |
US3688765A (en) * | 1969-10-03 | 1972-09-05 | Jack S Gasaway | Hypodermic injection device |
US3945379A (en) * | 1974-08-08 | 1976-03-23 | Smithkline Corporation | Injection device |
JPS51130094A (en) * | 1975-05-08 | 1976-11-12 | Asahi Chemical Ind | Twoostage pressure injector |
CA1178503A (en) * | 1982-05-27 | 1984-11-27 | Health-Mor Personal Care Corporation | Needleless hypodermic injector |
HU186718B (en) * | 1983-06-29 | 1985-09-30 | Radelkis Electrokemiai | Automatic needleless syringe operable by cardox cylinder suitable for personal giving injection e.g. insulin |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4680027A (en) * | 1985-12-12 | 1987-07-14 | Injet Medical Products, Inc. | Needleless hypodermic injection device |
EP0250022A3 (en) * | 1986-06-17 | 1988-06-22 | SICIM SpA | Portable endermic injector |
US4722728A (en) * | 1987-01-23 | 1988-02-02 | Patents Unlimited, Ltd. | Needleless hypodermic injector |
US4940460A (en) * | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
DE3814023A1 (en) * | 1987-07-13 | 1989-01-26 | Medizin Labortechnik Veb K | Injection device with drug depot |
AU628029B2 (en) * | 1987-11-16 | 1992-09-10 | Sy-Quest International Limited | Improved apparatus for hypodermic injection of liquids |
US5073165A (en) * | 1988-02-05 | 1991-12-17 | Marpam International, Inc. | Hypodermic jet injector and cartridge therefor |
US4913699A (en) * | 1988-03-14 | 1990-04-03 | Parsons James S | Disposable needleless injection system |
US5024656A (en) * | 1988-08-30 | 1991-06-18 | Injet Medical Products, Inc. | Gas-pressure-regulated needleless injection system |
CA1325149C (en) * | 1989-08-31 | 1993-12-14 | Gavin Mcgregor | Variable intensity remote controlled needleless injector |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5062830A (en) * | 1990-04-04 | 1991-11-05 | Derata Corporation | Dry disposable nozzle assembly for medical jet injector |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
-
1992
- 1992-07-24 US US07/920,106 patent/US5383851A/en not_active Expired - Lifetime
-
1993
- 1993-07-23 DE DE69327165T patent/DE69327165T2/en not_active Expired - Lifetime
- 1993-07-23 WO PCT/US1993/006940 patent/WO1994002188A1/en active IP Right Grant
- 1993-07-23 EP EP93918344A patent/EP0651663B1/en not_active Expired - Lifetime
- 1993-07-23 CA CA002140772A patent/CA2140772C/en not_active Expired - Lifetime
- 1993-07-23 US US08/097,266 patent/US5399163A/en not_active Expired - Lifetime
- 1993-07-23 AU AU47827/93A patent/AU676490B2/en not_active Expired
- 1993-07-23 AT AT93918344T patent/ATE187083T1/en not_active IP Right Cessation
- 1993-07-23 JP JP50471494A patent/JP3633615B2/en not_active Expired - Lifetime
-
1995
- 1995-03-21 US US08/407,867 patent/US5520639A/en not_active Expired - Lifetime
-
2003
- 2003-12-24 JP JP2003426219A patent/JP2004141667A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221347B2 (en) | 2004-12-01 | 2012-07-17 | Acushot, Inc. | Needle-free injector |
Also Published As
Publication number | Publication date |
---|---|
WO1994002188A1 (en) | 1994-02-03 |
US5399163A (en) | 1995-03-21 |
ATE187083T1 (en) | 1999-12-15 |
JPH07509161A (en) | 1995-10-12 |
AU676490B2 (en) | 1997-03-13 |
US5520639A (en) | 1996-05-28 |
JP2004141667A (en) | 2004-05-20 |
DE69327165D1 (en) | 2000-01-05 |
EP0651663A4 (en) | 1995-08-30 |
JP3633615B2 (en) | 2005-03-30 |
US5383851A (en) | 1995-01-24 |
EP0651663A1 (en) | 1995-05-10 |
EP0651663B1 (en) | 1999-12-01 |
AU4782793A (en) | 1994-02-14 |
DE69327165T2 (en) | 2000-08-24 |
CA2140772A1 (en) | 1994-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2140772C (en) | Needleless hypodermic injection methods and device | |
WO1994002188A9 (en) | Needleless hypodermic injection methods and device | |
US6939319B1 (en) | Process and device for single use, needle-free intradermal, subcutaneous, or intramuscular injections | |
US10918791B2 (en) | Devices, systems and methods for medicament delivery | |
US5312335A (en) | Needleless hypodermic injection device | |
EP0427457B1 (en) | Ampule for Needleless Hypodermic Injection Device | |
WO2004101025A2 (en) | Needle free hypodermic injector and ampule for intradermal, subcutaneous and intramuscular injection | |
US8361029B2 (en) | Devices, systems and methods for medicament delivery | |
US4623332A (en) | Needleless jet injector | |
AU675534B2 (en) | Multiple medication injection apparatus and method | |
CA2476076C (en) | Injector with bypass channel | |
US5891086A (en) | Needle-less injector | |
US4194505A (en) | Containerized hypodermic module | |
US20020099329A1 (en) | Gas power sources for needle-less injector and needle-less injectors incorporating the same | |
WO1982002835A1 (en) | Vacuum-compression injector | |
JPH04500166A (en) | Needleless injection system controlled by gas pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |